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Abstract
Abstract
Antimicrobial resistance is a major problem in the treatment of typhoid fever; a 
systemic human infection caused by Salmonella Typhi {S. Typhi). The co-existence of 
multidrug resistant and fluoroquinolone resistant S. Typhi isolates is increasingly 
common. Therefore, it is essential to understand the molecular mechanisms and the 
epidemiology of antimicrobial resistant S. Typhi in endemic countries such as Viet 
Nam. A cross section of S. Typhi strains isolated from 8 Asian countries and a 
Vietnamese S. Typhi collection were investigated for antimicrobial resistance patterns. 
Molecular approaches were used to identify the mechanisms of (fluoro)quinolone 
resistance in S. Typhi isolates. Specific phenotypic characteristics of each of the 
naturally mutations were assessed in S. Typhi isolates that were reconstructed in an 
isogenic strain. The antimicrobial resistance phenotypes of both wild type and 
reconstructed mutants were calculated using antimicrobial susceptibility tests and time - 
kill experiments. To predict the relative fitness of these mutants, the strains were 
subjected to independent and competitive growth assays. Finally, we developed a 
molecular epidemiological tool which was used to genotype and identify 
fluoroquinolone resistant S. Typhi strains circulating in Asia. The findings of this study 
show that antimicrobial resistant S. Typhi is continuing problem in Asian countries, 
especially in Viet Nam. Fluoroquinolone resistance in S. Typhi is caused by mutations 
in specific locations of the gyrA and parC  genes. The majority of reconstructed mutants 
had a selective growth advantage when placed in competition with a non - mutant S. 
Typhi strain. Strains that had the highest level of fluoroquinolone resistance had a 
selective disadvantage. We conclude that S. Typhi haplotype H58 with associated 
nalidixic acid resistance is dominant across Asian countries.
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Introduction
1. Introduction
1.1 The genus Salmonella
Salmonella is genus of the bacterial family Enterobacteriaceae. Enterobacteriaceae or 
(more commonly) enteric bacteria generally inhabit the intestinal tract of both warm and 
cold blooded animals. This large family consists of genetically related bacteria, which 
have similar phenotypic and biochemical properties. The most closely related species to 
Salmonella is Escherichia and both these groups of organisms share common traits 
which aid survival and transmission [1]. Salmonella are facultative anaerobic bacilli that 
are gram negative and generally mobile (with the ability to swarm and swim on the 
basis of flagella). Microscopically they measure between 2 -  4 x 0.4 -  0.6 pm in size 
and are biochemically identified by the production of gas from glucose, manitol, 
maltose and sorbitol and the production of hydrogen sulphide [1].
1.2 Taxonomy
According to the CDC classification system, the genus of Salmonella is divided into 2 
species, Salmonella enterica and Salmonella bongori [2], Salmonella enterica is further 
subdivided into six subspecies that are designated by names and Roman numerals (I; S. 
enterica subsp. enterica, II; S. enterica subsp. salamae, Ilia; S. enterica subsp. 
arizonae, Illb; S. enterica subsp. diarizonae, IV; S. enterica subsp. houtenae and VI; S. 
enterica subsp. indica). S. enterica subspecies can be differentiated by biochemical 
properties and by genomic relatedness. The organisms in S. enterica subsp. I cause 
approximately 99% of all Salmonella infections in humans and other warm-blooded 
animals and are the general focus of global Salmonella research [2].
1
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1.3 Salmonella biochemical and microbiological identification
Salmonella can be cultured on blood agar and MacConkey agar media [1]. Colonies on 
blood agar and MacConkey agar media have a grey opaque appearance with an average 
diameter of 2-3 mm. The colony morphology is generally circular, with a smooth 
surface, or flatter with a less regular surface [1]. Currently, chromogenic agar 
(CHROMagar) and Xylose Lysine Deoxycholate agar (XLD) are recommended for 
Salmonella isolation [3].
Salmonella enterica serovar Typhi (all Salmonellae serovars will follow the naming 
from here onwards, e.g. Salmonella enterica serovar Typhi; S. Typhi) ferments 
carbohydrates, to produce acid; however it produces little or no gas [4] . S. Typhi 
ferments glucose and manitol but does not ferment lactose, sucrose, salicin or adonitol. 
The O-nitrophenyl-3-D-galactopyranoside (ONPG) test is negative with respect to S. 
Typhi [5]. Some exceptional strains of-S. Typhi do not ferment arabinose or dulcitol. 
Similar to other Salmonella species, S. Typhi decarboxylases the amino acids, lysine, 
ornithine and arginine, but cannot decarboxylate glutamic acid [1].
1.4 Salmonella serotyping
Members of the genus Salmonellae are distinguished from other enteric bacteria on the 
basis of their physiological characteristics. The Salmonellae are classified into different 
serotypes by the Kauffmann-White scheme [2]. The Kauffmann-White scheme 
(serotyping) is based on the immuno-reactivity of two main surface structures, the O 
antigen (somatic) and H antigen (flagella). The various Salmonella serotypes are 
identified by biochemical testing of these two antigenic structures. The O antigens and 
the H antigens are detected in independent agglutination assays using specific antisera 
that react with the group of related antigens or a single antigen.
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Primary identification is based upon antibody agglutination of specific repeating units 
of the bacterial lipopolysaccharide (LPS). The LPS is assembled of between four and 
six sugars, depending on the O antigen [6]. They are hydrophilic and enable the bacteria 
to form stable, homogeneous suspensions in saline solution [1]. To date, over 60 
different Salmonella O antigens had been recognized and are designated by numbers 
and are divided into O serogroups [1].
The H antigen, the filametous portion of the bacterial flagella, is made up of repeating 
protein subunits, called flagellin. The end region of flagellin is conserved and gives the 
filament its characteristic structure [6]. The antigenically variable portion of flagellin is 
the central region of the protein, which is exposed on the surface [6]. The majority of 
the genus Salmonella can express two different H antigens, which are encoded by two 
different genes, i.e. they are biphasic and the flagella are referred as Phase 1 and Phase
2. However, due to gene regulation only one gene can be expressed at a single time in 
an individual bacteria cell. Organisms such as S. Typhi express only one flagella type 
and is monophasic. In phase I (the specific phase), different antigens are designated by 
small letters, a to z. The phase 2 antigens (the group phase) first discovered were given 
Arabic numerals, but then, certain phase I antigens, especially e, n, x and z were also 
found to be present in the phase 2 of some strains [1]. Some Salmonella, for example, S. 
Typhi can express an additional antigen, known as the Vi capsule. Vi is thought to be 
vital for the pathogenesis of the organism and can also be detected by specific antisera 
and is therefore an additional identification test.
The combination of the O and the H antigen (and Vi) give the organisms a specific 
antigenic structure, of which each variant is called a serovar. Serotyping is essential for
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laboratory identification of the Salmonellae, on the basis of testing there are currently 
over 2,500 different Salmonella serovars [4].
1.5 Nomenclature
Each individual serovar is given a specific name to identify the organism. Originally the 
organisms were named by medical microbiologists to reflect the disease they caused 
e.g. S. Typhi (as the organism causes typhoid fever) and S. Typhimurium (causing 
typhoid in mice). Latterly serovars were named after the location they were first 
discovered, e.g. S. Newport, S. Sendai and S. Stanleyville.
1.6 Salmonella disease in humans
The majority of the members of sub-species I of the genus Salmonellae are zoonotic and 
can survive in the gastrointestinal tract of their vertebrate hosts and in the environment 
[7]. Transmission generally occurs via the faecal -  oral route, whereby a potential host 
eats or drinks contaminated food or water. The nature of the infection in humans is 
dependent on the serovar, the strain, the dose and the status of the host. The 
Salmonellae are generally associated with a self-limiting gastrointestinal infection in 
humans [7]. Ingested bacteria are consumed, usually in contaminated foodstuffs like 
dairy products and colonize the small intestine where they stimulate inflammation. 
Salmonella food poisoning causes stomach cramps, persistent diarrhea and vomiting 
and can last for several days [8]. It is seldom life threatening, but complications can 
occur in the elderly or the immunocompromised [9]. Salmonella food poisoning 
(gastroenteritis) can be caused by wide spectrum of Salmonella serovars and is a global 
problem [10-12].
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Some members of the genus Salmonella are non - zoonotic and are host adapted. Host 
adapted means that they can only cause a specific disease syndrome in an individual 
host [13]. For example, S. Typhimurium causes a typhoid like disease in mice and a 
gastrointestinal infection in humans. The level of host specialization is further 
exaggerated by Salmonella that are host restricted, this means that the organism can 
only cause a disease in a specific host. S. Typhi is probably the best example of this as it 
causes typhoid fever in humans and higher primates but does not infect any other hosts; 
therefore, humans are the only known reservoir of infection [14].
1.7 Typhoid (enteric) fever
Typhoid fever is a severe systemic infection caused by the bacterium S. Typhi. The 
disease typhoid is classically characterized by a fever which is generally prolonged and 
is caused by bacteria entering the bloodstream [9]. A similar disease syndrome is caused 
by other human restricted Salmonella, serovars Paratyphi A, B and C, however, these 
organisms are less common than S. Typhi and are geographically isolated [15].
The term “typhoid fever” is interchangeable with the term “enteric fever”, but enteric 
fever is the disease name for all human invasive Salmonellae, whilst typhoid is only 
associated with the bacterium S. Typhi. Enteric fever is seldom fatal in those patients 
whom are appropriately managed, but may result in fatality if untreated; the mortality is 
related to complications and it may be as high as 10% in untreated individuals [16] and 
varied from 4.8 % to 30.5% in children [17]. Due to improvements in sanitation, enteric 
fever no longer poses a serious health problem in developed countries. The main burden 
of enteric fever lies in developing and undeveloped countries where inadequate 
sanitation appears to aid the ongoing transmission of the organisms [18].
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1.7.1 Clinical features of typhoid
Symptoms of typhoid fever vary from a mild illness with low-grade fever, malaise and a 
dry cough to a more severe manifestation with abdominal discomfort and multiple 
complications [19]. The disease may be categorized into two groups on the basis of 
clinical features and severity, these are described as below:
Acute non - complicated typhoid fever is characterized by prolonged fever, disturbances 
of bowel function (diarrhea or constipation), headache, malaise and anorexia. A 
bronchial cough is a common symptom in the early stage of the illness. During the 
period of fever, 25% of patients show rose spots on the chest, abdomen and back [19].
About 10% of typhoid patients with acute typhoid fever may progress and develop 
serious complications. Approximately 10 -  20 % of patients with severe illness present 
with bloody stools, abdominal discomfort or intestinal perforation [19]. Other 
symptoms such as neurological complications, such as hallucinations occur, but are less 
reported [19].
The clinical features of other enteric fevers (associated with S. Paratyphi serovars), are 
historically considered milder than those associated with S. Typhi [15]. However, a 
prospective, descriptive study from Kathmandu, Nepal, found no difference in disease 
severity or duration in patients infected with S. Typhi or S. Paratyphi A [20]. It is 
believed that S. Paratyphi A has a shorter incubation period and can manifest with 
jaundice. Relapse may also be common in patients with S. Paratyphi A, which maybe 
occur in up to 8 % of patients, depending on location and the treatment [15].
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1.7.2 Diagnosis
Since the symptoms of typhoid fever are often non - specific, the disease is often 
difficult to diagnose clinically. Owing to the locations where typhoid is endemic the 
disease syndrome may be confused with other illnesses where patients are febrile [16]. 
In general, typhoid should be considered in the differential diagnosis in those patients 
who have not been confirmed to have malaria, pneumonia, appendicitis or meningitis 
[21]. Whilst there are several methods of diagnosis which are commonly used, there is 
only one method which permits a guarantee that the patient has typhoid fever. The 
mainstay of enteric fever diagnostics relies on the isolation of S. Typhi (or other 
invasive Salmonellae) from the peripheral blood, faeces or bone marrow [21]. The 
sensitivity of blood culture decreases with the duration of illness and the use of 
antimicrobials prior to blood Collection greatly reduces the isolation rate [21].
Bone marrow culture is a more sensitive procedure, but due to the invasive nature of the 
method it is not generally routinely performed [22]. Culture from stool is less sensitive 
than blood and bone marrow culture, owning to the transient nature of shedding the 
organism [9]. Isolation of the pathogen from faecal specimens is the only realistic 
method for identifying asymptomatic carriers, thus making identification of these 
people a considerable challenge.
There are several serological tests available for the diagnosis of typhoid fever, both in 
the form of laboratory assays and point-of-care diagnostic tests. The classical typhoid 
diagnostic test is the Widal test, which is used to identify antibodies against the O 
(Somatic) and the H (flagella) [23]. S. Typhi antigens which usually appear a week to 
10 days after disease onset. Therefore, the Widal test utilizes paired serum samples 
from the acute and the convalescent phase of the infection. The Widal test method is
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often a test of choice in many endemic locations yet is difficult to interpret due to false- 
positive and false-negative results [19,24]. A single sample method for the Widal test 
was assessed in Viet Nam; this study found that whilst this method did have some 
clinical use, the test is limited due to cross-reactivity of other bacterial antigens and the 
exposure rate in an endemic location [25].
Newer diagnostic tests have been developed to confirm typhoid fever quicker and may 
offer a higher degree of sensitivity and specificity. These tests are mainly based on the 
binding of specific antibodies to S. Typhi antigens and maybe more sensitive and 
specific than the Widal test [19]. However, the cross reactivity of bacterial antigens also 
hinders such newer generation tests, such as Typhidot and Tubex [19]. These assays 
were assessed in population-based typhoid surveillance studies in several countries and 
in all locations the sensitivity and specificity for Tubex and Typhidot was only around 
70% and 80% respectively [26,27].
Molecular diagnostic approaches have also been introduced to improve typhoid fever 
diagnostics such as nested and real time PCR [21,28]. However, a molecular approach 
using PCR, despite its advance in methodology is relatively complicated and costly to 
perform, and is probably not a suitable routine use test in clinical microbiological 
laboratories where typhoid is endemic [9].
1.7.3 Epidemiology
It is estimated that typhoid caused 21.7 million new infections and 216,510 deaths in the 
year 2000 [29]. Humans are the only natural host and reservoir of S. Typhi and the main 
sources of infection are food and water contaminated with faeces containing the 
organism [19]. Little is known about direct transmission of the organisms, but disease is
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associated with poor sanitation and it is suggested that Salmonella have the ability to 
survive for prolonged periods within the environment [30,31]. As the organism is 
transmitted in this maner, children, like with many other enteric pathogens are most at 
risk from the disease, due to increased contact and a potential lack of immunity [32,33].
Due to lack of sanitation, typhoid fever incidence in developing countries is 
significantly higher than that of industrialized countries and the incidence is highly 
dependent on the location [29]. In 2000, the incidence of typhoid fever in Asia was 
reported as the highest rate globally with 274 per 100,000 persons per year [29]. The 
areas of high incidence in Asia were in South Central Asia (622 / 100,000 / year) and 
South East Asia (110 / 100,000 / year). In other locations in Asia the incidence of 
typhoid fever was negligible. For example in Taiwan < 3 per 100,000 people per year 
were infected and 25 % of these cases originated from travel to other South East Asian 
countries [34]. On the African continent the incidence is approximately 50 cases per
100,000 people per year and the highest rate of infection is found in South Africa, with 
233 cases per 100,000 people per year [15].
The incidence of typhoid fever continues at low levels in developed countries and 
reported cases are generally imported by travelers returning from areas which are 
endemic. Amongst 282 cases of reported typhoid cases in the United States from June 
1, 1996 to May 1, 1997, the patient travel history could confirm disease in 81 % (229 / 
282) of these [35]. Similarly, the incidence of typhoid fever in the United Kingdom and 
Australia is less than one case per 100,000 people per year [29,36].
Some simplistic steps may be employed to prevent the transmission of typhoid fever in 
endemic areas and in travelers to these locations. Specifically, attention should be made
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to appropriate food handling procedures and hand washing with soap before preparing 
or eating food. In endemic areas other simple strategies such as avoiding consuming 
uncooked food, shellfish and taking ice in drinks may prevent infection [19].
1.7.4 Epidemiology of typhoid in Viet Nam
The nationwide incidence rate of typhoid fever in Viet Nam is approximately 15 per
100,000 people per year; with 56 % of cases occurring in children between the ages of 5 
to 14 years [37]. The highest burden is isolated mainly to six provinces (Dong Thap, An 
Giang, Kien Giang, Can Tho, Vinh Long, Soc Trang) [38]; these provinces have 
incidence rates of greater than 100 / 100,000 people per year [37,38], Like in other 
endemic areas the majority of the infections in the south of Viet Nam occur in locations 
which lack an adequate clean water supply [39]. These places have been shown to have 
water with high feacal contamination, a low level of general public hygiene and limited 
access to good sanitation [40].
Between 1993 and 1994, three serious outbreaks occurred in southern provinces of Viet 
Nam. These included Kien Giang (1993) with 2,459 cases, Soc Trang (1994) with 520 
cases and Ho Chi Minh City (1994) with more than 400 defined cases [38]. The 
outbreak in Ho Chi Minh City was of particular importance due to the isolated 
organisms having a high rate of multidrug resistance [38].
Using pulsed-field gel electrophoresis, bacteriophage typing, plasmid typing, and 
antimicrobial susceptibilities, Connerton et al. demonstrated that independent outbreaks 
of multidrug resistant typhoid fever in southern Viet Nam were caused by a single 
bacterial strain [41]. However, different outbreaks were not derived from the clonal 
expansion of a single multidrug resistant S. Typhi strain. The clonal transmission of S.
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Typhi may be a consequence of the inhabitant’s habit of using river and rain water as a 
primary source of water for drinking and cooking [42]. During the period of high 
incidence in Viet Nam, 90% of the households in the Mekong Delta region were using 
“fish pond latrines”, a latrine over a pond used to cultivate fish for farming. 
Surveillance also showed that the peak incidence of typhoid in Mekong Delta was at the 
beginning of the wet season in March and April, a period when the water table is high 
and the potential for drinking water to become mixed with effluent, from fields or other 
sources of faecal contamination may be higher [42].
1.7.5 Prevention of typhoid fever
In addition to improvements in sanitation and improvements in public health, typhoid is 
a vaccine preventable disease [19]. Vaccination for typhoid is cost effective and highly 
efficacious. The first parental vaccine (a killed whole cell vaccine) was introduced in 
1896 and was shown to control the disease in Thailand. However, the vaccine produced 
strong side effects, presumably due to the LPS and the immunogenic nature of other 
bacterial proteins [19,43]. This live, killed vaccine caused local discomfort and swelling 
in between 25 -  50 % of all recipients, and is no longer recommended for routine use
[9].
Two safe and effective vaccines are now commonly available and recommended by the 
WHO. Ty21a is a live attenuated vaccine, which is taken in three doses over a week 
[19]. This vaccine is used less than the Vi polysaccharide vaccine due to cold chain 
limitations and requires a strict adherence to the dosing schedule. There are other live 
attenuated typhoid vaccines in development, namely CVD909 and M01ZH09. CVD909 
is an aroClaroDlhtrA mutant which was engineered to constitutively express the S. 
Typhi Vi antigen [44]. M01ZH09 is an S. Typhi strain also containing an aroC mutation
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combined with an ssa V mutation which prevents expression of the SPI-2 Type Three 
Secretion System (TTSS) [45].
The most commonly used vaccine is a single dose vaccine containing purified Vi 
polysaccharide [43]. The vaccine is suitable used for adults and children above two 
years of age and has no serious side effects. Production of Vi vaccines in non - 
industrialized countries such as Viet Nam has greatly reduced the cost of this 
prophylaxis and the Vietnamese ministr y of health has an ongoing Vi vaccination 
programme [46].,Studies conducted in Nepal and South Africa have demonstrated that 
the Vi vaccine provided two years protection and had a three year cumulative efficacy 
of 55 % [47,48]. A new modified Vi conjugate vaccine bound to non - toxic 
recombinant fragment of Pseudomonas aeruginosa exotoxin A (rEPA) has enhanced 
immunogenicity in adults and in children between 5 - 1 4  years of age, and provided 
induced booster responses in children aged between 2 - 4  years [49]. The Vi conjugate 
vaccines that are currently under development are widely considered as the future in 
terms of controlling typhoid fever [39]. Yet Vi based vaccines do not protect against S. 
Paratyphi A or B, since these strains do not express the Vi polysaccharide. Therefore, 
attenuated vaccines which may confer cross-protection against other invasive 
Salmonella [50] should also be considered for typhoid prevention in countries with high 
rate of paratyphoid fever [51].
1.8 Salmonella Typhi pathogenicity
Like other Salmonellae, S. Typhi has specific virulence machinery that permits the 
organism to live a pathogenic lifestyle [52,53]. The cornerstone of Salmonella 
pathogenicity are Salmonella Pathogenicity Islands (SPI’s), horizontally acquired 
fragments of DNA which are inserted into the genome of the organism and contain a
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multitude of virulence associated genes [54]. Overall, the mechanisms of S. Typhi 
pathogenicity are complex and rely on a number of coordinated events to permit 
invasion of the intestinal mucosa and intracellular survival. However, it is these gene 
islands and the ability to invade the gut mucosa and then survive in deeper tissues 
which distinguish these organisms from other non - pathogenic enteric bacteria [55].
Whilst the overall mechanisms of pathogenicity cannot be explained simply by two 
individual gene islands, SPI-1 and SPI-2 are vital for invasion and intracellular survival 
and are, therefore, the most well described and the most important pathogenicity islands 
inthe genus Salmonella [56,57].
SPI-1 is an approximately 40 Kb gene island encoding a type three secretion system and 
multiple effector proteins which are essential for the organisms to invade the intestinal 
mucosal surface [58], Type three secretion systems are biological syringes carried by 
some pathogenic organisms which permit the secretion of proteins (effectors) from the 
bacterial cell into the host cell. The secreted proteins can influence host cell function 
and facilitate bacterial invasion. The type three secretion system carried on SPI-1 is 
involved in the early stages of infection and acts at the Peyers patches (the location of 
invasion of Salmonella) to facilitate invasion of the cell [59].
% . .Similar to SPI-1, SPI-2 is an approximately 40 Kb gene island encoding a type three 
secretion system and multiple effector proteins [53]. However, the type three secretion 
system encoded by SPI-2 plays an entirely different function to SPI-1, yet is also 
essential for the pathogenesis of the Salmonellae. SPI-2 is involved in the survival and 
persistence of infection in Salmonella once the organism has invaded the mucosal 
surface. The type three secretion system and its secreted effectors are vital for systemic
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infection in mice and permit the organism to survive intracellularly inside macrophages 
[60].
The pathogenesis of typhoid disease in man has received only limited attention, due to 
the host restricted nature of the organism and complexity of studying infection with a 
human host. The incubation period for S. Typhi in a particular individual depends on the 
quantity of inoculum and usually ranges from 3 days to more than 60 days [19]. 
Experimentation using surrogate hosts and S. enterica serotypes (e.g. S. Typhimurium) 
suggest that tissue invasion occurs predominantly through M cells on Peyers patches in 
the terminal ileum [61]. Tissue invasion drives a potentially close encounter with the 
immune system. However, S. Typhi is an immuno-modulatory pathogen which goes to 
great lengths to avoid detection by the immune host defenses. S. Typhi multiplies in 
mononuclear phagocytic cells before being released into the bloodstream and spreads 
throughout the body. As a result of this silent primary bacteraemia, the pathogen 
reaches one of several organs, such as spleen, liver and bone marrow (probably within 
24 hours after ingestion), through the reticulo-endothelial system [62]. The infection 
eventually localizes to the gall bladder where the internal transmission cycle is 
completed as S. Typhi organisms are shed in bile. Chronic carriers are a major public 
health problem as S. Typhi persists within the gallbladder and the bacteria can be shed 
in faeces for years which subsequently may contaminate food or water and initiate 
transmission to other people [63]. Whilst these mechanisms have never been proven for 
typhoid, it is clear that by utilizing SPI-1, SPI-2 and other virulence factors that S. 
Typhi has predominantly forsaken the luminal lifestyle of most enteric bacteria.
In contrast with S. Typhimurium, which can (but not routinely) disseminate from the 
intestine and cause bacteremia with a rapid onset of symptom which progresses to
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sepsis shock, S. Typhi has a gradual onset of symptoms and does not rapidly progress to 
hypotension [64]. A recent study conducted on S. Typhimurium has shown that 
expression of the Vi capsule but not expression of the TviA regulatory protein (a protein 
encoded by a gene in the ViaB locus which regulate the expression of Vi capsule) 
reduced tumor necrosis factor alpha (TNFa) and interleukin 6 (IL-6 ) in murine bone 
marrow derived macrophages. The same study also found that the Vi capsule prevented 
both in vitro and in vivo recognition by TLR-4 and the expression of interleukin 8 (IL- 
8) and FliC was modulated by the TviA regulatory protein but not by the Vi capsular 
antigen [65]. These data suggest a role for flagella gene regulation in the process of 
human adaption that is seen in S. Typhi.
1.9 The evolution and genomics of Salmonella Typhi
In 2001, the genome sequence of an S. Typhi strains from southern Viet Nam was 
sequenced and it represented the first genome of the Salmonellae to be sequenced in its 
entirety. The organism was named CT18 and was found to encode over 4,000 genes and 
contain multiple insertions and deletions when compared to E. coli K12, these insertions 
ranged from individual genes to large islands. The genome sequence additionally 
identified over two hundred pseudogenes (inactivated genes) [6 6 ], demonstrating that 
the organism is in an ongoing state of evolution. Gene acquisition and somewhat more 
surprisingly gene degradation appear to have generated the host restricted pathogen we 
find circulating in human populations today [67]. The CT18 genome sequence also 
contained two plasmids, named pHCMl and pHCM2. pHCMl was a 218,160bp incHl 
plasmid that conferred multiple antimicrobial resistance. Whilst pHCM2 was a 106,516 
bp plasmid and was believed to phenotypically cryptic but demonstrated some sequence 
homology with the Yersinia pestis virulence-associated plasmid, pMTl [66].
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It is understood from comparing DNA sequences from related bacteria that S. Typhi has 
been in existence for approximately 50,000 years since evolving from its last common 
ancestor [6 8 ]. Using single nucleotide polymorphisms (SNPs) to identify genetic 
variation demonstrated that evolution from the last common ancestor probably arose on 
the African continent [69]. Whilst sequence diversity within the genome may be 
limited, the organisms are known to exhibit some genetic re-arrangements and some 
areas of the genome which may demonstrate diversity due to the acquisition of gene 
clusters, this is described as genome plasticity [67,69].
Defining the circulating population is particularly challenging for studies of S. Typhi, as 
this organism is monophyletic and sequence diversity is limited [70]. This was 
demonstrated by the sequencing of 199 gene fragments from a global collection of 105 
S. Typhi isolates detected only 82 SNPs [71] . This study described the molecular 
epidemiology of various S. Typhi genotypes and generated a population structure on the 
basis of the evolution of nucleotide variation. Fifty-nine haplotypes of S. Typhi were 
found to circulating globally, of which one haplotype, named H58 was found to be the 
dominant genotype circulating in southern Asia in recent years. There is a strong 
correlation of the H58 haplotype with the presence of mutations in the topoisomerase 
genes related to nalidixic acid resistance [71]; this is presumed to be related to 
antimicrobial selective pressure on the population [71]. However, H58 is not a unique 
genotype related to a nalidixic acid resistant phenotype, but represents a clonal 
population expansion. Often local populations of S. Typhi consist of a mixture of 
nalidixic acid sensitive and resistant organisms of the same haplotype [71,72].
The formation of a rooted phylogenetic tree based upon these SNPs permitted greater 
understanding of the global population of S. Typhi and provides a potential system for
16
Introduction
tracking the pathogen in an endemic setting. By assaying the varying SNP loci Baker et 
al. were able to identify several genetically distinct S. Typhi haplotypes circulating in 
an urban area of Jakarta, Indonesia and demonstrate the clonal nature of antigenic 
variation within the local population [73].
Only limited studies have been performed on the S. Typhi strains circulating in Viet 
Nam. Roumagnac et al found four haplotypes (HI, H50, H58 and H63) of S. Typhi 
strains in Viet Nam. Of these haplotypes, two (HI and H50) have been persisted in the 
population for at least 37 years until 2004. As in other locations the H58 haplotype with 
mutations in topoisomerase genes is the predominant strain currently in southern Viet 
Nam [71]. A potential hypothesis explaining the clonal expansion of H58 is the use and 
selective pressure of antimicrobials in Viet Nam. Throughout the 1990’s this haplotype 
became dominant and spread to other locations, however, this is unproven and spread 
may be unrelated to use of fluoroquinolones.
More recently, high-throughput sequencing technologies were used to determine the 
genomes of 19 S. Typhi isolates that were selected to maximize diversity according to 
available variation data. This study revealed nearly 2,000 additional SNPs within the S. 
Typhi population, providing additional loci for SNP typing of clinical isolates. 
Importantly, the study detected relatively few examples of other forms of genetic 
variation such as insertions and deletions (fewer than 30 in total), which could 
potentially be used as phylogenetically informative markers for studying S. Typhi 
populations [69].
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1.10 Antimicrobial agents and antimicrobial resistance mechanisms
The management of typhoid fever is relatively straightforward, as all typhoid patients 
are treated with antimicrobials and many patients can be treated effectively as 
outpatients. For those that are treated as inpatients, good nursing care, adequate 
nutrition, attention to fluid and electrolyte balance and prompt treatment of complicated 
cases are vital to prevent mortality. Appropriate antimicrobial theriapy effectively 
reduces the illness’s morbidity, mortality and complications. The deployment of 
appropriate antimicrobials is essential for the treatment of this infection [74].
Typhoid fever was first treated by chloramphenicol, ampicillin and trimethoprim- 
sulfamethosazole in the 1960’s. The emergence of multidrug resistant S. Typhi strains 
which resisted to chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole 
urged the need of more effective antimicrobials. Fluoroquinolones have been used as 
the drugs of choices for typhoid treatment with third generation cephalosporins and 
azithromycin as alternatives [74].
1.10.1 First line antimicrobials
Chloramphenicol was introduced in 1948 and shows remarkable effectiveness for 
enteric fever treatment worldwide [75]. Chloramphenicol binds to the 50s bacterial 
ribosomal subunit and inhibits bacterial growth by inhibiting protein synthesis. In the 
1960s, S. Typhi strains with plasmid-mediated resistance to chloramphenicol appeared 
and later these strains became widespread in many endemic countries in America and 
South East Asia, urging the need for alternative agents [75].
Amoxicillin and trimethoprim - sulfamethoxazole became the mainstay of typhoid 
treatment in 1970’s [76]. Amoxicillin disrupts the synthesis of cell wall mucopeptides
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during active multiplication, resulting in bactericidal activity against susceptible 
bacteria. Trimethoprim - sulfamethoxazole inhibits bacterial growth by inhibiting 
dihydrofolic acid synthesis.
Chloramphenicol, amoxicillin and co-trimoxazole are appropriate treatments for 
typhoid fever in areas where the bacteria are still susceptible to these drugs. The 
advantages of these drugs are that they inexpensive, widely available and rarely 
associated with side effects. These antimicrobials have a high cure rate (95 %), a low 
relapse rate (1 - 7 %) and a rate of convalescent excretion of between 2 - 10 % [9]. 
According to the WHO, 1 - 5 % of untreated typhoid patients progress to become 
chronic carriers, this is reduced by treatment with first line antimicrobials [19].
Cefotaxime and ceftriaxone, which are third generation cephalosporins, arrest bacterial 
cell wall synthesis and hence inhibit bacterial growth. These antimicrobials have high 
power in vitro against S. Typhi and other Salmonellae and have acceptable efficacy in 
the treatment of typhoid fever [75].
1.10.2 Fluoroquinolones: the structures, mode of action and resistance
mechanisms
Studies have shown that fluoroquinolones are safe and effective in fluoroquinolone- 
susceptible, uncomplicated typhoid fever [9]. Fluoroquinolones and 4-quinolones are 
derivatives of nalidixic acid, which was the first analogue released for treatment of 
urinary tract infections in 1962, this group was the first man-made class of 
antimicrobials [77].
19
Introduction
Nalidixic acid shows a narrow antibacterial spectrum; it has a short half-life but high 
protein binding efficiency [78]. Norfloxacin, the first generation of fluoroquinolone, 
was introduced with a piperazine at position C7 (with respect to nalidixic acid), it 
demonstrates broader Gram negative activity, with a longer half life but less protein 
binding capabilities when compared to nalidixic acid [78]. The second generation of 
fluoroquinolone was created with the addition of fluorine at position C6 , thus increasing 
the activity against the target (DNA gyrase) and having increased penetration into the 
bacterial cell [78]. The three-ringed benzoxazyne fluoroquinolones (ofloxacin and 
perfloxacin) are connected at positions C8 and N1 with a bridge which contains an 
oxygen molecule and two carbon atoms [78]. While ofloxacin contains stereoisomers, 
R- and S-enatiomers, levofloxacin has only S-enantiomer that is 10- to 50- fold more 
potent than the R-enantiomer. The cyclopropyl moiety group attached at position N 1 of 
ciprofloxacin enhances bactericidal potency compared to the older fluoroquinolone 
generations [78], this was proved in animal model of infection [79]. Amongst the third 
generation of fluoroquinolones, gatifloxacin with a methoxyl group at C8 has greater 
potency against Gram-positive bacteria by targeting both topoisomerase II and IV and 
also has good activity against anaerobic bacteria. Trovafloxacin, moxifloXacin and 
gemifloxacin are fourth generation fluoroquinolones and have potent activity against 
anaerobes and increase activity against pneumococci [78,80-82].
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Figure 1.1 (Fluoro)quinolones representatives structures
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1.10.2.1 Gyrase and topoisomerase IV as therapeutic targets
The quinolones and fluoroquinolones target the topoisomerase enzymes in the bacterial 
cell [83]. Topoisomerases are essential enzymes in DNA in replication, transcription 
and other cellular functions in bacteria [84]. Topoisomerases are categorized into 2 
groups: type I and type II [84]. Type I enzymes rapidly break the DNA strands 
individually. Type II enzymes transiently break the pair of strands in the DNA double 
helix in concert by a dimeric enzyme molecule [84]. The two types of topoisomerases 
can be further divided into four subfamilies: I A, IB, IIA and IIB. Members of the same 
subfamily are structurally and mechanistically similar, whereas those of different 
subfamilies have distinct properties [85].
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The topoisomerases are enzymes that maintain genomic integrity during replication by 
forming a covalent linkage between the active site tyrosine and the newly generated 
DNA termini via phosphotyrosyl bonds [83]. The covalent topoisomerase - DNA 
cleavage complexes are fleeting catalytic intermediates, but these breakages are of 
potentially great harm to the genome integrity [83], Shortly after the discovery of these 
enzymes, the DNA gyrase and topoisomerase IV (topo IV) proteins were recognized as 
targets for antimicrobials.
1.10.2.2 Structures and functions of gyrase and topoisomerase IV
DNA gyrase and topo IV are type IIA topoisomerases, these enzymes are present in all 
bacteria [83,85]. Although, gyrase and topo IV only share approximately 40% amino 
acid sequence homology [8 6 ], they play fundamental but distinct roles in the bacterial 
cell. DNA gyrase is involved primarily in supporting nascent chain elongation during 
replication of the chromosome, whilst topo IV separates the topologically linked 
daughter chromosome during the terminal stages of DNA replication [83].
DNA gyrase is unique among type IIA enzymes in that it can introduce negative 
superhelical turns to DNA. Additionally, DNA gyrase can play a role during 
chromosome decatenation [83]. DNA gyrase requires ATP as a cofactor for activity 
[87]. The protein is a tetramer with two A and two B subunits which are encoded by 
gyrA and gyrB gene respectively [87]. The gyrA gene maps at 50.3 minutes on the E. 
coli chromosome and encode a 97 kDa protein (875 amino acids), whereas gyrB maps 
to 83.5 minutes and encodes a 89.9 kDa protein (804 amino acids). Topoisomerase IV is 
encoded by the parC  and parE  genes. The parC and parE  genes map to 68.1 minutes 
and encode an 83.7 kDa protein and map to 68.3 minutes and encode 70.2 kDa protein
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respectively. The ParC and ParE proteins are highly homologous with the GyrA and 
GyrB proteins.
The GyrA and ParC proteins are the subunits responsible for DNA binding at the 
cleavage and re-ligation reaction. They execute cleavage and re-ligation processes by 
forming a covalent phosphotyrosine bond between an active site tyrosine and the DNA 
phosphate backbone. The tyrosine active site is located at the amino acid residue 122 in 
GyrA and 120 in ParC. Both gyrase and topo IV cleave DNA in a site-specific manner, 
but site recognition is distinct between these two enzymes [83].
DNA gyrase was first recognized by its unique ability to introduce negative supercoils 
into DNA, which is a requirement for the negatively supercoiled DNA template for 
initiation of the replication bubble. DNA gyrase is wrapped around the enzyme in a 
positive supercoil. Subsequently, one segment of the duplex DNA is passed through 
another via DNA breakage and rejoining [83]. Topo IV also catalyzes the breakage and 
rejoining of DNA strands but does not wrap DNA during functional activity [83].
1.10.2.3 Mechanisms of quinolone action
As mentioned above, DNA gyrase is the primary target for the quinolones. The most 
potent group for activity of the quinolones is the cyclopropyl group at position N 1 in 
ciprofloxacin [8 8 ]. At position C5, substitutions may increase activity due to enhanced 
permeability rather than to increase potency against the DNA gyrase [89]. Whilst the 
addition of a fluorine at C6 substantially improves potency, substitutions at C7 and C8 
alters potency against DNA gyrase [90,91]. Among various modes of quinolones 
binding to DNA, the interaction with single stranded DNA, mediated by Mg+ correlates 
strongly with drug potency [92]. Quinolones bind to the DNA phosphodiester backbone
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via a Mg+bridge, which is coordinated by the C-3 and C-4 groups and requires guanine 
specific contact at the 4-base region downstream of the gyrase cleavage site. T he 
presence of guanines is important for higher-affinity interaction. In other words, the 
greater the affinity for single stranded DNA, the greater the potency of the quinolones 
[92].
1.10.2.4 Bactericidal activity of fluoroquinlones
Norfloxacin rapidly kills E. coli within one or two hours of exposure, then slows in 
activity on reaching a killing plateau [93]. The sub-population of surviving cells 
represents the persistant proportion of the population. Cells are killed by forming 
bacterial filaments, swelling (losing membrane integrity) and lysis [94]. The rate of 
bacterial killing by exposure to quinolones increases proportionally with drug 
concentration and eventually decreases at higher drug concentrations (30 to 60 times the 
minimal inhibitory drug concentration). A decrease in activity at higher concentrations 
is called the paradoxical bactericidal effect [95]. Therapeutically, the bactericidal 
activity of quinolones is decreased by chloramphenicol, rifampin, nutrient starvation 
and other treatments that also inhibit protein synthesis [9 5 ].
1.11 Molecular mechanisms of antimicrobial resistance
The resistance of bacteria to antimicrobials can occur either due to mechanisms driven 
by the functionality carried on the core genome (intrinsic) or be acquired from 
additional genetic sources (plasmids or bacteriophages). Acquired antimicrobial 
resistance genes are generally carried on plasmids, integrated into transposons or 
integrons and often can be transferred naturally from donor to recipient cells by the 
three mechanisms of DNA transfer, namely transformation, transduction or conjugation 
[96].
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In principle, bacteria have three commonly described systems of initiating antimicrobial 
resistance [97]. The first process involves enzyme secretion from the bacterial cell. 
Organisms can produce enzymes that may degrade, destroy or alter the chemical agent. 
These enzymes break antimicrobials into small molecules that have little or no 
bactericidal effect on the bacterial cells. For example, those bacteria that are resistant to 
penicillins and cephalosporins can produce (3-lactamase enzymes that break down these 
chemicals and prevent activity. In addition, other secreted enzymes can modify some 
antimicrobials. These modifying enzymes convert an activated antimicrobial into an 
inactivated variant. An enzyme produced by Streptomyces spectabilis which can 
acetylates the 2 '-amino group of the hexose ring of gentamicin is an example of the 
modifying enzymes initiating resistance [98]. Limiting antimicrobial accumulation 
inside the bacterial cell is the second common resistance mechanism. Some membrane 
proteins of bacteria can be under-expressed by the bacterial cell to protect cells from 
chemicals entering the cell. Additionally, active efflux-pumps produced by protein over 
expression may additionally limit the bactericidal activity of the antimicrobial by 
actively ejecting the chemical agent from within the cell. Active antimicrobial efflux 
mediates resistance to tetracylines, chloramphenicol and the fluoroquinolones. The third 
resistance mechanism in bacteria is the ability of the organism to modify the target of 
the antimicrobial. For example, bacteria can modify ribosomes, metabolic enzymes or 
proteins involved in DNA replication and cell wall synthesis. Some of these three 
mechanisms can occur in tandem and often multiple mechanisms are required for a 
substantial increase in resistance levels.
Generally, many enteric bacteria are highly adaptable when placed under strong 
selective pressure. Antimicrobial resistant organisms can be positively selected on the 
basis of the antimicrobial (and other chemicals) they come in close proximity to.
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Whether the organism produces a specific enzyme to destroy or alter antimicrobials, 
prevents drug transport into the cell or regulates the expression of a specific protein, all 
these mechanisms play a major role in bacteria survival, evolution and adaptation.
1.12 Fluoroquinolone resistance
Mechanisms of quinolones resistance can occur by all of the three main mechanisms of 
resistance as illustrated in Figure 1.1 [99], The commonest mechanisms are mutations in 
the target site (generally the gyrA gene), efflux pumps and reduced permiability to 
chemicals, however more recently, fluoroquinolone resistance mechanisms related to 
plasmid and antimicrobial - modifying enzymes have been demonstrated [100].
4. Efflux pump
3. Reduced  
perm iability
1. Mutations
2. Plasmid-
mediated
protections
Gram (-) Gram (+)
Figure 1.2 The three mechanisms of fluoroquinolone resistance
A schematic diagram of the three mechanisms of fluoroquinolone resistance was 
modified from Bambeke et <3 /. [82]. These are (1) mutations in the target genes, (2) 
plasmid mediated resistance enzymes and reduced antimicrobial accumulation by (3) 
reduced permeability and (4) efflux pump enhancement.
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1.12.1 Alterations in the gyrase and topoisomerase IV target enzymes
Mutations in the gyrA gene account for first step fluoroquinolone resistant mutants 
whilst mutations in the parC  gene are second step fluoroquinolone resistant mutants 
[101]. Resistance mutations can also occur in the gyrB gene, often to intermediate [102] 
and sometimes to low quinolone concentrations [103]. The most common mutations 
causing fluoroquinolone resistance in S. Typhi occur at positions 83 and 87 in gyrA 
gene and at position 80 in the parC  gene [104], whilst no mutations in gyrB gene or the 
parE  gene have yet been detected in the S. Typhi population.
1.12.2 Alteration in drug permeability
To reach their targets in the cell cytoplasm, fluoroquinolones must cross the outer and 
cytoplasmic membrane. Depending on their hydrophobicity, fluoroquinolones pass 
through the outer membrane either directly through the lipid bilayers (nalidixic acid) or 
through water filled protein pores, the porins (ofloxacin, ciprofloxacin) [99,105]. 
Resistance due to reduced drug accumulation involves at least one or two different 
mechanisms. The first mechanism is an energy - independent passive mechanism which 
is based on structural alterations or reduced expression of porin proteins responsible for 
quinolone passage through the outer membrane [106]. The second mechanism requires 
energy and involves active efflux of the quinolones [107,108]. Efflux as a mechanism 
of antimicrobial resistance was originally described for tetracyclines [109] and is also 
described for fluoroquinolones. This resistance mechanism is related to mutations in the 
endogenous ArcAB - TolC mediated membrane efflux pump [110]. Thus, reduced porin 
channels in combination with enhanced efflux capabilities of AcrAB complete the 
resistance pathway from cytoplasm or inner membrane to the exterior of the cell [111].
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1.13.1 Plasmid mediated quinolone resistance
Plasmid mediated resistance to quinolones was first identified in Shigella spp. and was 
considered rare [112]. However, since identification, plasmid mediated quinolone 
resistance was confirmed in Klebsiella pneumoniae in 1998 and is now common in 
other enteric bacteria [113]. The gene family responsible for plasmid mediated 
quinolone resistance is the qnr family. These genes encode the Qnr proteins, which 
have 218 amino acid residues and belong to the pentapeptide repeat family [114]. The 
Qnr proteins share homology with another pentapeptide, McbG, which protects the 
DNA gyrase from microbin B17 action. The Qnr proteins probably protect the DNA 
gyrase from inhibitory effect of the fluoroquinolones [114]. Hypothetically, the 
formation of a Qnr-gyrase complex occurs before the formation of cleavage complex. 
Another transferable gene responsible for fluoroquinolone resistance is the aac (6 ) - lb 
gene. The aac (6 ) - lb gene encodes an aminoglycoside acetyltransferase that is capable 
of acetylating and thus reducing the activity of certain fluoroquinolones. This gene 
solely does not stimulate a high level of resistance; however, when combined with other 
plasmid encoded resistance mechanisms (such as the qnr genes) it leads to a higher 
resistance level.
S. Typhi strains with reduced susceptibility to fluoroquinolone are now common in Asia 
and can be identified on microbial culture by resistance to nalidixic acid. Although 
fluoroquinolones are considered to be an effective antimicrobial with rapid therapeutic 
response, fluoroquinolone resistance has been reported in typhoid endemic regions, 
including India and Pakistan [115].
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1.13 Determination of antimicrobial resistance
1.13.1 Measurement of resistance phenotype
Antimicrobial resistance is evaluated via measurement of resistance and killing 
capabilities of bacteria in vitro. For determination of the level of susceptibility or 
resistance to quinolones, disk susceptibility is efficiently used for screening of clinical 
isolates. Agar, broth dilutions and E - test for the determination of MICs are 
straightforward methods used in clinical microbiological laboratories. Such methods 
have also been used for distinguishing quinolone sensitive and quinolone resistant 
mutants [111].
The determination of bactericidal activity of quinolones is performed by measurement 
of colony - forming units (CFU) by dilution of cells and plating on nutrient agar media. 
Comparing killing effects of strains by chemicals (time - kill analysis) is the most 
effective method to measure bactericidal activity. The time - kill technique correlates 
with therapy and cure rate in patients and is a reliable means of tolerance determination 
and it useful for identifying any synergy or antagonism between two antimicrobial 
agents [116].
Bactericidal activity can also be determined by broth and agar dilution methodology. 
The agar dilution method immobilizes inoculums of bacteria in an agar - gel matrix and 
depends upon inactivation of the antimicrobial agent in order to determine regrowth of 
viable organisms after a defined period of incubation. The broth dilution method is 
performed by a standard broth dilution technique, as used for MICs. However, in the 
later stages of the experiment, sampling of dilutions with no visible growth is performed 
with a calibrated device to determine the concentration at which 99.9 % of the final 
inoculum is killed [116].
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1.13.2 Determination of resistance mechanism
Determination of resistance caused by alterations in DNA gyrase can be accomplished 
in several ways. Identification of mutations conferring resistance is limited to 
laboratories which have the capabilities to perform molecular methods. Association of 
quinolone resistance to genetic loci linked to gyrase encoded gene may be accomplished 
by conjugation and transduction methods. It is also possible to introduce plasmid clones 
containing gyrA or gyrB genes from susceptible wild type strains into resistant strains or 
vice versa by transformation [117,118]. The cloning of resistance genes is a more 
definitive method and may also be accomplished by direct selection for quinolone 
resistance, using strains with altered chromosomal gyr genes [119]. Direct 
demonstration of enzyme activities can be determined by purification of the bacterial 
DNA gyrase. Assays of DNA gyrase activities and their inhibition by quinolones have 
been performed using purified DNA gyrase. An indirect method has been used to 
identify the presence of an altered DNA gyrase in quinolone resistant mutants. This 
method involves a comparison of the concentration of quinolone inhibiting ATP - 
dependent replicative DNA synthesis in treated mutant and wild type cells [95].
The determination of resistance caused by altered permeation can be identified by 
characterization of outer membrane proteins or measurement of quinolone 
accumulation. A reduction of outer membrane proteins can be checked by the use of 
lytic bacteriophages that attach specifically to proteins on the bacterial cell surface. The 
commonest method used for this is the ‘spot test’ in which bacteriophage exhibit a 
failure to initiate lysis or show a decreased efficiency of plaque formation with mutants 
when there are substantial decreases in appropriate respective porin.
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1.14 Aims of study
The aims of this study are to describe and then further investigate the resistance patterns 
of S. Typhi organisms isolated in Viet Nam and in other localities in Asia. Furthermore, 
here I determine the common resistance mechanisms of S. Typhi to fluoroquinolones in 
Asia and the effect of these mechanisms on the bacterial population. The specific aims 
of this work are as follows.
1. To describe the antimicrobial susceptibility patterns of S. Typhi in Asia
2. To investigate the molecular mechanisms of nalidixic acid resistance and reduced 
susceptibility to fluoroquinolone in S. Typhi isolates and to evaluate the effect different 
mutations have on fluoroquinolone susceptibility and MIC.
3. To reconstruct the gyrA and parC mutations in S. Typhi BRD 948 (an attenuated S. 
Typhi strain) and characterize the effect on phenotype. Phenotypic screening with 
respect to MIC testing, time - kill analysis and biological costs experiments.
4. To genotype fluoroquinolone resistant and sensitive S. Typhi isolates using MLPA 
(Multiplex Ligation dependent Probe Amplification) in comparison to the GoldenGate 
SNP typing technique. This will permit the development of a simplified typing scheme 
that can be applied universally to S. Typhi populations and can be used in resource poor 
settings.
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2i Materials and Methods
2.1 Bacterial strain collection
2.1.1 Clinical isolates
The S. Typhi strains used in this study were isolated from clinical samples from 
research programmes conducted in Viet Nam from 1993 to 2005 and from seven other 
Asian countries from 2002 to 2006 (Table 2.1).
Table 2.1 The S. Typhi collection from Viet Nam and other Asian countries used
for analysis in the study
No Country Y ear Num ber of strains
1 Bangladesh 2003 40
2 China 2002 21
3 India_2003 2003 23
4 India_2006 2006 259
5 Indonesia 2002 17
6 Pakistan 2002-03 34
7 Laos, Mahosot Hospital 2002-03 50
8 Nepal- Patan hospital 2003 149 .
9 Central Viet Nam 2002-04 47
10 Southern Viet Nam 1993-2005 1388
Total 2028
2.1.1.1 S. Typhi isolated in southern Viet Nam from 1993 to 2005
One thousand three hundred and eighty eight S. Typhi strains were isolated 
consecutively from patients with uncomplicated typhoid fever during prospective 
hospital-based clinical studies between 1993 and 2005 conducted at four hospitals 
located in southern Viet Nam, namely Dong Thap Provincial Hospital, Dong Nai 
Pediatric Hospital, An Giang Provincial Hospital and the Hospital for Tropical 
Diseases, Ho Chi Minh City. Results from these studies have been reported in several 
publications [120-127].
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2.1.1.2 S. Typhi isolates from eight Asian countries from 2002 to 2006
The Asian isolates used in this study were collected in a several locations from a 
number of investigations. These locations and strains are described in turn. One hundred 
and forty-nine S. Typhi isolates were collected between March and April 2003, during a 
hospital-based descriptive study at Patan Hospital, Kathmandu, Nepal [20]. Fifty 
isolates were collected consecutively during a clinical trial in 2002 and 2003 at the 
Wellcome Trust-Mahosot Hospital, in the Lao People's Democratic Republic [128]. One 
hundred and eighty-two S. Typhi were collected as part of population-based prospective 
surveillance studies conducted by multiple teams in collaboration with the International 
Vaccine Institute (IVI), Seoul, South Korea [129]. These surveillance sites included 
townships (China, Viet Nam), specific temporary urban settlements (Bangladesh, 
Pakistan, and India) and an impoverished urban sub-district (Indonesia). In the 
collection contributed by the IVI, forty isolates were collected between February and 
December 2003 in a temporary urban settlement in Dhaka, Bangladesh [130]. Twenty 
one isolates were collected during 2002 in Hechi city, Guang Xi, China; 23 strains were 
collected from May to July 2003 in an urban area in Kolkata, West Bengal, India along 
with 259 strains collected across India in 2006; 17 isolates were collected from July to 
September 2002 in North Jakarta; Indonesia; 34 strains were isolated between January 
2002 and March 2003 in one slum area in Karachi, Pakistan and 47 isolates were 
collected between July 2002 and September 2004 in Hue city, central Viet Nam.
All S. Typhi isolates were collected from febrile patients during the indicated period and 
from geographically contiguous areas. The isolates were believed to be an accurate 
representative of the strains circulating in the population they came from.
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2.1.2 Non - clinical isolates
2.1.2.1 S. Typhi BRD 948
S. Typhi BRD 948 was a gift from the Sanger Institute in Cambridge, United Kingdom.
S. Typhi BRD 948 is a laboratory mutant strain which is certified for use at containment 
level 2 and has been described and used extensively [131]. S. Typhi BRD 948, is a 
derivative of S. Typhi Ty2 with deletions in the aroC, aroD and htrA genes. This S. 
Typhi strain was used as the parent S. Typhi in mutation reconstruction and the in vitro 
selection of mutant experiments. The aroC and aroD genes encode enzymes of the 
aromatic amino acid pathway, thereby rendering the bacteria auxotrophic for para- 
aminobenzoic acid (PABA) and dihydroxybenzoate (DHB). The htrA genes encodes a 
heat shock protein (DegP), when mutated in Salmonella, the mutant is less virulent 
because of impaired ability to survive and replicate in host tissues [132,133]. The S. 
Typhi BRD 948 strain has been shown to be safe for genetic manipulation and so 
overcomes any potential issues associated with the introduction of antimicrobial 
resistance genes into wild type strains [118].
2.1.2.2 The Escherichia Coli (E. coli) strains
E. coli CC118A./?zr and E. coli SY  321 Xpir were used as hosts for the suicide vector 
pJCB12 and its derivatives. These strains, which contain a functional pir gene in the 
chromosome, are essential for the replication of the recombinant plasmids generated in 
the mutagenesis experiments.
2.1.3 The suicide vector pJCB 12
Constructed mutants were made using the suicide vector pJCB12 (Figure 2.1). This 
suicide vector is a derivative of the vector pDM4, and has more than 50 % of the 
nonfunctional DNA removed. The vector pJCB12 retains the orz'R6 K origin, mobRP4
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mobilization origin, multiple cloning sites, and the cat and sacB genes. In particular, the 
sacB gene en codes levansucrase, this chemical converts sucros e to levan which is 
harmful to the bacteria [134]. Thus, bacteria containing this suicide plasmid cannot 
survive on media containing sucrose. The cat (chrolramphenicol acetyl transferase) 
gene which encodes chloramphenicol acetyl transferase enzyme inactivates 
chloramphenicol by formation of mono -  and diacetylated derivatives [134]. Therefore, 
bacteria containing functioning cat gene are resistant to and can be selected on media 
containing chloramphenicol.
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pW T gyrA
4179  bp
oriR6K
N-gyrA 
Asp87  
G>A in NaIR 
C>A in NaIR 
Ser83
R e p e a t  reg ion
47125
sa c B
Figure 2.1 A schematic representation of the plasmid vector pJCB12 containing a 
mutant gyrA loci containing an amino acid substitution
pJCB12 and derivative plasmids contain the cat gene for chloramphenicol resistance 
and the sacB gene which is responsible for the counter-selection of recombinants. 
oriR6K (R6K origin) is a replication origin for recipients. Rpt (Repeats) 1 to 7 are DNA 
polymerase binding sites for replication. The mob (mobilization) region is necessary for 
plasmid mobilization into recipient strains. IR (Inverted Repeat) is the inverse sequence 
of the polymerase binding site. oriT  is the origin of transfer which is for functional 
transfer of the plasmid from a host to a recipient during bacterial conjugation.
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2.2 Identification
All S. Typhi isolates were isolated from blood, bone marrow or stool cultures from 
patients who were admitted to the hospitals in the locations outlined previously. The 
process was firstly to identify the bacteria at the time of sample collection using routine 
laboratory methods including screening bacteria on MacConkey agar (MC) (Oxoid, 
UK) and Xylose Lysine Deoxycholate agar (XLD) (Sigma-Aldrich, Switzerland). S. 
Typhi isolates were recognized as a colourless and transparent colony on MacConkey 
agar (Figure 2. 2a) as S. Typhi cannot utilize lactose as a carbohydrate source. On XLD 
agar, S. Typhi is seen as red colonies with a black centre (Figure 2.2b). This is the result 
of pH change because S. Typhi strains exhaust the xylose and decarboxylate the Lysine. 
Therefore, S. Typhi strains produce sulphide on XLD agar which is recognized by a 
blackening in the colony centre. All isolated colonies were then subjected for the short 
biochemical and serological testing.
Figure 2.2 S. Typhi morphology on selective media
(a) S. Typhi morphology on MacConkey agar, seen as a colourless and transparent 
colony.
(b) S. Typhi morphology on XLD agar, S. Typhi can be recognized as red colonies with 
black centre.
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2.2.1 Serological agglutination method
Serological agglutination was carried out using specific agglutination antisera. S. Typhi 
strains were defined when positive agglutinations occurred between cell suspension and 
poly 0 , O9 and Vi (Murex, Dartford, UK) antisera. If O9 was positive but Vi was 
negative, the colony was then inoculated and re - tested after grow in 1 mL of Luria 
Bertani media overnight.
One drop of agglutinating sera of S. Typhi was placed on a clean glass slide. One 
colony of test strain which was picked with a loop from nutrient agar plate was mixed 
slowly with the agglutinating serum. When fully mixed, the slide was rotated for 5-10 
seconds. Agglutination was observed by the naked eye. Positive and negative controls 
were also performed concurrently.
2.2.2 Short biochemical test
Tests were performed in parallel using specific media; S. T yphi was identified as 
organisms with weak sulphite production, glucose but not lactose fermentation, no gas 
production in Kliglar iron agar, citrate and urea and indole negative and motility 
positive (Figure 2 . 3). Isolates with unclear biochemical characteristic were confirmed 
by the API 20E (Biomerieux, Paris, France).
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Figure 2.3 A short set of the biochemical testing for S. Typhi identification
(a) Biochemical testing consistent with the identification of S. Typhi. (b) The same 
biochemical testing as in (a) but without bacterial inoculation. Tests are as follows, (1) 
Methyl red test; methyl red is added after an overnight bacterial culture, if the organism 
can ferment glucose, acid is produced and the media turns red, S. Typhi ferments 
glucose and therefore, generates a positive result. (2) Urea utilization; the yellow colour 
will turn to pink after a positive reaction. S. Typhi cannot not use urea as a substrate for 
metabolism and is therefore, negative. (3) Citrate utilization; S. Typhi can be 
distinguished from other Salmonella by not being able to utilize citrate. The green will 
turn to blue after a positive reaction. (4) Motility test, S. Typhi is motile in liquid media. 
The motility test detects hydrogen sulphide production from a sulphur source medium. 
Motile organisms produce hydrogen sulphide which reacts with ferrous sulfate and is 
precipitated as a black line in the media. (5) The KIA, Alkaline / acid formation test; S. 
Typhi can utilize glucose but not lactose, in KIA media, S. Typhi changes the butt 
colour to yellow (acidity) due to the acid production, the same is not observed in media 
due to ammonia maintaining the overall alkalinity. Additionally a small amount of FfS 
can be observed in the butt.
2.2.3 The API 20E
The API 20E is a biochemical identification system for the Enterobacteriaceae. The 
system consists of a plastic strip with 20 microtubes containing dehydrated substrate of 
ornithine, citrate, hydrogen sulphide, urea, tryptophane, indole, voges-proskauer, gelatin 
glucose, manitol, inositol, sorbitol, rhamnose, saccharose, melibiose, amygdaline and 
arabinose (Figure 2. 4). The procedure was according to the manufacturer’s 
recommendations (Biomerieux). Briefly, test substrates were reconstituted when 
inoculated with a suspension of the test organism in sterile saline. After inoculation the 
cupula sections of arginine, lysine, ornithine, TfS, and urea microtubes were overlaid 
with mineral oil. The incubation box was prepared by putting 5 mL of sterile water into 
the honey combed wells of the tray. The strip was placed in an incubation tray
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containing water and the colony emulsified in sterile saline was transferred to the 
cupules After 24 hour incubation at 37 °C, the strip was read by referring to the 
interpretation table. Reagents were added into the VP, TDA, indole, nitrite cuptules and 
the results were recorded. The 21 test results, which include oxidase detection which 
detected cytochrome c oxidase, is converted to a seven digit profile using the octal 
coding system following the manufacturer’s instruction. Identification was made 
through the analytical profile index by the use of a differential chart. Oxidase test was 
perfonned separately.
By API 20E, S. Typhi was detected while giving positive reaction to LDC and H2S. It 
utilized glucose (GLU), manitol (MAN), sorbitol (SOR), melibiose (MEL) and 
arabinose (ARA) as metabolite resources, and S. Typhi was negative to oxidase test. S. 
Typhi was coded as 4404540 by the definition manual (Bio Merieux) (Figure 2. 4).
H2S
Figure 2.4 Representative biochemical characteristic of S. Typhi using API 20E 
test
The API20E test strip includes reactions for, ONPG (b-galactosidase), ADH 
(decarboxylation of the amino acid arginine by arginine dihydrolase), LDC
(decarboxylation of the amino acid lysine by lysine decarboxylase), ODC
(decarboxylation of the amino acid ornithine by ornithine decarboxylase), CIT
(utilization of citrate as sole carbon source), H2S (hydrogen sulfide), URE (urease),
TDA (tryptophan deaminase), IND: (tryptophanase, Indole is detected by addition of 
Kovac's reagent), VP (Voges-Proskauer test for the detection of acetoin (acetyl 
methylcarbinol) produced by fermentation of glucose), GEL (gelatinase which liquefies
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gelatin) , GLU (fermentation of glucose), MAN (mannose), INO (inositol), SOR 
(fermentation of sorbitol) RHA (fermentation of rhamnose), SAC (fermentation of 
sucrose), MEL (fermentation of melibiose), AMY (fermentation of amygdalin), ARA ( 
fermentation of arabinose) and OX (cytochrome oxidase).
2.3 Growth supplements and storage
Isolates were cultured on nutrient agar (Oxoid, UK) and stored in Brain Heart Infusion 
(BHI) (Fisher Scientific, UK) with 15% Glycerol at -30 °C for further studies. Luria- 
Bertani (LB) broth (Sigma-Aldrich, Germany) was used in bacterial growth curves and 
molecular experiments. LB was made by suspending 20g LB powder in 1L distilled 
water and autoclaving for 15 minutes at 121 °C.
When culturing strains containing plasmids and attenuated S. Typhi strains, media were 
supplemented with chloramphenicol (Sigma) (15 pg / mL) and “aromix” (40 pg / mL L- 
phenylalanine, 40 pg / mL L-tryptophan, 10 pg / mL p - aminobenzoic acid, 10 pg / mL 
2, 3-dihydroxybenzoic acid and 40 pg / mL L-tyrosine). When selecting attenuated S. 
Typhi strains which did not harbor the suicide vector, medium was supplemented with 5 
% sucrose and NaCL was excluded from the recipe [118].
Oxgall, dehydrated fresh bile salts, is a known, culture medium for isolation of 
Salmonella from blood [135]. Bile salts have a detergent - like activity, which can 
permealize bacterial membranes and can eventually lead to membrane collapse and cell 
damage [136-138]. Eight percent concentration of oxgall is the natural concentration of 
bile salts in the human gall bladder [139]. Although the tolerance of S. Typhi to oxgall 
was demonstrated to influence the persistence of S. Typhi in the chronic carrier state
[140], in this study, oxgall (Difco) Supplemented in LB aro was used as a stress factor in 
order to evaluate the growth ability of the reconstructed S. Typhi mutant under a growth 
pressure. The following concentrations of oxgall were applied for screening the most
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appropriate concentration of oxgall for differentiating growth abilities of the 
reconstructed mutants. The various concentrations of oxgall supplemented in LB aro 
were 0.0193 %, 0.186 %, 0.375 %, 0.625 %, 1.25 %, 2.5 %, 5 %, 6 %, 7 %, 8 %, 9 %, 
1 0 %, 11 % and 1 2 %.
2.4 Antimicrobial susceptibility
Antimicrobial containing disks and strips were supplied by Difco (UK) and AB Biodisk 
(Solna, Sweden), respectively. Nalidixic acid, ofloxacin, ciprofloxacin, gatifloxacin, 
chloramphenicol and ampicillin powders were supplied by Sigma-Aldrich (Germany).
2.4.1 Disk diffusion method
Antimicrobial susceptibility testing was performed at the corresponding concentrations 
to five non - fluoroquinolones; ampicillin (10 pg), chloramphenicol (30 pg), 
trimethoprim-sulfamethoxazole (1.25 / 23.75 pg), ceftriaxone (30 pg) and azithromycin 
(15 pg); one quinolone (nalidixic acid (30 pg) and three fluoroquinolones; ofloxacin (5 
pg), ciprofloxacin (5 pg) and gatifloxacin (5 pg) (Oxoid, Basingstoke, UK) by disc 
diffusion according to Clinical Laboratory Standards Institute (CLSI) methods [141], 
and interpreted following CLSI guidelines [141]. No CLSI MIC breakpoints of 
azithromycin for enterobacteriacea are currently recommended according to these 
guideline, therefore, to analyse AZM susceptibility for S. Typhi we used the current 
MIC breakpoints described for Staphylococcus spp. [141]. An equivalent bacterial 
suspension to a 0.5 McFarland standard was used for disc diffusion method. The control 
strains used for all susceptibility tests were E. coli ATCC 25922, Pseudomonas 
aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 29213. The discs are 
impregnated with a specified amount of the antimicrobial agent and are placed on the 
Mueller-Hinton (MH) agar (diameter 90 mm, thickness 4 mm) by the modified Kirby-
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Bauer disc diffusion method [142]. The plate was seeded uniformly with bacteria. Four 
to seven antimicrobial disks were applied onto the plate after allowing the surface 
moisture to be absorbed. After incubation for 24 hours, the size of the zones of 
inhibition of growth produced by the antimicrobial agents diffusing from the discs into 
the surrounding' agar was measured [141].
2.4.2 E - test
The MIC is the most commonly used parameter to describe the efficacy of an 
antimicrobial agent against a bacterial strain. This is an in vitro measure reflecting the 
efficacy of a constant antimicrobial exposure to a specified bacterial inoculum after an 
incubation period of 16 to 20 hours. The MIC is an estimate of the susceptibility of a 
bacterial strain to an antimicrobial that can guide the choice of an appropriate 
antimicrobial therapy [141].
The MIC was determined by E - test (AB Biodisk, Solna, Sweden) according to the 
manufacturer’s instructions. Similar to the disk diffusion method an MH plate was 
swabbed with the organism and allowed to dry before E - test strips were placed on the 
surface. Plates with strips containing the tested antimicrobials (two strips per plate) 
were incubated for 24 hours and the results were interpreted following CLSI guidelines
[141].
Multidrug resistance (MDR) of isolates was defined as resistance to chloramphenicol 
(MIC > 32 pg / mL), ampicillin (MIC > 32 pg / mL) and trimethoprim- 
sulfamethoxazole (MIC > 8 / 152 pg / mL). Nalidixic acid resistance was defined as 
MIC > 32pg / mL. The breakpoints for ofloxacin and gatifloxacin were < 2 pg / mL 
susceptible and > 8 pg / mL resistant, for ciprofloxacin < lpg / mL susceptible and > 4
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pg / mL resistant. The breakpoints for ceftriaxone were < 8 pg / mL susceptible and > 
64 pg / mL resistant [141]. All tests were performed at the Hospital for Tropical 
Diseases (HTD), Ho Chi Minh City, Viet Nam, except for the isolates from Nepal, 
which were tested at Patan Hospital, Kathmandu, Nepal, using identical methods.
2.5 Biological cost evaluation
2.5.1 Growth curves assay
The fluorostar system is a spectrophotometer that measures UV based absorbance 
(Halmington, Switzerland). The Omega microplate reader is capable of capturing an 
absorbance spectrum (220 - 850 nm) at a resolution of 1 nm. This system was used for 
monitoring bacterial growth dynamics.
Three individual colonies were grown in 5mL LB (supplemented with 1 % aromix 
when working with BRD 948 derivatives). One microliter of overnight culture was 
inoculated in 200 pi of LB (LB aro) or LB supplemented with oxgall in Nunc96 plate 
(ThermoFisher Scientific, US). The growth rate was performed in BMG Fluorostar 
Omega system (Halmington, Switzerland) using below absorbance protocol. Each 
culture was incubated in 5 random positions in the plate at 37 °C with 300 rpm shaking 
speed and 60 seconds additional shaking before each cycle. Optical density readings at 
600 nm were performed for each well every 10 minutes over 24 hours and plotted 
against time. The resulting data was analyzed using Omega software supplied.
2.5.2 Competitive assay
The relative competitive fitness of bacteria was quantified experimentally with the use 
of competition assays [143].
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The nalidixic acid susceptible ancestor (S. Typhi BRD 948) and nalidixic acid resistant 
S. Typhi strains (engineered mutants) were mixed and competed directly in a non - 
selective medium (LB aro). The S. Typhi BRD 948 strain and the engineered mutant 
were initially grown separately in 10 mL of LB aro at 37°C with shaking to stationary
o •
phase (10 CFU / mL). One microliter of each was co-inoculated into a new 10 ml LB 
aro, and 10 pi of the mixed overnight culture was continuously transferred to a fresh 
10ml LB aro every day for 15 days. Two methods were used to determine the relative 
fitness of nalidixic acid resistant S. Typhi, namely colony counting and quantitative 
pyro-sequencing.
Colony counting of the mixture was performed by serial ten-fold dilution in MRD and 
then plating. Fifty microlitres of each solution was diluted serially in 450 pi of MRD in 
96-well microtitre plate. After mixing by pipetting thoroughly, 20 pi of 10"5, 1 O'6, 10' 7
o
and 10' dilutions were dropped onto both LB aro plates and LB aro plates 
supplemented with 20 pg / mL nalidixic acid. All plates were incubated at 37°C 
overnight. Plates with between 10 and 100 colonies were counted. The counting was 
carried out at the beginning of the experiment (Time 0) and every 24 hours for 15 days.
Additionally, lmL of overnight culture from the competition assay was subjected to 
DNA extraction (Section 2.7.1.3). DNA was directly applied for quantification of the 
growth rate of each strain in the mixture using pyrosequencing technique, by 
monitoring the proportion of individual SNPs. (Section 2.1.52). Competition 
experiments were performed in triplicate and independently.
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2.6 In vitro time - kill analysis
Time - kill experimentation is usually applied to evaluate the pharmacodynamic of 
fluoroquinolones on bacterial strains [116]. This method allows measuring the effects of 
different concentrations of an antimicrobial at definite time points. In this study, time - 
kill experiments were applied to measure the efficacy of fluoroquinolones on different 
S. Typhi mutants which conferred nalidixic acid resistance and reduced susceptibility to 
fluoroquinolone in S. Typhi strains.
All time - kill experiments were performed in duplicate. Ofloxacin powder was 
purchased from Sigma, Steinheim, Germany and gatifloxacin powder was purchased 
from Bristol-Myers Squibb, New Brunswick, USA. Three S. Typhi colonies were 
selected and inoculated in 10 mL Mueller-Hinton broth (Oxoid, UK) and were 
incubated at 37 °C for 15 to 18 hours. 100 pi of the overnight culture was inoculated 
into 10 mL of Mueller-Hinton broth and incubated at 37 °C for one hour to give 2 x 106 
CFU / mL. 10 mL of Mueller-Hinton broth containing ofloxacin or gatifloxacin at 32x 
MIC were added at time 0 to give a final concentration of 16 x MIC; serial two fold 
dilutions were used to obtain 8x, 4x, 2x and lx MIC. The growth control contained no 
antimicrobial. The cultures were incubated at 35 - 37 °C for 24 hours. Viable counts 
were measured immediately prior to the addition of the antimicrobial and at 30 minutes 
and 1, 2, 4, 6 , 8 and 24 hours after the addition of the antimicrobial. Viable counts were 
performed on nutrient agar plates following serial ten-fold dilution in MRD broths 
[144]. The lower limit of detection was 10 CFU / mL.
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2.7 Molecular methods
2.7.1 Genomic DNA isolation
DNA was extracted either by phenol-chloroform (or CTAB) method [145], Promega kit 
(Promega, Madison, WI), or rapid boiling, which depended on each experimental 
requirement or the availability of DNA extraction kits.
2.7.1.1 Genomic DNA extraction using Phenol-Chloroform or CTAB (Cetyl 
Trimethyl Ammonium Bromide) method
All S. Typhi strains and other bacterial strains from which DNA was extracted were 
grown overnight in 5 ml of LB broth at 37°C with agitation. 1.5 mL of the overnight 
bacterial culture was centrifuged, the supernatant was removed and the resulting pellet 
was re-suspended in 567 pL of TE buffer (pH 8); 30 pL of 10 % SDS and 3 pl of 20 mg 
/ mL proteinase K. The solution Was mixed and incubated for 1 hour at 37°C. 100 pi of 
5M NaCl was added and the solution was mixed thoroughly. To this solution, 800 pi of 
CTAB / NaCl solution was added and incubated for 10 minutes at 65 °C. An equal 
volume of chloroform / isoamyl alcohol was added and mixed thoroughly. The solution 
was centrifuged in a microfiige at 13,000 rpm for 5 minutes. In samples where no 
interface was formed after centrifugation, the samples were mixed again and subjected 
to further centrifugation. The aqueous layer was transferred into a clean microfuge tube 
and an equal volume of phenol : chloroform : isoamyl alcohol was added, gently mixed 
and centrifuged for 5 minutes at 13,000 rpm. The upper layer was collected and the 
nucleic acid was precipitated with 0 .6  volumes of isopropanol after centrifugation at
14,000 rpm for 15 minutes. The nucleic acid was stored at -70 °C for an hour or at -20 
°C over night to yield more DNA. The DNA was washed in 70 % ethanol twice and 
dried for 10 minutes at 50 °C. The DNA pellet was re-suspended in 50 pi of TE buffer
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and lp l of DNA solution was analyzed by electrophoresis on a 0.8 % agarose for purity 
and concentration.
2.7.1.2 Genomic DNA extraction using Promega kits
A single colony was inoculated in 1.5 mL of LB broth and incubated overnight at 37 °C 
with shaking at 300 rpm to reach 108 CFU / mL. One milliliter of the bacterial culture 
was transferred to a clean eppendorf and centrifuged the tube at 13,000 rpm for 2 
minutes. The supernatant was removed and bacterial pellet was used for DNA 
extraction using Wizard genomic DNA purification kit (Promega, USA) according to 
the manufacturer's recommendations. The extracted DNA was stored at -20 °C until 
required.
2.7.1.3 DNA extraction using the boiling technique
For screening for the presence of plasmid-mediated quinolone resistance gene including 
qnrA and qnrS genes, a quick DNA extraction method was applied. This method allows 
harvesting a small amount of DNA that could be subjected to PCR. However, the DNA 
cannot be stored for a long time use or for further molecular investigations because of 
the lack of purity and degradation. A single colony was inoculated in 1 mL of LB broth 
and incubated overnight at 37 °C with shaking at 3,000 rpm. Five hundred microliters 
of the culture was denatured in a 1.5 mL eppendorf at 100 °C for 10 minutes, five 
hundred microliters of chloroform was added and mixed thoroughly. After 
centrifugation at 13, 200 rpm for 10 minutes, DNA in the upper layer was used directly 
applied for PCR.
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2.7.2 Polymerase chain reaction (PCR)
The PCR methods were applied to amplify DNA targets. In general, all PCR were 
performed using standard PCR programme with 3 steps, denaturation, annealing and 
elongation. Bioline Taq pol ymerase ( Bioline) was employed for conventional PCR 
reactions for all templates except large target fragments which were predicted to be 
more than 20 kb in length. For long templates, the Expand Long Template PCR system 
was used (Roche Lifesciences).
Four PCR methods were applied in this study depended on the purpose of each 
experiment. There are subtle differences in the principle used between conventional 
PCR, CEQ sequencing system (Beckman Coulter, USA) and PCR for pyrosequencing 
(Biotage, Sweden). Whilst dideoxynucleotide (ddNTP) is used in PCR for sequencing, a 
primer labeled with biotin at 5' end is applied in PCR for pysosequencing. Multiplex 
PCR and colony PCR were conducted to simultaneously amplify more than one target 
and for rapid screening of PCR products, respectively. All PCR amplifications were 
carried out using the DNA Engine2Tetrad thermal cycler (Biorad, USA).
2.7.2.1 Conventional polymerase chain reaction (PCR)
Oligonucleotide primer pairs for detection mutations and deletion fragments are 
presented in Table 2.2 and Table 2.3. PCR amplifications of gyrA (347 bp), gyrB (345 
bp), parC (270 bp), parE  (240 bp) and PCR for investigating the deletion haplotype 
representatives were performed with 30 cycles of denaturation at 92 °C for 45 seconds 
to one minute, annealing at 45 - 62 °C for 45 seconds to one minute and extension at 74 
°C for 45 seconds to 2 minutes, followed by a final extension step at 74°C for 2 to 5 
minutes.
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Table 2.2 List of primers for gyrA, gyrB, parC  and parE  genes amplification
Gene Prim er Prim er sequence (5'-^3') References
GyrA GYRA/P1 TGTCCGAGATGGCCTGAAGC [146]
GYRA/P2 TACCGTCATASGTTATCCACG
GyrB Sty gyrB 1 CAAACTGGCGGACTGTCAGG [147]
StygyrB2 TTCCGGCATCTGACGATAGA
ParC StmparCl CTATGCGATGTCAGAGCTGG [148]
StmparC2 TAACAGCAGCTCGGCGTATT
ParE StmparEl TCTCTTCCGATGAAGTGCTG [148]
StmparE2 ATACGGTATAGCGGCGGTAG
Table 2.3 List of primers used in PCR - based typing for Insertion - deletion
investigation
Nam e o f  
deletion
Prim er sequence (5'->3')
Forward Reverse
A AGCGATGTGATGATCAGGATT AATGGCGTGTTCAGTGGATT
B TCCGTCTCTTTCTCCAGC AATTGATGCTGCTGCTGGACG
C ACGGGTGAAATACTCGAACG CACCAAGCAGATTGTTCAGG
D CGCTATTTTTTCCGCCCATGC TAATAACATCGGCGTGCCG
E CCGTCGCCAAAGTGACGC CCGTTGAATCGGAAGTAATAATCG
F AAGCAAATGCTTAGCACCAC CAATGCATAAAGTTAATTTAATCAGGA
K ATGGGTGAGCGCCTCTTTGG GACTGGCTGGACATTTTGTG
N ATGTTTCATGTGTGGGTAGGGTTGCC AAGAATGCCCATTGAGCGG
Q CAACACCCGTGCGGACGAT AGCTTACTTCCGGCTCCGAC
s TTGGTGATAAAATTGGCTCGGG AAAGAATGGAAACCAGAGTTTCC
H GTGGCAAAACAACGCATCG CGGTGGAGTTAGTGATGCTGA
2.7.2.2 PCR for screening qnr genes
The positive control used in for qnr genes detection was a Citrobacter spp. isolate 
(identified by API20E) harbouring both qnrA and qnrS genes which was confirmed by 
sequencing PCR products [149]. The PCR primer pairs for qnrA and qnrS identification 
were qnrAF (5'- T C AGC AAGAGG ATTTCTC A - 3') and qnrAR (5'-
GGCAGCACT ATT ACTCCC A- 3'); and qnrSl (5' - ATGGAAACCTACAATCATAC 
-3")  and qnrS2 (5'- AAAAACACCTCGACTTAAGT - 3'). Twenty five microliters 
PCR reactions for qnrS gene detection was used containing, 2.5 pi buffer, 1 pi of 50 
mM MgCE 1 pi of 5 pM each primer, 2.5 pi of 2.5 mM dNTPs, 0.8 pi Bioline Taq
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polymerase, 2 pi DNA which was extracted by boiling technique (Section 2.7.1.3) and
14.2 pi distilled water. The 25 pi PCR mixture for qnrA gene detection included 2.5 pi 
10X buffer, 1 pi of 50mM MgCH, 0.05 pi of lOOpM each primer, 2.5 pi of 2.5mM 
dNTPs, 0.8 pi Bioline Taq polymerase, 2 pi DNA which was extracted by boiling 
technique and 16.1 pi distilled water. PCR amplification was performed using 34 cylces 
of denaturation at 94°C for 45 seconds, annealing at 45 °C (for qnrS gene) and 53°C (for 
qnrA gene) for 45 seconds and extension at 72°C for 45 seconds, followed by a final 
extension step at 74°C for 5 minutes.
2.7.2.3 PCR for sequencing
The principle of PCR for sequencing is based on the fact that the deoxynuxleotides 
(dNTP) and dideoxynucleotides (ddNTP) are co-present in the PCR reaction and each 
ddNTP is labeled in four different fluorescence colours. In addition, the -OH group at 
C3 of ddNTP is replaced by -H, therefore the elongation step of the PCR reaction is 
stopped when a ddNTP is incorporated on the adjacent on the template.
Purified PCR products were subjected for the sequencing reactions. Both strands of 
each DNA sample were independently sequenced; therefore, two PCR reactions were 
carried out using either forward or reverse primers (Table 2.2). Twenty microliters PCR 
reaction included; 4 pi DTCS master mix, 2.5 pi 1 pM primer, 2 pi of 10 ng / pi DNA 
and 11.5 pi distilled water. PCR was performed with 30 cycles of denaturation at 96 °C 
for 20 seconds, annealing at 55 °C (for gyrA gene) and 62 °C (for gyrB, parC  and parE 
genes) for 20 seconds and extension at 60 °C for 2 minutes.
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2.1.2A PCR for pyrosequencing
The PCR reaction for pyrosequencing was carried out with a primer pair in which a 
forward primer was labeled with biotin at the 5' end. A hundred microliter PCR 
reaction was performed including 1.25U Hotstart Taq polymerase, IX NH4 buffer 
(10X), 1.5mM MgCh (25 mM), 200 pM dNTPs (2.5 mM), 10 pM gyrApyro-F (1 pM) 
(5'-TGGGCAATGACTGGAACAAAG - 3'>, 10 pM GYRA / P2 Biotin -  
TACCGTCATAGTTATCCACG - 3' (1 pM) and 400 ng of DNA which was adjusted 
to 100 pi with distilled water. PCR programme for gyrA (291 bp) was performed with 
25 cycles of denaturation at 94 °C for 5 minutes, annealing at 55 °C for 1 minute and 
extension at 72 °C for 1 minute, followed by a final extension step at 72 °C for 10 
minutes. The PCR programme for parC was 94 °C for 5 minutes, 94 °C for 30 seconds, 
57 °C for 30 seconds, 72 °C for 1 minute and 72 °C for 5 minutes. PCR products were 
visualized on 1 % agarose gel before being subjected to the pyrosequencing procedure.
2.7.2.5 Expand long template PCR
Expand Long Template PCR system (Roche, Germany) was used to amplify large target 
sequences, as per the manufactures recommendations.
2.1.2.6 Colony PCR
The multiplex PCR and colony PCR amplifications were applied to screen the presence 
of nucleotide sequences in a PCR based typing method or to examine genetic 
constructs. PCR reactions were prepared including 20 pi Platinum ® PCR Supermix 
(Invitrogen, USA) and lpl of a solution which was a colony suspended in 100 pi 
distilled water (or 200 ng of stock DNA). Standard PCR programme was performed 
with 29 cycles of denaturation at 95 °C for 10 seconds, annealing at 55 °C for 1 minutes 
and extension at 72 °C for 1 minute 20 seconds, followed by a final extension step at 72
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°C for 3 minutes. The primer pairs using in the reconstruction of gyrA and parC  genes 
are listed in Table 2. 4.
Table 2.4 List of primers for reconstructed mutations on gyrA and parC  genes
Nam e Sequence (5 '—>3") Target
47125 TTCATTATGGTGAAAGTTGGAACC
screening for CVD908-htrA parC::pWT- 
parC15 derivatives
Cat-12 CCATAATCAGTCGACGGTATCGATAAGCTT Amplification pJCB12 fragment
GyrA-07 GGGTCGACTGATTATGGTTTATGCCTCC construction o f all gyrA mutations
GyrA-10 GCGCATGCCACGACCGGTACGGTAG construction o f  all gyrA mutations
GyrA-11 TCGCGTCAGCTTCAACTTCC
screening for BRD 948 gyrA::pWT-gyrA 
derivatives
gyrA-23 CTCTTCAGCTCTTCCTCAAT construction o f all gyrA mutations
GyrA-31 CTATTCGGGAACTTTGTACCC construction o f  all gyrA mutations
GyrA-45 AACGATGGTGCCATACACTGCGGAATC construction o f  gyrA S83F and D87G
GyrA-46 TTCCGCAGTGTATGGCACCATCGTTCG construction o f gyrA S83F and D87G
GyrA-47 AACGATGGTGCCATACACTGCGAAATC construction o f  gyrA S83F and D87G
GyrA-48 TTTCGCAGTGTATGGCACCATCGTTCG construction o f  gyrA S83F and D87G
GyrA-49 ATACCGTCGACTGATTATGGTTTATGCCTCC construction o f gyrA D 87A  mutation
GyrA-50 CGATGGTGGCATACACTGCGGAAC construction o f  gyrA D87A mutation
GyrA-51 CGCAGTGTATGCCACCATCGTTCG construction o f  gyrA D87A mutation
GyrA-52 CGATGGTGGCATACACTGCGAAATC construction o f  gyrA D 87A  mutation
GyrA-53 CGCAGTGTATGCCACCATCGTTCG construction o f  gyrA S83F and D87A
GyrA-54 GGCGATTCCGCAGTGTATGC construction o f  gyrA S83F and D87A
ParC-18 GCGGTCGACGTTGGCGTGGTGAATAG construction o f  all parC  mutations
ParC-21 CGCGCATGCGGCAACGCGGTGATCA construction o f  all parC  mutations
ParC-23 GCCAGCAGTCAAACTTTTGG construction o f  all parC  mutations
ParC-25 CCAGACCGATCATGTTCAGG construction o f  parC  S80I mutation
ParC-27 ATAGCAGGCGATGTCGCCATG construction o f  parC  S80I mutation
ParC-28 CATGGCGACATCGCCTGCTAT construction o f  parC  S80I mutation
ParC-29 TATCACCCGCATGGCGACAT construction o f  parC  S80I mutation
R6K-01 GTGACACAGGAACACTTAACGGC screening for BRD 948parC::pWT-parC 
derivatives
R6K-03P P-CCATGTCAGCCGTTAAGTGTTC amplification pJCB12 fragment
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2.7.3 PCR product purification
Depending on the requirement of further investigations, PCR products were purified 
using QIAquick PCR purification kit following the manufacturer’s instructions 
(QIAGEN GmbH, Germany).
2.7.4 DNA quantification
2.7.4.1 Quantification of DNA by spectrophotometers
The absorbance at 260 nm was determined using a Nanodrop ND - 1000 
spectrophotometer (NanoDrop technologies Inc., USA) which is a cuvette free 
spectrophotometer. A drop of distilled water was used as a blank. The concentration of 
DNA was calculation using the following formula:
c  = (A260x 50)/0.1
Where c is the nucleic acid concentration in ng / microliter, A26o is the absorbance in 
AU, and the path length is 0.1 cm. The wavelength-dependent extinction coefficient of 
double stranded DNA is 50 ng - cm / pi.
2.7.4.2 Quantification of DNA using agarose gel electrophoresis
One microliter of DNA sample was mixed with 5 pi of 6x loading buffer and samples 
were loaded into the wells. Two and half microliters of controls of the Precision 
Molecular Mass standard (BioRad, USA) were loaded simultaneously. The 
concentrations of the standard are 10 ng for 100 bp band and 20 ng, 50 ng, 70 ng and 
100 ng for 200 bp, 500 bp, 700 bp and 1000 bp, respectively.
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2.7.5 Sequencing
2.7.5.1 Conventional (Sanger) sequencing
Sequencing reaction was performed by the CEQ DTCS - Quick Start Kit and analyzed 
using CEQ2000XL software (Beckman Coulter, USA). A sequencing reaction involves 
3 steps including preparation of the DNA sequencing reaction (section 2.7.2.3), ethanol 
precipitation of sequencing products and sequence data analysis.
Excess PCR reagents were removed from the PCR products by ethanol precipitation in 
the presence of sodium acetate. The precipitation reaction included 4 pi of stop solution 
(3M NaOAc and 100 mM EDTA) and lpl of 20 mg / mL glycogen (supplied in DTCS 
Quick Start kit) and 20 pi of a sequencing reaction. The solution was mixed thoroughly 
before and after the addition of 60 pi of cold 95 % ethanol. The DNA pellet was 
harvested after centrifuging at 14,000 rpm for 15 minutes and washed twice with 200 pi 
of cold 70 % ethanol. For each wash, the eppendorf was centrifuged immediately at
14,000 rpm for 2 minutes. The DNA pellet was allowed to dry for 15 minutes before 
rehydrated in 40 pi of sample loading solution for at least 15 minutes (supplied in 
DTCS Quick Start kit, USA). Finally, the DNA product was subjected for an 
electrophoresis in the CEQ 8000 capillary sequencer, and the result was analyzed using 
CEQuence Investigator_CEQ2000XL.
2.7.5.2 Pyrosequencing
Pyrosequencing is a DNA sequencing technique that is based on the transformation of 
released pyrophosphate (PPi) during DNA synthesis into measurable light. Visible light 
generated is proportional to the number of incorporated nucleotides. During the nucleic 
acid polymerization, a PPi is released as a result of nucleotide incorporation by 
polymerase. The PPi released is subsequently converted to ATP by ATP sulfurylase,
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which provides the energy to luciferase to oxidize luciferin and generates light. Because 
the added nucleotide is known, the sequence of the template can be determined [150]. 
The light produced in the luciferase-catalyzed reaction is detected by a charge coupled 
device (CCD) camera and seen as a peak in a pyrogram.
In this study, pyrosequencing was applied for detection and quantification of SNPs in 
the gyrA gene (Figure 2.5); The 3'- end of a primer was designed to hybridize to one or 
several bases before the polymorphic position. PCR products were sequenced using 
Pyro Gold SQA sample preparation kit and a PSQ 96MA analyzer (Biotage, Sweden). 
Generally, biotinylated PCR products were immobilized onto streptavidin-coated 
Sepharose beads (Streptavidin Sepharose HP, Amersham Biosciences, Sweden) in a 
sealable 96 - well PCR plate by adding 40pl of the binding buffer - Streptavidin 
Sepharose bead mix (3pi per sample PSQ 96, PSQ 96MA and 37 pi Binding buffer) 
into 80pl of a well-optimized PCR reaction. The plate was sealed and incubated with 
shaking at room temperature for 5 minutes with agitating constantly to keep the beads 
dispersed. Beads containing immobilized DNA templates were captured on the filter 
probes, washed in 70 % ethanol, denatured in denaturation solution, washed again in 
washing buffer then released the beads in a PSQ HS 96 plate low, prefilled with 
Annealing buffer containing 40 pi of 3.5 pM pyroGDSD-3 (5' -
CGGTAAATACCATCGCCA -3' )  per well. Labeled nucleotides were added by cyclic 
dispensation. Sequencing results were analyzed using the IdentiFire software (Biotage, 
Sweden).
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Figure 2.5 The principle of pyrosequencing methodology
The pyrosequencing procedure utilizes 3 reactions. (1) The DNA synthesis releases 
pyrophosphate (PPi), (2) The conversion of PPi to ATP by ATP sulfurylase, (3) The 
oxidization of luciferin and generation of light using the energy from reaction (2). 
Then, the light is detected by a charge coupled device (CCD) camera and seen as a 
detectable peak.
2.7.6 Reconstruction of mutation on gyrA and parC  genes
2.7.6.1 The gyrA and parC  mutations were reconstructed in S. Typhi BRD 948 by 
the allelic exchange method.
The allelic exchange for integrating gene into the chromosome occurs inside a cell 
following a two-step procedure. Firstly, the gene is cloned into a plasmid and the entire 
plasmid is integrated into the chromosome by a single-crossover between the 
homologous genes thereby producing a chromosomal duplication. Second, the 
chromosomal duplication is segregated by homologous recombination between the 
flanking direct repeats, ultimately leaving one of the copy of the genes on the 
chromosome (either the wild type or the mutant copy) [151]. Because the direct repeats 
are often short, the desired recombination event may be very rare. To select against the 
integrated plasmid, bacteria are grown in the selective media supplemented with 5 % 
sucrose [151].
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2.1.6.2 DNA digestion and ligation
The target DNA fragments were digested with restriction endonucleases Sail and Smal 
(or SphI) (New England Biolabs, UK) and ligated to similarly digested pJCB12 using 
the Quick ligation kit (New England Biolabs, UK) following the manufacture’s 
instruction. The resulting plasmid was transformed into the target cells.
2.7.6.3 DNA plasmid isolation
A single colony was inoculated in 5 mL LB medium containing 15 pg / mL 
chloramphenicol for 8 hours at 37 °C with shaking at 300 rpm. Two hundred microliters 
of the starter culture was inoculated in 100 mL of selective medium at 37 °C for 12 - 16 
with shaking at 300 rpm. The cell density was approximately 3-4 x 109 cells / mL. DNA 
plasmid was extracted using Qiagen plasmid maxi kits following the manufacturer’s 
instruction (Qiagen, USA). In order to gain pure DNA, the DNA was extra-precipitated 
in 80 pi 3M NaOAc pH 5 and 500 pi isopropanol and washed twice in 70 % ethanol. 
Finally, the DNA pellet was dissolved in 50 pi TE which was a solution of 5 pi Tris 
0.1EDTA pH8 and 45 pi H20.
2.7.6.4 Competent cell preparation
Competent cells are cells that can uptake foreign DNA during electrotransformation, the 
method used here was adapted from Bjorkman et al. with modification [152].
A colony of bacteria was grown in 8 mL of LB overnight. Then, the broth was 
transferred to a 400 mL prewarmed-LB flask and incubated at 37 °C for 3 hours (or 
when OD6oo = 0.3 - 0.4 and < 0.6). The culture was kept on ice and aliquoted into 8 
falcon 50 mL tubes- 50 mL / tube. Cells were harvested by centrifugation at 4,000 rpm 
for 10 minutes which were subsequently re-suspended in 25 mL Elga water for each
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tube. Two tubes were combined into one. The cells were centrifuged at 7,000 rpm for 
10 minutes. Latterly, cells were then resuspended in 25 mL Elga water / tube. Tubes 
were combined into 4 tubes (37.5 mL / tube). The cells were resuspended in 25 mL Elga 
water / tube. Finally, all tubes were combined together. The cells were harvested and 
resuspended in 800 pi Elga water and supplemented with 15 % glycerol. Competent 
cells were store in -  80 °C until use.
2.7.6.5 Electro-transformation
This method was adapted from Dower et al. [153] with modifications. Competent cells 
were thawed at room temperature, and placed on ice. Forty microliters of cells were 
transferred to a cold 1.5 pi eppendorf; 1 to 2 pi of DNA solution was added to give a 
final concentration of 7.5 pg / mL (from 10 pg / mL). The suspension was mixed and 
transferred to a chilled 1 mm electroporation cuvette (Invitrogen, USA). The pulsing 
was carried out with an electroporator (Bio-rad) which was set to 1.8 kV, 25 pF and 200 
Q. After the electrical pulse, the cells were immediately re-suspended in 1 mL fresh 
S.O.C solution (Invitrogen, USA) (supplemented with aromix when using BRD 948), 
transferred to the 20 mL LB tube and incubated at 37 °C in 35 minutes. The 
transformants were screened by plating 50-100 pi on the LB supplemented with 15 pi / 
mL chloramphenicol. Mutations were confirmed by sequencing before susceptibility 
testing was performed for the mutants [153].
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2.8 Genotyping methods
A subset of S. Typhi isolates which were selected for genotypic investigation is 
represented in Table 2.5.
Table 2.5 List of S. Typhi strains selected for genotyping
Seventy three S. Typhi strains from seven Asian countries were selected for SNP typing 
by GoldenGate assay. Sixteen S. Typhi strains which were kindly provided by the 
Sanger Institute and two Vietnamese strains (CT18 and AG 3) along with an Indonesian 
strain (J 185SM) were used as haplotype controls. (*) Gifts from the Sanger Institute, 
Cambridge, United Kingdom.
No Strain identification Country Year Origin
1 AS 18977 Bangladesh 2003 Clinical Isolate
2 AS31279 Bangladesh 2003 Clinical Isolate
3 AS32308 Bangladesh 2003 Clinical Isolate
4 AS-3808 Bangladesh 2003 Clinical Isolate
5 AS-9242 Bangladesh 2003 Clinical Isolate
6 Doni C26 China 2002 Clinical Isolate
7 Doni C36 China 2002 Clinical Isolate
8 Doni C4 China 2002 Clinical Isolate
9 Doni C42 China 2002 Clinical Isolate
10 DoniC51 China 2002 Clinical Isolate
11 B116 India 2003 Clinical Isolate
12 D15 India 2003 Clinical Isolate
13 D186 India 2003 Clinical Isolate
14 D43 India 2003 Clinical Isolate
15 E48 India 2003 Clinical Isolate
16 J-2018XM Indonesia 2002 Clinical Isolate
17 J-359BM Indonesia 2002 Clinical Isolate
18 J-80YM Indonesia 2002 Clinical Isolate
19 L250 Laos 2003 Clinical Isolate
20 L380 Laos 2003 Clinical Isolate
21 L54 Laos 2003 Clinical Isolate
22 L599 Laos 2003 Clinical Isolate
23 BL16599 Pakistan 2002 Clinical Isolate
24 BL21095 Pakistan 2002 Clinical Isolate
25 BL2513 Pakistan 2002 Clinical Isolate
26 BL3723 Pakistan 2002 Clinical Isolate
27 BL820 Pakistan 2002 Clinical Isolate
28 113 Viet Nam 1994 Clinical Isolate
29 255 Viet Nam 1999 Clinical Isolate
30 304 Viet Nam 1998 Clinical Isolate
31 318 Viet Nam 1999 Clinical Isolate
32 436 Viet Nam 2001 Clinical Isolate
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No- Strain identification Country Year Origin
33 1592 Viet Nam 1999 Clinical Isolate
34 1697 Viet Nam 2000 Clinical Isolate
35 1727 Viet Nam 2001 Clinical Isolate
36 2017 Viet Nam 2001 Clinical Isolate
37 2062 Viet Nam 2000 Clinical Isolate
38 2694 Viet Nam 1995 Clinical Isolate
39 3069 Viet Nam 2000 Clinical Isolate
40 4313 Viet Nam 1995 Clinical Isolate
41 5623 Viet Nam 1995 Clinical Isolate
42 7560 Viet Nam 1996 Clinical Isolate
43 8071 Viet Nam 1996 Clinical Isolate
44 8699 Viet Nam 1996 Clinical Isolate
45 8951 Viet Nam 1996 Clinical Isolate
46 9019 Viet Nam 1994 Clinical Isolate
47 9183 Viet Nam 1996 Clinical Isolate
48 10158 Viet Nam 1994 Clinical Isolate
49 10877 Viet Nam 1996 Clinical Isolate
50 10880 Viet Nam 1996 Clinical Isolate
51 14308 Viet Nam 1997 Clinical Isolate
52 14635 Viet Nam 1997 Clinical Isolate
53 AG 112 Viet Nam 2004 Clinical Isolate
54 AG 152 Viet Nam 2005 Clinical Isolate
55 AG 165 Viet Nam 2005 Clinical Isolate
56 AG 169 Viet Nam 2005 Clinical Isolate
57 AG 175 Viet Nam 2005 Clinical Isolate
58 AG 25 Viet Nam 2003 Clinical Isolate
59 AG 26 Viet Nam 2005 , Clinical Isolate
60 AG 33 Viet Nam 2003 Clinical Isolate
61 AG 336 Viet Nam 2004 Clinical Isolate
62 AG 45 Viet Nam 2004 Clinical Isolate
63 AG 53 Viet Nam 2004 Clinical Isolate
64 DT 2 Viet Nam 2002 . Clinical Isolate
65 DT 47 Viet Nam 2002 Clinical Isolate
66 D T Y 1 9 4 Viet Nam 1997 Clinical Isolate
67 HTD798 Viet Nam 2003 Clinical Isolate
68 HTD810 Viet Nam 2003 Clinical Isolate
69 Ly Van Tan Viet Nam 2006 Clinical Isolate
70 Ty.05909 Viet Nam 2004 Clinical Isolate
71 UI-5106 Viet Nam . 2004 Clinical Isolate
72 V.04844 Viet Nam 2004 Clinical Isolate
73 V.07641 Viet Nam 2004 Clinical Isolate
74 E98-2068 Bangladesh 1998 Control*
75 E98-3139 M exico 1998 Control*
76 AG3 Viet Nam 2004 Control
77 8(04)-N Viet Nam 2004 Control*
78 E02-2759 India 2002 Control*
79 E03-9804 India 2003 Control*
Materials and Methods
No Strain identification Country Year Origin
80 ISP-03-07467 Morocco
Central
2003 Control*
81 ISP-04-06979 Africa 2004 Control*
82 CT18 Viet Nam 1993 Control
83 E03-4983 Indonesia 2003 Control*
84 404ty Indonesia 1983 Control*
85 E00-7866 Morocco 2000 Control*
86 E 02-1180 India 2002 Control*
87 E98-0664 Kenya 1998 Control*
88 J185SM Indonesia 1985 Control
89 M223 Unknown 1939 Control*
90 150(98)S Viet Nam 1998 Control*
91 Ty2 Russia 1916 Control*
92 E0.-6750 Senegal 2001 Control*
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2.8.1 Single Nucleotide Polymorphisms (SNP) typing
The high throughput GoldenGate method was applied for analyzing single nucleotide 
polymorphism (SNP) of S. Typhi isolates in this study. This method allows multiplex 
detection of between 96 and 1,536 nucleotide changes. The procedure of the 
GoldenGate assay includes 9 steps. Firstly DNA is activated and then is combined with 
oligonucletides, hybridization buffer and paramagnetic particles. Three primers (oligos) 
are designed for each SNP locus. Two primers are specific to each allele of the SNP 
site, called the Allele - Specific Oligos (ASOs). A third primer that hybridizes several 
bases downstream from the SNP site is the Locus - Specific Oligo (LSO). All three 
primer sequences contain regions of genomic complementarities and universal PCR 
primer sites; the LSO also contains a unique address sequence that targets a particular 
bead type. Secondly, the excess and mis - hybridized primers are removed via several 
stringency washes. Step 3 is the extension of the appropriate ASO and ligation of the 
extended product to the LSO; this combines information about each SNP site to the 
address sequence on the LSO. The full length product from these jointed products 
provides a template for PCR using universal PCR primers PI, P2 and P3. The universal 
primers PI and P2 are labeled with Cy3 and Cy5 dyes. After binding the PCR product, 
eluting dye - labeled strand, the single - stranded dye - labeled DNAs are hybridized to 
their complement bead type through their unique address sequences. The assay products 
are separated onto a solid surface for individual SNP genotype readout. After 
hybridization, the beadArray Reader is used to analyze fluorescence signal on the 
Sentrix Array Matrix or BeadChip (8), which is in turn analyzed using software for 
automated genotype clustering and calling (9) (www.Illumina.com) [154] (Figure 2. 6 ).
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SNP locus
1. M ake ac tiva ted  ON A
/
J 'L S O
A S O l  5 ; . w
A S 0 2  5
2 *
4. U niversal PCR cycle a t 1536-plex
2. Add DMA to  o ligonucleotides, hibridize
3. Extend, ligate, cleanup
A /A  A /G  G /G
6. H ybridize to  th e  Sentrix Array m atrix
7. W ash and dry array matrix
8. Im age array m atrix
9. Auto call geno type and g en era te  re p o r t
ASO Allelic specific Oligo
LSO Locus specific Oligo
P1,P2,P3 Universal PCR primers
Address Sequence unique targeting
a particular bead type
Figure 2.6 The principles of the GoldenGate SNP detection assay methodology
See text for description of protocol.
In this study, 1,508 loci including chromosomal SNPs, chromosomal deletions, IncHIl 
plasmid SNPs, other plasmid genes, and resistance genes were designated in a platform. 
The SNPs were designed based on previous study [69]. A subset of seventy three Asian 
S. Typhi strains selected for genotyping by the GoldenGate assay were represented in 
Table 2. 5. In brief, 30 pi of a 10 ng / pi DNA template was made up and duplicated in 
two plates. AG3 and J185SM DNA templates which were whole genome sequenced 
were used as SNP typing controls; water was used as a negative control. The DNA 
samples were arrayed randomly on the plate. The plates of S. Typhi DNA were
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processed and analyzed using the GoldenGate system at the Sanger Institute, 
Cambridge, UK following manufacturer’s recommendations (www.Illumina.com).
a
2.8.2 Multiplex Ligation Dependent Probes Amplification (MLPA)
MLPA is a simple and robust multiplex assay that has been applied to observe 
antimicrobial resistance mutations previously [155]. The specificity and sensitivity of 
the assay were ensured at the initial ligation step and PCR amplification. The sizes of 
the MLPA product correspond to the targeted SNPs. This assay offers great advantages 
in which multiple mutations distributed throughout the genome can be targeted in a 
single assay without compromising the sensitivity, specificity, or simplicity of the 
method [155]. Generally, the target sequence was identified by hybridization of two 
adjacent complementary probes. The probes are subsequently joined by a ligation 
reaction, and copy sequences are amplified in a multiplex PCR reaction using unique 
primers attached to the probes (Figure 2.7). Only probes hybridized to the target 
sequence will be ligated and subsequently amplified in the PCR reaction. After 
separation by capillary gel electrophoresis, the amplification product can be analyzed 
[156].
2.8.2.1 Design of probes
Sixteen discriminatory markers were selected and MLPA probes were designed 
accordingly following manufacturer’s recommendation [157]. These markers including 
11 insertion - deletion regions which were haplotype representative published 
previously [69,71], two indicators of gyrA andparC  mutations conferring nalidixic acid 
resistance and reduced susceptibility to fluoroquinolone and three species controls 
including aroC, ssaV and fliC  genes. These genes are vitally responsible for the S. 
Typhi metabolism. Wherein, the aroC gene encodes chorismate synthase, an enzyme
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involved in the biosynthesis of aromatic compounds [158]. The ssaV  gene encodes a 
component of the type III secretion system located on Salmonella pathogenicity island 2 
(SPI-2) which is required for Salmonella enterica survival and growth within 
macrophages [159], Finally, the fliC  gene encodes bacterial flagella [160]. The probe 
sequences are represented in Table 2. 6.
MLPA. Multiplex Liaation-dependent Probe Amplification 
1. Denaturation & hybridisationC'
PCR primer J  ^
sequence Y Hybridization 
sequence 
5'
PCR primer sequence X
Stuffer sequence (different for 
each probe)
Target A 5' 3' Target B
2. Ligation
Target A
3. PCR
Target B
The two parts of each probe hybridize to 
adjacent target sequences and are 
ligated by a thermostable ligase.
All probe ligation products are amplified by PCR using only one primer pair.
Y X y X The amplification product of each
— ■ probe has a unique length (130-480
5' 3 '  S ' 3' nt).
4. Separation of amplification products by electrophoresis
Amplification products are separated by electrophoresis. Relative amounts of probe amplification products, as 
compared to a control DNA sample, reflect the relative copy number of target sequences.
i  JLLU j JU U -Jj J x LL lT
Schouten, J.P. et al. Nucl. Add Res. 30, e57.
Figure 2.7 MLPA-Multiplex PCR Ligation-dependent probe amplification
The figure was adapted from Schouten (2002) [157].
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Among these probes, the gyrA probe was optimized to give lower signal if any other 
variant of wild type (TCC - GAC) is presented. The variants need to be sequenced to 
verify the exact nucleotide change.
The MLPA reagents and method was kindly provided and instructed by the MRC- 
Holland, Amsterdam, The Netherlands [157]. The MLPA procedure includes three 
following steps.
2.8.2.2 DNA hybridization and ligation
Five microliters of DNA samples (100 ng / pi) were heated at 98 °C for 10 minutes in a 
thermocycler (ICycler, BioRad, USA) with a heated lid. These tubes were subsequently 
cooled to 25 °C before adding a mixture of 1.5 pi SALSA probemix and 1.5 pi MLPA 
buffer to each tube. Samples were heated for 1 minute at 95 °C and then incubated for 
16 hours at 60 °C. Ligation of annealed oligonucleotides was performed by diluting the 
sample to 40 pi with dilution buffer containing 3 pi Ligase-65 buffers A, 3 pi ligase-65 
buffer B, lpl ligase - 65 and 25 pi water, and incubated 15 minutes at 54 °C, then heated 
for 5 minutes at 98 °C.
2.8.2.3 DNA amplification
Forty microliters PCR reaction was performed by adding 10 pi polymerase mix 
containing 2 pi SALSA Enzyme Dilution buffer, 5.5 pi water, 0.5 pi SALSA 
Polymerase and 2 pi SALSA PCR-primers which include a forward primer (labeled) (5' 
-GGGTTCCCTAAGGGTTGGA - 3') and a reverse primer (unlabeled) (5' - 
GTGCCAGCAAGATCCAATCTAGA - 3') into 30 pi PCR buffer mix while at 60 °C. 
In which, the PCR buffer mix was made up in advance by suspended 4 pi SALSA PCR 
buffer and 26 pi water into 10 pi of the ligation reaction. A thirty five-cycle PCR
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programme was performed and included 30 s at 95 °C, 90s at 65 °C, and 60 s at 60 °C, 
and following by 72 °C for 20 minutes.
2.9 Analysis methods
2.9.1 Fragment analysis
MLPA products were either simply visualized using the agarose gel electrophoresis 
(Section 2.8.3) or the capillary sequence system ABI 3130XL with fragment analysis 
software (Genemapper V4.0 ABI Applied Biosystems, USA). A half microliter of PCR 
product which was amplified with one unlabelled and one FAM - labeled primer was 
mixed with 9.25 pi Hi-di Formamide and 0.25 pi LIZ - 500 size standard (GeneScan, 
ABI Applied Biosystems, USA). The mixture was incubated in 3 minutes at 95 °C, then 
immediately chilled on ice for few minutes before analyzed on a 3130XL ABI capillary 
electrophoresis system.
2.9.2 MLPA analysis
Generally, the combination of 16 peaks appeared with the length varied from 130 bp to 
494 bp along with other 9 control fragments covering the region 68 bp - 114 bp which 
were the manufacturer’s controls. Among these 9 control peaks, four fragments of 68 
bp, 74 bp, 80 bp and 87 bp were designed to give a signal if too low input DNA was 
used. These peaks gave similar heights. If an appropriate amount of DNA was used in 
the experiment, these peaks rose to half or less than half of the general peak heights of 
the S. Typhi probes.
2.9.3 Electrophoresis
Agarose gels (0.8 - 3 %) (Biorad, USA) were used to visualize DNA amplifications. 
Different agarose concentrations were used depending on the purpose of each
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experiment. Agarose gels were stained with 0.3 mg / mL ethidium bromide and 
visualized under UV light and examined using the Gel Doc system (Biorad, USA), 
bands were interpreted using Quantity One software (Biorad, USA).
2.9.4 Bioinformatics analysis
The DNA sequences that were selected for further analysis were searched via the 
website of the National Centre for Biotechnology Information (NCBI) 
(http://ncbi.nlm.nih.gov/BLAST) usin g the BLAST alignment tools. DNA sequence 
alignment was conducted using AlignX programme of the VectorNTI Suit 7 software.
2.10 Statistics and mathematical methods
2.10.1 Statistical analysis for the competition assay
For each competition experiment, the mean of 6 readings in two plates was used for the 
calculation of the relative competitive fitness. The CFU counts on nalidixic acid agar 
indicate the number of nalidixic acid resistant cells in the mixed cultures. The number 
of susceptible cells was calculated by subtracting the number of resistant cells from the 
total cell number revealed by the CFU counts on the plates that did not contain 
antimicrobials.
2.10.2 Statistical method for other calculations
Means, medians, drug resistance sample correlations and graphs of standard statistical 
distributions were analyzed using R commander software v2.9.0 [161].
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3. Characterization of Salmonella Typhi antimicrobial susceptibility patterns in 
Viet Nam and other Asian countries
3.1 Introduction
There are approximately 21 million cases of typhoid fever worldwide per year with the 
majority of those cases occurring in Asia [29]. An estimated 220,000 deaths per year 
occur as a consequence of typhoid fever [29]. Since the isolation of multidrug resistant 
(MDR) S. Typhi, which shows resistance to all first-line antimicrobials 
(chloramphenicol, ampicillin and sulfamethoxazole-trimethoprim) in the 1980s, the 
fluoroquinolone class of antimicrobial has become the preferred treatment for enteric 
fever [15,19]. Outbreaks of typhoid caused by S. Typhi strains that were resistant to 
nalidixic acid (the prototype quinolone, which is used for in vitro screening testing) 
have been reported in a number of countries [9]. Whilst nalidixic acid is not used 
therapeutically for treatment of typhoid, these strains also have reduced susceptibility to 
fluoroquinolones. Viet Nam, particularly the Mekong Delta region of southern Viet 
Nam, has faced a series of typhoid fever epidemics over the last decade [38,162-164]. 
These epidemics were imposed on a background of endemic disease, however, these 
outbreaks may have reflected a change in resistance patterns of the organisms and we 
hypothesized that antimicrobial resistance was becoming a serious problem in 
hampering effective typhoid treatment in southern Viet Nam [165].
In order to investigate the magnitude of antimicrobial resistance and the patterns of drug 
sensitivity in southern Viet Nam we amassed a collection of S. Typhi isolates that were 
representative of this location and would offer a snap-shot of any antimicrobial 
resistance transition occurring over this period of time. In total, the collection that was 
analyzed was comprised of 1,388 S. Typhi isolates. These S. Typhi isolates were 
collected from 18 southern provinces of Viet Nam between 1993 and 2005. The
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provinces that these strains were collected from are outlined in Table 1 and the 
provincial locations are pictorially represented in Figure 3.1.
Figure 3.1 The map of provinces in southern Viet Nam where S. Typhi strains 
were collected
The provinces where S. Typhi isolates were collected were An Giang, Ba Ria, Ben Tre, 
Binh Thuan, Dak Lak, Dong Nai, Ho Chi Minh, Kien Giang, Long An, Soc Trang, Song 
Be, Tay Ninh, Thuan Hai, Tien Giang, Tra Vinh, Phu Dong and Vinh Long.
Typhoid fever is endemic and a public health issue in Viet Nam and in other Asian 
countries in the vicinity. Whilst the collection of strains that was representative of those 
in Viet Nam, are important to understand the national situation, it is essential to relate 
this information to the antimicrobial resistance patterns in other locations. The 
movement of people in South East Asia is significant; therefore, the dissemination of 
any antimicrobial resistant S. Typhi may occur at high frequency.
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To compare the national situation to the overall Asian situation we generated a cross 
sectional sample collection of S. Typhi isolates from eight Asian countries. Many of 
these strains were collected as part of a multi-centre, multi-faceted study of typhoid in 
Asia. This study fonned part of the International Vaccine Institute’s (IVI) Diseases of 
the Most Impoverished (DOMI) investigation [129]. The DOMI project sought to 
calculate the burden of typhoid fever and other diseases related to poverty in southern 
Asia. Our laboratory directed the sample collection and description of the strains 
circulating in Asia during this period of investigation. The S. Typhi strains were 
collected over a five year period (2002 -  2006) in eight Asian countries where typhoid 
is known to be endemic. These countries are highlighted in Figure 3.2, and were 
Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan and some additional strains 
from central Viet Nam. Typhoid is endemic in all the countries described and these 
nations are home to more than 80 % of the world's typhoid fever cases [29] (Figure 3.2).
C h in a
Figure 3.2 The map of Asian countries involved in this study
(*) Red stars represent the locations of the countries where S. Typhi were collected. The 
countries were Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan and Viet 
Nam.
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The emergence and spread of antimicrobial resistant S. Typhi means limited treatment 
options for typhoid fever in many countries where the disease is endemic. The 
information of extension and patterns of drug resistant S. Typhi across Asia is vital to 
guide treatment policy and is also important for governments planning potential 
vaccination campaigns. Areas with high transmission and high levels of antimicrobial 
resistant strains should be a potential target for intervention strategies. Here we compare 
and contrast the antimicrobial resistance profile in the S. Typhi population in Viet Nam 
and in other locations in the South of Asia. This collection of 2,028 strains represents 
the largest number of S. Typhi isolates investigated in this manner and permits a 
snapshot view of the situation of antimicrobial resistance in these locations.
3.2 Results
3.2.1 S. Typhi collection
3.2.1.1 Vietnamese S. Typhi strain collection
Of the 1,388 strains constituting the Vietnamese S. Typhi collection used for analysis, 
85 % of strains were collected in three locations in southern Viet Nam. These three 
locations represent areas of high incidence and were An Giang province, Dong Thap 
province and Ho Chi Minh City. Five hundred and twenty three strains, 366 strains and 
323 strains were isolated from Dong Thap province, An Giang province and Ho Chi 
Minh City respectively. The strains were collected over a 13 year period. However, 
1994 (214 strains), 1995 (256 strains) and 2004 (201 cases) were the 3 years with the 
highest number of organisms isolated (Table 3.1).
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3.2.1.2 Asian strain collection
One hundred and forty-nine S. Typhi isolates were collected in March and April 2003 
during a hospital-based descriptive study at Patan Hospital, Kathmandu, Nepal. Fifty 
isolates were collected consecutively during a clinical trial in 2002 and 2003 at the 
Wellcome Trust-Mahosot Hospital, in the Lao People's Democratic Republic [128]. 
Forty isolates were collected between February and December 2003 in an urban slum in 
Dhaka, Bangladesh [130]. Additionally, 21 isolates were collected during 2002 in Hechi 
city, Guang Xi, China; 23 strains were collected from May to July 2003 in slum areas in 
Kolkata, West Bengal, India and 259 strains were collected across India. Seventeen 
isolates were collected from July to September 2002 in North Jakarta, Indonesia. Thirty 
four strains were isolated between January 2002 and March 2003 in one slum area in 
Karachi, Pakistan and 47 isolates were collected between July 2002 and September 
2004 in Hue city, central Viet Nam.
3.2.2 Identification
Two thousand six hundred and twenty seven (2,627) strains previously identified in 
other laboratories as S. Typhi were re-cultured and we sought to confirm accurate 
identification. Microbiological and biochemical identification methodology were 
performed as described in section 2.2. Of all the strains that constituted the S. Typhi 
strain collection amassed for this study, we confirmed accurate biochemical 
identification (using short set or API 20E) on 2,028 strains (Table 3.2). The additional 
strains were confirmed to be either S. paratyphi A strains or other Salmonella spp.
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All isolates subjected for further investigations were confirmed by serological testing. 
This was performed according to WHO guidelines (2003) as described in section 2.2:1. 
Serological identification results are presented in Table 3.3. All S. Typhi isolates 
defined by short biochemical set or API20E tests were positive to polyO and O9 
agglutination reactions, regardless of the Vi antigen reaction. In total 68  % (572 / 841) 
of all tested isolates were confirmed as S. Typhi using serological testing. The Vi 
antigen is known to be variable during culture and some S. Typhi strains have been 
found in Pakistan that are Vi Negative and incapable of expressing the Vi antigen [166]. 
Our data demonstrates that 93 % (531 / 572) of the isolates tested had positive 
agglutination when tested for expression of the Vi antigen, 6 % (37 / 572) were negative 
for agglutination and 1 % (4 / 572) gave un-interpretable results.
Table 3.3 Serological identification of S. Typhi strains isolated in Asia (2002 -2006)
(+); agglutination, (-); no agglutination. polyO, polyvalent O antigen, the somatic 
antigen specified Salmonella species. O9, somatic antigen specified S. Typhi. Vi+; 
providing agglutination to virulent antigen, Vi-; not providing agglutination to Vi 
antigen, Vi-/+, not providing clear agglutination to Vi antigen.
Country
Strains
(N=841)
polyO O , Vi + V i-  Vi-/+
Bangladesh 40/49 + + 40
China 21/53 + + 21
India (2003) 23/27 ■ + + 19 4
India (2006) 259/417 .+ + 218 . 7 4
Indonesia 17/28 + + 17
Pakistan 34/54 + + 34
Laos 50/58 + + 50
Nepal 149/205 + + 59 15
Central Viet Nam 47/49 + + 36 11
Southern Viet Nam 201/326 + ' + 37
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3.2.3 Characterization of antimicrobial susceptibility
Two thousand and twenty eight isolates (including 1,388 isolates from Viet Nam and 
640 isolates from other Asian countries) which were confirmed S. Typhi were analyzed 
using MIC susceptibility testing (Figure 3.3). Five non - quinolone and four quinolone / 
fluoroquinolone antimicrobial agents were used for susceptibility testing. The five non - 
quinolone antimicrobials tested were ampicillin, chloramphenicol, sulfamethoxazole - 
trimethoprim (co - trimoxazole), ceftriaxone and azithromycin. The quinolone / 
fluoroquinolones tested were nalidixic acid, ofloxacin, ciprofloxacin and gatifloxacin. 
MIC values were interpreted according to CLSI guidelines in which the MIC 
breakpoints for the antimicrobial agents described in section 2.4.
Figure 3.3 Representative MIC E - tests for examining fluoroquinolone 
susceptibilities of S. Typhi strains
A, S. Typhi isolate CT 117 from Viet Nam, demonstrating sensitivity to nalidixic acid 
(NA) and ofloxacin (OF). The MIC of NAL (2 pg / mL) and OF (0.03 pg / mL) to this 
organism were read according to the manufacturers recommendation and are 
distinguished by arrows.
B, S. Typhi isolate 9180 from Viet Nam, demonstrating resistance to nalidixic acid 
(NA) and sensitivity to ofloxacin (OF). The MIC of NA (256 pg / mL) and OF (0.25 pg 
/ mL) to this organism were read according to the manufacturers recommendation and 
are distinguished by arrows.
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3.2.3.1 Multidrug resistance in Asian countries from 2002 to 2006
The antimicrobial susceptibilities of 841 S. Typhi strains isolated between 2002 to 2006
from eight Asian countries were analyzed to the five non - quinolone antimicrobials to
assess MDR rates (Table 3.4). MDR S. Typhi is defined as an organism that exhibits
resistance to chloramphenicol, ampicillin and co - trimoxazole. MDR S. Typhi
originated in the 1990s and is related to the organisms carrying an MDR plasmid.
There were variable rates of MDR across the seven sites. Over the collection period, 
there were two independent collections arising from India, in 2003 and 2006 (Figure 
3.4). The MDR rate in the Indian collections decreased over a period of three years, 
although the initial collection in 2003 only contained 23 strains. In locations where an 
MDR phenotype was found, the lowest was in the previously mentioned Indian 
collection from 2006 where 10 % (27 / 259) were MDR, whilst the highest was 45 % 
(90 / 201) from southern Viet Nam (Figure 3.4). Somewhat surprisingly, both China and 
Indonesia were exceptions with no MDR S. Typhi isolates identified.
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Figure 3.4 Multidrug resistant S. Typhi isolates from seven Asian countries (2002 
-  2006)
The blue bars indicate the percentage of multidrug resistant S. Typhi isolates which 
were collected from seven Asian countries including Bangladesh, China, India (2003 
and 2006), Indonesia, Pakistan, Laos, central and southern Viet Nam. The number in 
brackets is the number of S. Typhi isolates in each country, the total is 841 isolates.
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Comparing resistance to individual antimicrobials, the percentage of chloramphenicol 
resistant strain varied from 14 % (35 / 259) in India (2006) to 46 % (92 / 201) in 
southern Viet Nam (Table 3.4). The percentage of strains resistant to ampicillin ranged 
from 11 % (29 / 259) in India (2006) to 100 % (40 / 40) in Bangladesh (Table 3.4). The 
highest percentage of sulfamethoxazole - trimethoprim resistance was observed in 
southern Viet Nam, 49 % (89 /181), whilst the lowest percentage of sulfamethoxazole - 
trimethoprim resistance was in India in 2006 at 11 % (29 / 259).
In the Asian strains examined for an MDR phenotype, there were no ceftriaxone 
resistant strains identified. Only one S. Typhi isolate was found with reduced 
susceptibility to ceftriaxone (MIC= 6pg / mL), this strain was isolated in Nepal (1/149) 
(Table 3.4). Fourteen percent (3 / 21) of isolates from China, 7 % (71 / 259) and 4 % (1 
/ 23) of isolates from India 2006 and 2003 respectively were resistant to azithromycin 
(There are no CLSI azithromycin MIC breakpoints for Enter obacteriaceae, so this 
result were interpreted using MIC breakpoints of non -  enterobactereace [135]), which 
is one of the current recommendations for the treatment of patients with typhoid caused 
by MDR S. Typhi (Table 3. 4). In a recent randomized trial that evaluated the efficacy 
of gatifloxacin versus azithromycin for the treatment of typhoid fever in southern 
Vietnam, 58% (58/263) of S. Typhi isolates were MDR resistant and 96.5% (254/263) 
of S. Typhi were nalidixic acid resistant. The MIC 50 and MIC 90 (range) of the 263 S. 
Typhi isolates for azithromycin was 8 pg/ml and 12 mg/ml (1.5-16 |Lig/ml), respectively. 
In this trial patients showed excellent clinical response to both treatments [161].
3.2.3.2 Multidrug resistance in southern Viet Nam from 1993 to 2005
Between 1993 and 2005, we collected 1,388 isolates of S. Typhi from southern Viet 
Nam. All strains were tested for MDR. The proportion of MDR S. Typhi was 67 % (41
83
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/ 61 strains) in 1993 and increased to more than 80 % in the following years. The rate 
declined in the mid 1990’s and was maintained at approximately 90 % at the beginning 
of the 2000’s. The proportion of MDR S. Typhi finally increased to 76 % (53 / 70) in 
2005, however, this increase was not statistically significant when compared with 1993 
onwards (p = 0.685, using a Pearson chi-square test with Cl 95%). A subset of S. Typhi 
isolates from Dong Thap province of southern Viet Nam (1997-2002) was subjected to 
analysis to identify any increase in the proportion of MDR over a prolonged period of 
time (Figure 3. 5). The proportion of MDR strains was consistently at a high level and 
only varied between 81 % and 97 %. No statistically significantly difference in MDR 
percentages from 1997 to 2002 (p = 0.64 using Pearson’s chi-squared test) was 
observed.
3.2.3.3 Nalidixic acid resistance and reduced susceptibility to fluoroquinolones in 
Asian countries
The percentage of nalidixic acid resistant S. Typhi demonstrated significant variation 
when related to the location of isolation (Figure 3.6). No strains from Indonesia or Laos 
demonstrated resistance to nalidixic acid. Strains from China, Bangladesh and Pakistan 
had a relatively low incidence of nalidixic acid resistance (< 40 %). The rates of 
resistance to nalidixic acid in Nepal and India (2006 and 2003) were comparable (~ 50 
%) (Figure 3.6). The highest proportion of nalidixic acid resistant strains in this period 
(2002 -  2006) was also found in southern Viet Nam (90 %).
All isolates that were resistant to nalidixic acid were tested for resistance and reduced 
susceptibility to ofloxacin, ciprofloxacin and gatifloxacin. The MIC50 and MIC90 for 
these strains were calculated and are presented in Table 3.5. All tested strains, with the 
exception of two from India (2006) and two from Nepal were sensitive to ofloxacin.
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The highest MIC90 for ofloxacin was seen in Nepal and southern Viet Nam (1.5 pg / 
ml). Four percent of strains from Nepal were resistant to ciprofloxacin and all strains 
tested in all locations were sensitive to gatifloxacin. The highest MIC50 and MIC90 
values of S. Typhi to ciprofloxacin were 0.38 pg / mL and 0.5 pg / mL respectively, and 
those of S. Typhi to gatifloxacin were 0.125 pg / mL and 0.25 pg / mL, respectively 
(Table 3.5). The overall combination of MDR and nalidixic acid resistance was found to 
be 4.3 % (2 / 47) of S. Typhi strains from central Viet Nam, 8.7 % (2 / 23) from India, 
23.5 % ( 8  / 34) from Pakistan and 30 % (12 / 40) from Bangladesh. In Nepal, 18.1 % 
(27 / 149) of S. Typhi were resistant to chloramphenicol and nalidixic acid.
100.0%
95.0%
<L>
B  90.0%
a> 85.0% 
CL
80.0%
75.0%
70.0%
1997(32) 1998(43) 1999(89) 2000(37) 2001 (15) 2002(99)
Figure 3.5 Multidrug resistance of S. Typhi isolates in Dong Thap province of 
southern Viet Nam (1997 -  2002)
The blue bars indicate the percentage of multidrug resistant S. Typhi isolates which 
were collected from Dong Thap province of southern Viet Nam from 1997 to 2002. The 
number in brackets is the number of S. Typhi isolates in each year; the total number is 
315 isolates. Thep  mean = 0.64 with Cl 95% using Pearson’s chi-squared test.
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100%
Figure 3.6 Nalidixic acid resistance of S. Typhi strains across Asian countries 
between 2002 and 2006.
Red bars indicate the percentage of nalidixic acid resistant S. Typhi isolates which were 
collected from eight Asian countries including Bangladesh, China India (2003 and 
2006), Indonesia, Pakistan, Laos, Nepal central and southern Viet Nam. The number in 
brackets is the number of S. Typhi isolates in each country, the total number is 841 
isolates.
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3.2.3.4 Nalidixic acid resistance and reduced susceptibility to fluoroquinolone in 
southern Viet Nam
From the data of nalidixic acid resistance in southern Viet Nam between 1993 and 
2005, it was obvious that there was a significant drug resistance problem with the 
circulation of nalidixic acid resistant S. Typhi strains. Therefore, we hypothesized there 
had been an explosion in the incidence of nalidixic acid resistant S. Typhi in the years 
previous to this. We compared nalidixic acid resistant rates in S. Typhi strains over a 13 
year period from 1993 to 2005.
During the 13 year period, there was a sequential dramatic increase in nalidixic acid 
resistance (Figure 3. 7). In 1993, 2 out of 61 (3 %) S. Typhi isolated from patients in 
southern Viet Nam was nalidixic acid resistant (MICs to ofloxacin 0.250 pi / mL and 
0.125 pi / mL, respectively). Nalidixic acid resistance, surged to 88 % (104 / 118) in 
1998. It has remained at high levels since, with 91 % (182 / 201) of isolates in 2004. 
Since 1998, a high proportion of strains showed the combination of MDR and nalidixic 
acid resistance. The proportional increase in nalidixic acid resistance was highly 
statistically significant between 1993 and 2005 (p < 0.001 using Pearson chi-square test 
with Cl 95%).
From 1994 to 2005, the MIC of ofloxacin to southern Vietnamese S. Typhi isolates 
ranged from 0.008 pg / mL to 3 pg / mL (Table 3. 6). The highest MIC50 was 1 pg / mL 
and the highest MIC90 was 1.5 pg / mL. The highest MIC value of ofloxacin in 2003 
was 1.5 pg / mL, this value increased to 2 pg / mL in 2004 and reached 3 pg / mL in 
2005. MIC levels of ciprofloxacin to S. Typhi ranged between 0.008 pg / mL and 1 pg / 
mL, and the highest MIC50 and MIC90 were both 1 pg / mL.
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Figure 3.7 Nalidixic acid resistance proportions of S. Typhi isolates in southern 
Viet Nam between 1993 and 2005
Red bars indicate the percentage of nalidixic acid resistant S. Typhi isolates which were 
collected from 18 provinces of southern Viet Nam from 1993 to 2005. the number in 
brackets is the number of S. Typhi isolates in a province, the total number is 1,388 
isolates.
A subset of S. Typhi isolated from 2003 to 2005 was subjected to MIC testing with 
gatifloxacin. This was performed as gatifloxacin was being used therapeutically during 
this period and we wished to know if there was any additional resistance to this 
antimicrobial [167]. The MIC results ranged from 0.032 pg / mL to 0.5 pi / mL. The 
MICsoand MIC90 were 0.094 pg / mL and 0.19 pg / mL, respectively. Low MIC level to 
ciprofloxacin and gatifloxacin and intermediate MIC levels of ofloxacin to S. Typhi 
were detected. The trend in southern Viet Nam regarding the population of S. Typhi to 
fluoroquinolones is one of decreasing susceptibility, yet we could identify no strains 
that exhibited complete resistance to this group of antimicrobials.
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3.3 Discussion
New approaches have been recently developed for rapid screening of S. Typhi strains 
isolated from patients, these include PCR, DNA hybridization probes and Transia cards 
[28,168]. Although these assays have improved specificity and sensitivity compared to 
biochemical testing, they also show some disadvantages. The PCR based techniques 
need to be performed in specialized facilities with skilled technicians and at a higher 
reagent cost than standard microbiological techniques. In this study culturing on 
selective media and a short set of chemical tests were first applied for screening S. 
Typhi in a large number of gastrointestinal strains. S. Typhi strains were confirmed 
using serology and API20E tests. Several test steps were required to provide a final 
identification. This procedure is efficient for examination of S. Typhi in term of 
reliability and cost-efficiency. However, screening large numbers of isolates in this 
manor is laborious and time consuming and the development of machines for 
biochemical testing of microorganisms is probable the future of diagnostic 
microbiology laboratories.
Vi polysaccharide based vaccine has been demonstrated as an effective vaccine to 
protect children from typhoid fever [169]. However, 7 % (37 / 572) of S. Typhi in this 
study did not express the Vi antigen. Vi negative S. Typhi isolates have been described 
before in Pakistan [166]. Nevertheless, the overall impact of these strains on the 
bacterial population is unknown. The strains in previously described studies, have been 
shown to lack the genes which are essential for Vi antigen production [170]. In this 
study, we did not confirm is the Vi negative strains isolated had the genetic capability to 
express Vi, or if it was a laboratory artifact. We were able to identify Vi negative S. 
Typhi in three different countries; India, Nepal and Viet Nam. The actual role of Vi 
antigen is somewhat controversial, evidence suggests that it is important during host
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invasion and Vi is considered an important antigen in the pathogenicity of fever S. 
Typhi [171]. Looney showed the Vi inhibits complement mediated lysis and 
phagocytosis [172]. Hirose additionally demonstrated the presence of Vi on the surface 
of S. Typhi reduces TNFa secretion, which is a marker of macrophage activation [173]. 
However, Vi negative S. Typhi strains can cause infection, outbreaks caused by Vi 
negative S. Typhi have been described in India [174]. Furthermore, S. Paratyphi A, 
which causes an indistinguishable disease to S. Typhi, does not express the Vi antigen. 
Potentially, if S. Typhi has the ability to switch phase Vi antigen expression during 
systemic infection, it may allow the organism to evade the host immune response. The 
overall effect of Vi remains contentious, because Vi negativity can arise during in vitro 
passage, further investigation is required to understand the mechanism of this 
phenomenon; the deployment of Vi vaccinations in areas where Vi negative strains may 
circulate may be detrimental to the overall protective efficacy of the vaccine, yet the 
overall impact of Vi negative strains is not widely understood.
The majority of S. Typhi strains isolated globally have fluoroquinolone MICs which are 
usually within the susceptible range of the interpretive criteria of the CLSI. However, a 
growing body of clinical and microbiological evidence indicates that nalidixic acid 
resistant S. Typhi also exhibit a decreased clinical response to treatment with 
fluoroquinolones [175]. Whilst, our data does not include patient treatment and therapy 
responses, we hypothesize that the increase in nalidixic acid resistance strains will have 
a large impact on fluoroquinolone therapy in places where these strains predominate.
According to WHO (2005), among 1,055,178 diarrheal cases reported in Viet Nam in 
2002, 6,936 cases were typhoid fever [40], whilst a report in 1995 suggested that the 
incidence of typhoid cases was about five times higher (30,901 cases) [176].
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Approximately 90 % of strains that were compared here were isolated in southern Viet 
Nam which consists of 17 provinces and includes 39 % of the total population of Viet 
Nam [42], In 1993, during an initial outbreak of MDR S. Typhi in Kien Giang province 
in the south of Viet Nam, the fluoroquinolone antimicrobials were introduced for the 
treatment of typhoid fever [164]. Since 1993, the proportion of MDR S. Typhi in the 
south of Viet Nam has remained at high levels and there has been a dramatic increase in 
nalidixic acid resistance. Although there has been a reduction in the number of typhoid 
cases seen in southern Viet Nam, the severity of disease has increased (measured by 
prolonged fever and antimicrobial therapy). In our clinical studies typhoid was 
commonly caused by MDR and nalidixic acid resistant S. Typhi (63 -  78 %) 
[127,162,163]. The severity of infection was directly related to the resistance profile of 
the infection organism such as high failure cure rate, prolonged for fever clearance time 
and high feacal carriage rate [114, 115, 172, 173].
In 1998, five years after ofloxacin and ciprofloxacin become widely available in an 
uncontrolled market, 88 % of S. Typhi isolates were resistant to nalidixic acid, and this 
proportion increased to 90 % by 2004. The combination of MDR and nalidixic acid 
resistance is particularly problematic in Viet Nam, because it severely restricts the 
therapeutic options for patients with typhoid fever. Although MDR - nalidixic acid 
resistant strains were a serious problem in the south, no such strains were detected in the 
North of Viet Nam [177]; and there have been no reports of MDR - nalidixic acid 
resistant strains in central Viet Nam. The spread of MDR - nalidixic acid resistant 
strains in the south of Viet Nam may be related to an individual clone undergoing 
positive selection and consistent transmission. The overall incidence of typhoid is 
higher in southern Viet Nam (with respect to the other areas of Viet Nam), thus high 
transmission routes may permit clonal selection. This is potentially due to the overall
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water density in the Mekong Delta region that may aid transmission. An additional 
possibility for the emergence of MDR - nalidixic acid resistant strains in the south of 
Viet Nam may be the uncontrolled nature of antimicrobial distribution, allowing self- 
medication at a level which diminishes symptoms but does not prevent shedding and 
onward transmission.
Patients infected with nalidixic acid resistant S. Typhi show poor clinical responses, 
including, high failure rates (up to 36 %), prolonged for fever clearance and protracted 
faecal carriage when treated with both old (e.g ofloxacin) and new (e.g. ciprofloxacin) 
generation fluoroquinolones [120,121,178,179]. Fortunately, neither azithromycin nor 
ceftriaxone resistance was identified in Viet Nam, therefore, they would seem to be the 
treatment of choice for typhoid patients since the majority of strains showed nalidixic 
acid resistance and reduced susceptibility to fluoroquinolone. However, the cost of 
treatment for drug resistant strain with ceftriaxone is twice as costly in comparison with 
treatment for a patient infected with a sensitive strain [180]. Owing to the dramatic 
nature of antimicrobial resistance in' most bacterial pathogens there is an obvious 
requirement for new, cost effective antimicrobial agents to be developed.
The antimicrobial resistance data from southern Viet Nam is complemented by the 
results of the cross-sectional data from 7 Asian countries; Bangladesh, China, India, 
Indonesia, Laos, Nepal, Pakistan. From our collection, no antimicrobial resistant S. 
Typhi was detected in China or Indonesia, apart from 14 % (3 / 21) of strains in China 
being resistant to azithromycin. Wang et al. (2005) [34] reported similar antimicrobial 
resistance profiles, by studying 40 S. Typhi strains from China challenged with 12 
antimicrobial agents. Azithromycin resistance in S. Typhi in China and India (7 %) 
raises concern, as it is the antimicrobial agent currently is the drug of choice for
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nalidixic acid resistant S. Typhi strains [165,167]. Clinically, patients may respond 
satisfactorily to azithromycin even if isolates have intermediate resistance, according to 
current guidelines [19].
Antimicrobial resistance in Indonesia was not seen to be a problem (when compared to 
other areas). This is consistent with the finding of Hatta et al. [181], even though the 
sample size was small (17 strains), these finding are the first described with respect to 
the phenomenon. However, Hatta et al. has described more recent trends of 
antimicrobial resistance in Indonesia which appears to be similar to other locations in 
Asia [181].
Reduced susceptibility to ceftriaxone was found only in Nepal, the M IC ranged from 
0.002 pg / mL to 6 pg / mL and MIC50 and MIC90 were 0.094 pg / mL and 3 pg / mL 
respectively and no defined ceftriaxone resistance was detected among S. Typhi 
isolates. Some finding in Kuwait have shown that S. Typhi producing extended 
spectrum beta lactamases (ESBL) are circulating [182]. We did not confirm if the 
strains isolated from Nepal were ESBL producing, due to them only have reduced 
susceptibility. ESBL producing S. Typhi are rare and there are only limited reports 
[183,184],[185].
While in southern Viet Nam the MDR phenotype of S. Typhi has remained at high 
levels over the last 13 years, there have been reports of a return to chloramphenicol 
sensitive S. Typhi isolates in some regions [186,187]. In our study the prevalence of 
chloramphenicol resistance remained high in almost all Asian countries (with the 
exception of China and Indonesia) (18 % in Laos, 19 % in Nepal, 26 % in India 2003, 
which reduced to 14 % in 2006, 26.5 % in Pakistan, and 40 % in Bangladesh).
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Ampicillin resistance remained at a low level in Laos (20 %), Pakistan (17 %), and 
reduced from 26 % to 11 % in India in 2003 and 2006, respectively. Ampicillin 
resistance was particularly high in southern Viet Nam (49 %) and Bangladesh (100 %). 
The correlation between sulfamethoxazole - trimethoprim (co-trimoxazole) resistance 
and chloramphenicol resistance needs to be further defined and may be co-transferred 
on the same plasmid backbone.
The percentage of MDR S. Typhi decreased in India between 2003 and 2006. This 
finding was consistent with a previous report [188]. A study in New Delhi (2005) 
reported 60 % of MDR typhoid cases detected in a cross sectional study of samples 
from 5 different institutes. The increase in chloramphenicol sensitive isolates is 
assumed to be in response to the shift in using chloramphenicol, ampicillin and co- 
trimoxazole to fluoroquinolones as a first choice of typhoid therapy [127,189].
In 2002 to 2004, all countries in the region, with the exception of China and Laos, faced 
a problem of nalidixic acid resistance, with southern Viet Nam as a particular hot spot. 
Our findings were supported by a report of Capoor, 51 % of S. Typhi in the study were 
resistant to nalidixic acid, and nearly 100 % of strains had reduced susceptibility to 
ciprofloxacin [190]. The observation of S. Typhi ciprofloxacin resistance (2 / 259, 1 %) 
in India and (6 / 149, 4 %) in Nepal in this study, together with observations of high- 
level ciprofloxacin resistance in India, Tajikistan and Bangladesh [191-194] might be 
the prelude to a worsening drug resistance problem in Asia. The increase in gatifloxacin 
MIC values raised more concerns on the therapy alternatives in typhoid treatment. 
However, a correlation in increasing MIC between fluoroquinolones has not been 
clarified, and unrelated nalidixic acid sensitivity and decreased ciprofloxacin 
susceptibility has been reported in Europe [195].
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Whilst the collection amassed was the most comprehensive available, there are still 
limitations which may bias the interpretation of the data. The sampling is specifically 
biased to the location of the centers involved in the study. It is clear that S. Typhi 
population is dynamic and may fluctuate within countries and within local regions. Our 
finding may be biased by analyzing a limited sample size in each of the communities 
selected. There may also be different drug usage in the different locations; this in turn 
may affect the drug susceptibility pattern. Nonetheless, this work respects an exhaustive 
snapshot of the changing resistance patterns of S. Typhi in Asia.
In conclusion, the emergence and persistence of MDR and nalidixic acid resistant S. 
Typhi is a major problem across Asia. We suggest that outbreaks of fluoroquinolone 
resistant S. Typhi may be common in future years, owing to the pressure placed on 
fluoroquinolonses. Although the reduced susceptibility to ceftriaxone and resistance to 
azithromycin were found, it was rare. Thus, these antimicrobial agents would be safe to 
use clinically in order to potentially eliminate the development of fluoroquinolone 
resistance. No drug has ever been developed specifically for typhoid fever and there are 
very few potential targets in the Salmonellae against which new drugs could be 
designed [196]. Treating clinicians should consider the ongoing antimicrobial resistance 
problem and use current drugs more efficiently and use the best drugs available in the 
most sensible regime in order to prevent further resistance. Policies for the drug 
markets, especially in Viet Nam, where drugs are sold casually, should be emphasized 
in order to eliminate the development of drug resistance and the using of antimicrobial 
in farming should be legislated. Enhancing both education of health professionals and 
the community to ensure appropriate antimicrobial usage and to avoid self-medication 
respectively would be other urgent strategies [177], The knowledge of the extent of
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antimicrobial resistance should be an important issue when discussing 
implementation of a comprehensive typhoid vaccination strategy.
M olecular m echanism s o f  antim icrobial resistances in.& Typhi
4. Molecular mechanisms of quinolone resistance and reduced susceptibility to 
fluoroquinolones in S. Typhi
4.1 Introduction
Nalidixic acid resistance and reduced susceptibility to fluoroquinolones in S. Typhi 
correlates with treatment failure and has been reported in Viet Nam and internationally 
[165,192,197-201]. However, fluoroquinolones resistance in S. Typhi is relatively 
uncommon compared to the resistance frequency in other Enterobacteriaceae [99]. As a 
result, newer generations of fluoroquinolones remain the drug of choice for typhoid 
treatment [167,202]. It has been suggested that a number of different fluoroquinolones 
resistance mechanisms may play a role with this phenotype in the Salmonellae species 
[203]. As multiple mechanisms may be involved in fluoroquinolone resistance, an 
extensive study in the mechanisms of nalidixic acid resistance and reduced 
susceptibility to fluoroquinolones in S. Typhi is necessary.
All fluoroquinolones have an identical mechanism of action [204] implying that 
resistance to one fluoroquinolone will confer resistance to other fluoroquinolones [203]. 
They act by inhibiting the topoisomerase genes leading to inhibition of DNA 
replication. Four main mechanisms conferring fluoroquinolone resistance in 
Salmonellae have been extensively studied, wherein mutations in the genes encoding 
DNA gyrase and topoismerase IV are the most commonly observed. Decreased 
accumulation of drug molecules due to decreased fluoroquinolone uptake [205,206], 
increased active efflux pump activity [108,207] and more recently described plasmid 
mediated quinolone resistance (PMQR) are the other mechanisms accounting for 
fluoroquinolone resistance in Salmonellae. While, plasmid-mediated quinolone 
resistance of the Qnr has been widely observed in other Enterobacteriaceae worldwide, 
there are limited reports in Salmonellae [208-211],
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Nalidixic acid resistance and reduced susceptibility to fluoroquinolones in S. Typhi 
strains has linked to point mutations within codon 83 and codon 87 in the QRDR 
(Quinolone Resistance Determining Region) of gyrA gene. Some mutations have also 
been observed outside the QRDR of gyrA gene [190,212,213] and a high level of 
fluoroquinolone resistance could possibly be a combination of mutations in the target 
regions of the gyrA and parC genes [214].
Several methods have been reported for the detection of point mutations in bacterial 
genes including those within the QRDR of the gyrA, gyrB, parC  and parE  (Table 4.1). 
In this study we firstly applied the conventional dideoxy DNA sequencing to detect 
alterations in the target enzymes of S. Typhi isolates. More recently, due to 
improvements in DNA sequencing technology we have employed pyrosequencing for 
rapid screening of a large amount of S. Typhi strains for known mutations in gyrA gene. 
Here we have screened 462 strains (337 from southern Viet Nam, 121 from India and 4 
from Pakistan) and 14 nalidixic acid susceptible S. Typhi (2 from China, 5 from India, 2 
from Indonesia, 2 from Pakistan and 3 from Viet Nam) to identify the mechanisms of 
quinolone resistance and reduced susceptibility to fluoroquinolones in S. Typhi.
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4.2 Results
4.2.1 DNA sequence analysis of QRDR of gyrase and DNA topoisomerase IV 
encoded genes and effects of the mutations on fluoroquinolone susceptibility
Four hundred and seventy six S. Typhi strains were subjected to molecular analysis. 
DNA was extracted using two methods, CTAB (Cetyl Trimethyl Ammonium Bromide) 
method and Promega kit as described in section 2.7.1. In comparison, CTAB method 
produced more DNA than the Promega method. However, the Promega kit produced 
better DNA quality and was easier to perform, resulting from the use of the ready-to-use 
reagents. DNA extraction using Promega kit then was reproducible and not time 
consuming. Thus, depending on reagents availabilities, Promega kit was considered 
preferable.
DNA was quantified before using as a template for PCR reactions. A 347 bp fragment 
of gyrA (Figure 4.1), a 345 bp fragment of gyrB, a 270 bp fragment parC  and a 240 bp 
fragment parE of the QRDR (Quinolone Resistant Determining Region) were amplified 
by PCR.
The PCR amplicons from the gyrase and TopoIV genes including gyrA (100 strains), 
gyrB (85 strains), parC  (146 strains) and parE (62 strains) were directly sequenced by 
conventional sequencing in the first part of the experiment. The remainder of samples 
(376 strains) was screened for gyrA mutations using pyrosequencing since the available 
of new robust sequencing facility in the Unit. The Sanger sequencing using the CEQ 
8000 allows nucleotide sequencing length of up to approximately 700 bp. In 
comparison with other methodologies, this is an ideal technique to detect novel 
mutations in such length of fragment (Table 4.1). However, sequencing using the CEQ 
8000 system can only be performed after one PCR reaction, one step of PCR amplicon
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purification, one sequencing reaction followed by a capillary gel electroforesis. PCR 
amplicons have to be purified to avoid any possible inhibition during the sequencing 
process. The mutations in gyrA and parC  genes detected using CEQ8000 system are 
represented in Figure 4. 2.
2 0 7 2 -
600
300 -
100  -
L a d d e r 10 12 N e g
Figure 4.1 A representative agarose gel of the PCR amplicons for the QRDR
fragment of the gyrA gene (347bp)
Lanes 1 to 12 are gyrA gene PCR amplicons of S. Typhi DNA isolated from An Giang 
province, southern Viet Nam. The DNA from S. Typhi isolates that were amplified are 
lane 1; AG 146, lane 2; AG 152, lane 3; AG 160, lane 4; AG164, lane 5; AG 165, lane 
6 ; AG 166, , lane 7; AG 168, lane 8 ; AG 169, lane 9; AG 170, lane 10; AG 176, lane 
11; AG 177, lane 12; AG 178. Neg; negative control performed using the same PCR 
mix with distilled water instead of DNA sample.
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A - U I 5 1 0 6 .R .D 0 5  ANA PAC CAT CCC CAC GGC GAT TCC GCA GTG TAT g| c ACC ATC GTT CGT ATG GCG CAG CCA TTC TC
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C o n s e n s u s PAC CAT CCC CAC GGC GAT TCC GCA GTG TAT G f c ACC ATC GTT CGT ATG GCG CAG CCA TTC TC
C o n s e n s u s  AA T r a n s l . T I P T A I P Q C M A P S F V W R S H S R
<1 1 *•! w 1
Figure 4.2 A representative DNA sequence alignent from the gyrA gene of a 
mutant S. Typhi strain
The alignments were performed using CEQ 2000 XL software with the reference 
sequence was CT 18 (Gene ID 1248826) from NCBI webpage (www.ncbi.nlm.nih.gov). 
The strain amplified and sequenced here is strain UI 5106 from Laos and contains the 
substitution Asp87—>Gly (replacing GAC with GGC).
Pyrosequencing latterly appeared to be a robust assay for short sequence analysis. Also 
the assay was a reliable solution for rapid screening of known mutations. The
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sequencing reaction was performed directly after amplification of the target fragment. 
The limitations of pyrosequencing are that the technique is only applicable for 
fragments with less than 70 bp and the software has limitations in analyzing multiple 
mutations between 15 nucleotide sequences. However, the results can be analyzed by 
comparing the conventional trace files or using appropriate software, such as the alignX 
tool of the Vector NTI Suite 7 programme.
The percentage of each mutation observed in the gyrA and parC genes is depicted in 
Figure 4.3. Seven different types of mutation were detected in the 476 strains analyzed. 
The most prevalent amino acid substitution was Ser 83 —> Phe (TCC —> TTC) observed 
in 407 / 462 (88 %) strains. Forty seven isolates (10 %) had a substitution at codon 83 
changing Ser —> Tyr (TCC —» TAC). Two isolates showed an Asp 87 —> Gly (GAC —> 
GGC) substitution and two isolates had an Asp 87 —> Ala (GAC —» GCC) substitution. 
Two Vietnamese S. Typhi strains had a double amino acid substitution in the gyrA gene; 
these were isolates DT 18 (Ser 83 —> Phe and Asp 87 —► Gly) and AG 152 (Ser 83 —► 
Phe and Asp 87 —> Asn). Two isolates from India, C 2114 and C 2115 had triple amino 
acid substitutions including double mutations in gyrA (Ser 83 —> Phe and Asp 87 —> 
Gly) and a single mutation in parC (Ser 80 —> lie). All amino acid substitutions that 
were found are presented in Table 4.2.
S. Typhi strains observed for gyrA mutations were also analyzed for mutations in the 
QRDRs of gyrB (85 strains), parC  (146 strains) and parE  (62 strains) genes [147,225]. 
No mutations were detected in the gyrB, parC  or parE  genes of the strains analyzed 
apart from 2 strains which had a substituted Ser 80 —> lie in the parC  gene. One 
hundred and fifty two isolates were additionally screened for the presence of plasmid-
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mediated quinolone resistance genes qnrA and qnrS following the previous described 
method [210]; none were detected in these S. Typhi screened.
■S83F
■S83Y
•S83F<mdD87G 
■S83FandD87N 
■S83F, D87G and S80I
■ D87A
■ D87G
Figure 4.3 The proportions of amino acid substitutions detected in the gyrA and 
parC genes of S. Typhi strains from Asia
Colours depict the proportion of each mutation type found in the collection, red; the 
number of S. Typhi strains with the substitution Ser83 —> Phe (S83F), green; the 
number of S. Typhi strains with the substitution Ser83 —* Tyr (S83Y), light purple; the 
number of S. Typhi strains with the substitution Ser83 —> Phe and D87 —> Gly (S83F 
and D87G), purple; the number of S. Typhi strains with the substitution Ser83 —> Phe 
and Asp87 —> Asn (S83F and D87N), pink; the number o f S. Typhi strains with the 
substitution Ser83—»Phe, Asp87—»Gly (D87G) and Ser80—>Ile (S80I), light blue; the 
number of S. Typhi strains with the substitution Asp87—»Ala (D87A), blue; the number 
of S. Typhi strains with the substitution Asp87—>Gly (D87G).The number depicts the 
absolute number o f each mutant which were detected in 462 S. Typhi strains of the 
Asian collection.
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4.2.2 MIC comparison of quinoiones and fluoroquinolone susceptibilities of S. 
Typhi strains with and without mutations in the gyrA and parC  genes
The MICs to nalidixic acid and ofloxacin of strains carrying the different mutations 
were compared. Overall, the MIC values to nalidixic acid were significantly increased 
when groups with mutations were compared to non - mutants (p < 0.001). The MIC 
range for nalidixic acid varied from 2 pg / mL to 256 pg / mL for the mutants arid from 
0.012 pg / mL to 256 pg / mL for the non - mutants as shown in Figure 4. 4.
The MIC to ofloxacin in the nalidixic acid resistant S. Typhi mutants varied amongst 
the assorted mutant groups and ranged from 0.023 pg / mL to 12 pg / mL across all 
mutants (Figure 4.5). The MIC to ofloxacin of strains with single mutations varied
. r
<-r*'
within the susceptible range, from 0.023 pg / mL to 2 pg / mL (according to the CLSL 
guidelines, < 2 pg / mL for sensitive strains and > 8 pg / mL for resistant strains). The 
MIC to ofloxacin was significantly increased in mutants when compared to the nori -
mutants (p value < 0.001). However, this was not observed between non - mutants and
&■Tjf
the single mutation groups or amongst the differing single mutants themselves. Th% 
discrepancy is dependant on limited numbers of isolates in the double and triple mutant 
groups. Generally, double mutations caused a decreased susceptibility to ofloxacin in 
comparison with single substitutions (Figure 4.6),
The MIC values of the two double mutants (DT 18 and AG 152) to ofloxacin were 2 pg 
/ mL and 3 pg / mL respectively. A comparison between the two double mutations 
found that strain AG152 with S83F and D87N mutations demonstrated increased 
resistance to ofloxacin with respect to strain DT 18 with S83F and D87G substitutions. 
Strains C 2114 and C 2115 with triple mutations, a combination of double gyrA 
mutations (S83F and D87G) and single parC  (S80I) mutation caused the highest level
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of resistance to ofloxacin (Figure 4. 6 ) with ofloxacin MICs of 6  pg / mL and 12 jug / 
mL, respectively.
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Figure 4.4 The correlation between MIC to nalidicic acid between the no mutation 
and mutation groups in thegyrA gene of S. Typhi strains
The median value (with the interquartile range represented by the box at the 5th -  95th 
percentile by error bars) of the MIC of nalidixic acid of two S. Typhi groups, no 
mutation and mutation. Dots represent the outliers, n; the number of the S. Typhi was 
observed. The difference of MIC value between no mutation and mutation S. Typhi 
groups were evaluated by Wilcoxon test. (CLSI guideline MIC < 16 pg / mL for 
sensitive and MIC > 32 pg / mL for resistant strains).
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Figure 4.5 The MIC comparison to ofloxacin between the no mutation and the 
mutation groups of S. Typhi isolates in Asian countries
The median value (with the interquartile range represented by the box at the 5 th -  95th 
percentile by error bars) of the MIC of ofloxacin of two S. Typhi groups, no mutation 
and mutation. Dots represent the outliers, n; the number of the S. Typhi strains 
observed. The difference in MIC value between no mutation and the mutation S. Typhi 
groups was evaluated by Wilcoxon test. The y axis represents the logio value of 
ofloxacin. (According to CLSI guidelines, the MIC breakpoints are < 2 pg / mL for 
OFX (sensitive) and > 8  pg / mL for OFX (resistant)).
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Figure 4.6 The effect of multiple mutations in the gyrA and parC  genes on MIC to 
ofloxacin in S. Typhi isolates from Asian countries
t h  t hThe median value (with the interquartile range represented by the box at the 5 - 9 5  
percentile by error bars) of the MIC to ofloxacin of different mutations and no mutation 
groups. Dots represent the outliers. The y axis represents the logio value of the MICs 
ofloxacin.
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The MICs to ciprofloxacin were also compared between the mutant and non - mutant 
groups. The mutants demonstrated a significant increase in MIC to ciprofloxacin with 
p  < 0.001 using the Wilcoxon test (Figure 4.7). Mutations in gyrA gene again correlated 
with a reduced susceptibility to ciprofloxacin. Amongst the differing single mutation 
strains, there was no significant difference in the MICs to ciprofloxacin (MIC ranging 
from 0.006 pg / mL to 0.75 pg / mL). However, the MICs of the single substitution 
D87A (mean, 0.093 pg / mL) were slightly lower than that of the other single mutation 
groups. The MIC values of the substitutions at position 83 demonstrated the most 
variation when compared to strains with other substitutions. The ciprofloxacin MICs 
ranged from 0.06 pg / mL to 0.75 pg / mL for the strains with the S83F substitution and 
from 0.006 pg / mL to 0.38 pg / mL for those strains with the S83Y substitution. The 
difference in MIC levels to ciprofloxacin of this group may not only be the result of a 
single substitution but also other secondary contributing factors that were not detectable 
in these assays. There was no significant difference in MICs to ciprofloxacin within the 
double mutants, and similar to the MICs to ofloxacin, the triple mutant had the highest 
level of resistance to ciprofloxacin with MICs of 4 pg / mL for the strain C 2114 and 6 
pg / mL for the strain C 2115 (Figure 4.8).
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Figure 4.7 The MIC comparison to ciprofloxacin between the no mutation and the 
mutation groups of S. Typhi isolates in Asian countries
The median value (with the interquartile range represented by the box at the 5 th -  95th 
percentile by error bars) of the MIC to ciprofloxacin of two S. Typhi groups, no 
mutation and mutation. Dots represent the outliers, n; the number o f the S. Typhi strains 
tested. The difference of MIC value between non - mutant and mutant S. Typhi groups 
was evaluated by Wilcoxon test. The y axis represents the logio value of the MICs 
ciprofloxacin. According to CLSI guideline, the MIC breakpoints are < 1 pg / mL for 
ciprofloxacin sensitive and > 4 pg / mL for ciprofloxacin resistant strains).
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Figure 4.8 The effect of multiple mutation in the gyrA and parC genes on MIC to 
ciprofloxacin in S. Typhi isolates from Asian countries
The median value (with the interquartile range represented by the box at the 5th -  95th 
percentile by error bars) of the MIC to ciprofloxacin of different mutation S. Typhi 
groups. Dots represent the outliers. The y axis represents the logio of the MIC value of 
ciprofloxacin.
MIC levels were also assessed in all mutant groups to the newest therapeutic 
fluoroquinlone, gatifloxacin. According to the CLSI guidelines [141], all S. Typhi 
isolates were susceptible to gatifloxacin, the MIC to gatifloxacin ranged from 0.032 pg / 
mL to 0.5 pg / mL in all tested strains. There was a significant difference in MIC to 
gatifloxacin between the mutant strains and the non - mutant strains, p  < 0 . 0 0 1  using 
Wilcoxon test (Figure 4.9). There was no significant difference in MIC level to 
gatifloxacin amongst the differing mutant groups with the exception of the triple 
mutants (MIC 2 pg / mL for the strain C 2114 and MIC 2 pg / mL for the strain C 2115) 
(Figure 4.16).
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Figure 4.9 The MIC comparison to gatifloxacin between the mutation and the no 
mutation groups of S. Typhi isolates in Asian countries
The median value (with the interquartile range represented by the box at the 5 th -  95th 
percentile by error bars) of the MIC of gatifloxacin of two S. Typhi groups, no mutation 
and mutation. Dots represent the outliers, n; the number of the S. Typhi strains tested. 
The difference of MIC value between the non - mutant and the mutant S. Typhi groups 
was evaluated by Wilcoxon test. The y axis represents the logio value of the MICs 
gatifloxacin. According to CLSI guideline, the MIC breakpoints are < 2 pg / mL for 
gatifloxacin sensitive and > 8 pg / mL for gatifloxacin resistant strains).
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Figure 4.10 The effect of multiple mutation in the gyrA and parC  genes on MIC to 
gatifloxacin in S. Typhi isolates from Asian countries
The median value (with the interquartile range represented by the box at the 5 th -  95th 
percentile by error bars) of the MIC of gatifloxacin of different mutation S. Typhi 
groups. Dots represent the outliers. The y axis represents the logio of the MIC value of 
gatifloxacin.
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4.2.3 The correlation of increasing MIC of differing fluoroquinolones in S. Typhi 
mutants and non - mutants
The MIC data of all strains for ciprofloxacin, ofloxacin and gatifloxacin were compared 
to attempt to identify any linear correlation between MIC patterns of the three tested 
antimicrobials as shown in Figure 4.11, 4.12 and 4.13. There was a statistically 
significant linear correlation between all three antimicrobials tested using Pearson test 
for linear correlation by R software version 2.0, whereby an increase in MIC to either 
gatifloxacin, ciprofloxacin or ofloxacin correlated with a direct increase to a 
corresponding fluoroquinolones. A direct relationship was observed most clearly 
between ciprofloxacin and ofloxacin, where gradual increases in MICs were reflected 
the rise in the other two antimicrobials (Figure 4.12). The linear relationship in MIC 
increase between the different fluoroquinolones was also observed between 
ciprofloxacin and gatifloxacin and between ofloxacin and gatifloxacin; however, this 
effect was less pronounced (Figure 4.11 and Figure 4.13). An increase in MICs with 
gatifloxacin generated a step wise increase in MIC with both ciprofloxacin and 
ofloxacin. This effect may be due to the differing activities and binding location of the 
gatifloxacin when compared to both ofloxacin and ciprofloxacin.
116
M olecular m echanism s o f antim icrobial resistances in S. Typhi
Oo
CN P< 0.001
op
oin
d
o
<N
d
o
o
CNO
d
o
d
0.02 0.05 0.10 0.20 0.50 1.00 2.00 5.00 10.00
Ofloxacin ( jig/mL)
Figure 4.11 The relationship of ofloxacin and gatifloxacin MICs of S. Typhi 
mutants and non - mutants from Asian countries
The y axis represents the logio MIC value of gatifloxacin and the x axis represents the 
corresponding logio MIC value of the ofloxacin of each tested S. Typhi isolate. Each, 
point represents an individual S. Typhi strain (n = 297). The relationship is statistically 
significant (p < 0.001) using a Pearson test for linear correlation (cor = 0.812, Cl 95 %).
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Figure 4.12 The relationship of ciprofloxacin and ofloxacin MICs of S. Typhi 
mutants and non - mutants from Asian countries
The y axis represents the logio MIC value of ofloxacin and the x axis represents the 
corresponding logio MIC value of the ciprofloxacin of each tested S. Typhi isolate. Each 
point represents an individual S. Typhi strain (n = 297). The relationship is statistically 
significant (p < 0.001) using a Pearson test for linear correlation (cor = 0.867, Cl 95 %).
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Figure 4.13 The relationship of ciprofloxacin and gatifloxacin MICs of S. Typhi 
mutants and non - mutants from Asian countries
The y axis represents the logio MIC value of gatifloxacin and the x axis represents the 
corresponding logio MIC value of the ciprofloxacin of each tested S. Typhi isolate.. Each 
point represents an individual S. Typhi strain (n = 297). The relationship is statistically 
significant {p < 0.001) using a Pearson test for linear correlation (cor= 0.816, Cl 95 %).
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4.2.4 In vitro time - kill analysis
4.2.4.1 In vitro time - kill analysis of S. Typhi mutants to ofloxacin
MIC testing is useful for measuring resistance, however, it does not provide information 
on killing dose and how effective the antimicrobial is over a prolonged time period. One 
isolate that was representative of each of mutant groups (8 strains) and one non - mutant 
strain of S. Typhi was selected for in vitro time - kill experiments. The non - mutant 
strain was CT 76 (MIC 0.064 pg / mL to ofloxacin; MIC 0.008 pg / mL to gatifloxacin), 
and the mutant strains were DT54 (gyrA Ser 83 —> Phe; MIC 1.0 pg / mL to ofloxacin; 
MIC 0.25 pg / mL to gatifloxacin), D 43 (Ser 83 —> Tyr; MIC 0.5 pg / mL to ofloxacin; 
MIC 0.19 pg / mL to gatifloxacin), CT 144 (Asp 87 —» Gly; MIC 1 pg / mL to 
ofloxacin; MIC 0.19 pg / mL to gatifloxacin), 10880 (Asp 87 —> Ala; MIC 0.5 pg / mL 
to ofloxacin; MIC 0.032 pg / mL to gatifloxacin), A 54 (Asp 87 —> Asn; MIC 1 pg / mL 
to ofloxacin; MIC 0.094 pg / mL to gatifloxacin), DT 18 (Ser 83 —► Phe and Asp 87 —> 
Gly; MIC 2.0 pg / mL to ofloxacin; MIC 0.5 pg / mL to gatifloxacin), AG 152 (Ser 83 
—► Phe and Asp 87 —> Asn; MIC 3.0 pg / mL to ofloxacin; MIC 0.25 pg / mL to 
gatifloxacin) and C 2114 (Ser 83 -* Phe, Asp 87 —> Gly and S801{parQ; MIC 6.0 pg / 
mL to ofloxacin; MIC 2 pg / mL to gatifloxacin). The mean changes in logio CFU / mL 
over 24 hours at 1, 2, 4, 8 and 16 times MIC to ofloxacin are presented in Figure 4.14.
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Wild type strain CT 76 (a) and S. Typhi DT 54 (Ser83—>Phe) (b) were exposed to 
ofloxacin.
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-S.Typhi D 43 (Ser83—>-Tyr) (c) and S. Typhi 10880 (Asp87—>Ala) (d) were exposed to 
ofloxacin.
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S. Typhi CT 144 (Asp87—►Gly) (e) and A 54 (Asp87—>Asn) (f) were exposed to ofloxacin.
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S. Typhi DT 18 (Ser83—>Phe and Asp87—►Gly) (g), S. Typhi AG 152 (Ser83—>Phe and 
Asp87—>Asn) (h) were exposed to ofloxacin.
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S. Typhi C 2114 (Ser83—>Phe and Asp87—*Gly in gyrA and Ser80—Tie in parC) (i) was 
exposed to ofloxacin.
Figure 4.14 In vitro time - kill experiments of S. Typhi exposed to ofloxacin at 
concentrations of 1 x to 16 x MIC over 24 hours
In vitro experiments were performed in duplicate and results represent the mean of 
duplicate values, with error and standard deviation. The y axis represents the logio value 
of S. Typhi CFU / mL. The x axis represents the time in hour. The S. Typhi growth was 
sampled at 6 time points, 30 minute, 1 hour, 2hours, 4 hours, 6 hours and 24 hours 
(section 2.6). Each line depicts an individual ofloxacin concentration in MIC and the 
MIC concentrations used against the organism tested. The subtitle of each diagram 
represents the mutation, the name of the mutant and the antimicrobial used.
Ofloxacin showed rapid killing of the non - mutant, fluoroquinolone susceptible strain 
CT 76 at all concentrations, and we can also see concentration dependent killing (Figure 
4.14a). There was a slight effect of MIC concentration of ofloxacin on killing when 
comparing the overall effect on the mutants S83F and S83Y (Figure 4. 15b and 4. 15c). 
One time the MIC of ofloxacin was more effective at killing the S83F mutant than the 
S83Y mutant. However, the S83F substitution demonstrated a higher level of resistance 
over time (in comparison to the S83Y mutant), with more organisms surviving at 2x
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MIC after 6 hours of exposure (Figure 4. 15b and 4. 15c). The viable count of the S83F 
mutant reduced from 10s CFU / mL to 104 CFU / mL after six hours exposure at 2 x
o
MIC, whilst the concentration of the S83Y mutant was reduced from 10 CFU / mL to 
103 CFU / mL after the same exposure period. The majority of ofloxacin concentrations 
did not kill the strains with a single mutation at position 83, except after prolonged 
exposure at 16 x MIC (Figure 4. 15b and 4.14c). Time kill analysis of the position 87 
substitutions showed that the D87G strain was more resistant to ofloxacin than those 
strains with the substitution of Alanine or Asparagine for Aspartic acid at the same 
position. The number of viable D87G and D87A mutant bacteria decreased from 107 
CFU / mL to 102 CFU / mL after 6 hours with 16 x ofloxacin MIC. Whilst the D87N 
strain decreased from 107 CFU / mL to 10 CFU / mL over the same exposure duration 
and at the same concentration of ofloxacin (Figure 4.14d and 4.14e).
Time kill analysis comparison of the double gyrA gene mutations, DT 18 (S83F & 
D87G) and AG 152 (S83F & D87N), demonstrated that the viable counts of bacteria of 
both mutants decreased in the first 6 hours of exposure to 2x MIC tol6x MIC and lx 
MIC to 16x MIC of ofloxacin, respectively (Figure 4.14g and 4.14h). After six hours of 
exposure to ofloxacin the bacterial counts of the S83F D87G strains recovered to 107 
CFU / mL while the bacterial count of the S83F D87N mutation decreased to 102 CFU / 
mL after 24 hours (Figure 4.14g and 4.14h). Complete killing of both the double 
mutants could not be achieved at any MIC in the experiment over a 24 hour period. 
There was only limited bactericidal activity of ofloxacin against the triple mutant in 
comparison to the control. This lack of bactericidal activity was seen with all ofloxacin 
concentrations over a 24 hour period in strain C 2114 with the substitution S83F D87G 
in gyrA and S80I inparC gene (Figure 4.14i).
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4.2.4.2 In vitro time - kill analysis of S. Typhi mutants with gatifloxacin
A subset of representative mutations and the non - mutant strain were subjected to a
time - kill experiment to gatifloxacin. These strains were, CT 76, HTD 798 (Ser83 —>
Phe; MIC 1 pg / mL to ofloxacin; MIC 0.125 pg / mL to gatifloxacin), CT 144, DT 18
and C 2114. The mean changes in logio CFU / mL with exposure to differing
concentrations of gatifloxacin over a 24 hour period are presented in Figure 4.15.
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Wild type S. Typhi strains CT 76 (a) and the mutant HTD 798 (Ser83—>Phe) (b) were 
exposed to gatiloxacin.
128
M olecular mechanism s o f antim icrobial resistances in S. Typhi
c D87G CT144 vs. Gatifloxacin
10
o
3 '
u_O
0 2 4 6 8 10 12 14 16 18 20 22 24
Tim e (hour)
—^ - - C o n t r o l  - ® - l * M I C  “•~ itr~2*M IC  «-A~~*4*M IC  - ~ * r ~ 8*M IC  “ ♦ » ~ 16*M IC
d S83FD87G_DT 18 vs. Gatifloxacin
12
o
E
3u_
0 2 64 8 10 12 14 16 18 20 22 24
Time (hour)
S. Typhi CT 144 (Asp87->Gly) (c) DT 18 (Ser83-^Phe and Asp87->Gly) (d) were 
exposed to gatifloxacin.
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S. Typhi C 2114 ((Ser83—►Phe, Asp87—>Gly in gyrA and Ser80—>Ile inparC) (e) was 
exposed to gatifloxacin.
Figure 4.15 In vitro time - kill experiments of S. Typhi strains exposed to 
gatifloxacin
In vitro experiments were performed in duplicate and results represent the mean of 
duplicate values, with error and standard deviation. The y axis represents the logio value 
of S. Typhi CFU / mL. The x axis represents the time in hour. The S. Typhi growth was 
sampled at six time points, 30 minute, 1 hour, 2hours, 4 hours, 6 hours and 24 hours 
(section 2.6). Each line depicts an individual gatifloxacin concentration in MIC and the 
MIC concentrations used against the organism tested. The subtitle of each diagram 
represents mutation type, the name of the mutant and antimicrobial used.
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Gatifloxacin at 4 x MIC had the largest effect on decreasing the viable number of S. 
Typhi strains CT 76, HTD 798 and CT 144 (Figure 4.15 a,b,c) in the first 30 minutes of 
exposure and demonstrated total killing after 6 hours. Gatifloxacin rapidly killed strain 
CT 76 after 4 hours, this occurred independently of the concentration of the 
antimicrobial (Figure 4.15a). The survival of the HTD 798 (S83F mutant) was only 
observed in lx MIC of gatifloxacin yet the viable bacterial count decreased from 10 
CFU / mL to 105 CFU / mL (Figure 4.15b). CT 144 (D87G mutant) was more 
susceptible to gatifloxacin than the HTD 798 (S83F mutant) mutant since the viable 
bacterial concentrations were reduced from 107 CFU / mL to 103 CFU / mL after 4 
hours at all concentrations of gatifloxacin (Figure 4.15c).
Viable counts of S. Typhi DT 18 (S83F and D87G mutant) decreased after 4 hours 
followed by some re-growth, higher concentrations (8x and 16x MIC) of gatifloxacin 
showed a more pronounced bactericidal effect against this double mutant (Figure 
4.15d). There was no total killing activity of gatifloxacin against the triple mutation S. 
Typhi C 2114 with a double gyrA substitution (S83F D87G) and a single substitution in 
theparC  gene (S80I) (Figure 4.15e).
The mean S. Typhi inoculum calculated from all mutants against 4 times MIC of 
ofloxacin and gatifloxacin at the starts of the killing assay (Time 0) were 5.26 x 107 
CFU/mL (3.30x 107 -  7.20 x 107, Cl 95%) and 2.99 x 107 CFU/mL (1.23 x 107 -  7.20 x
y
10 , Cl 95%), respectively. Therefore, the results calculated after 4 hours exposure to 4 
times MIC of ofloxacin were dependant on the experimental behavoiur of the individual 
mutants and not the initial starting innoculum.
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Time - kill analysis demonstrated that an increase in survival ability significantly 
correlated with the number of mutations at 4x MIC of ofloxacin at 4 hours of exposure 
(p  linear trend <0.001) (Figure 4. 16), However, the number of mutations did not 
statistically influence the concentration of bacteria in 4x MIC of gatifloxacin at 4 hours 
(p  linear trend was 0.002, the linear correlation is significant if p  linear trend is less than 
0.001) (Figure 4.17).
p(lineartrend)<0.001
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Figure 4.16 The killing rate relationship with ofloxacin to different S. Typhi 
mutants and non - mutants from Asian countries
The y axis represents the logio CFU/mL of S. Typhi strains after 4 hours of exposure to 
4x MIC of ofloxacin. The x axis represents 4 S. Typhi groups including non - mutant, 
single, double and triple mutation groups. Each point represents an individual S. Typhi 
strain (n = 11). The relationship is statistically significant with p  linear trend < 0.001 
using linear regression test.
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Figure 4.17 The killing rate relationship with gatifloxacin to different S. Typhi 
mutants and non - mutants from Asian countries
The y axis represents the logio CFU/mL of S. Typhi strains after 4 hours of exposure to 
4x MIC of ofloxacin. The x axis represents 4 S. Typhi groups including non - mutant, 
single, double and triple mutation groups. Each point represents mean of logioCFU / mL 
of an individual S. Typhi strain (n = 8). p  linear trend was 0.002 using linear regression 
test.
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4.3 Discussion
This is the first extensive, systemic molecular characterization of a large number of 
nalidixic acid resistant and reduced susceptibility to fluoroquinolones S. Typhi isolates 
across Asian countries. All S. Typhi isolates (n = 462) which were resistant to nalidixic 
acid and had reduced susceptibility to fluoroquinolones haboured at least one mutation 
in the gyrA gene; our findings were supported by previous studies looking at 
fluoroquinolone resistance in the Salmonella [147,162,199,226].
The majority of the mutations in gyrA and parC  genes caused resistance to nalidixic 
acid and reduced susceptibility to ofloxacin, ciprofloxacin and gatifloxacin. Whilst 
statistical calculations demonstrated significant differences in MIC levels between 
mutant and non - mutant groups, all the MIC values were still lower than the MIC 
corresponding to resistance according to the current CLSI guidelines [141]. We 
originally observed only two S. Typhi isolates in India which were completely resistant 
to ofloxacin and ciprofloxacin and these strains had only intermediate resistance to 
gatifloxacin, thus demonstrating differing biological activities of the various classes of 
fluoroquinolones.
Substitutions at position 83 of the gyrA were the most common mutation detected in the 
Vietnamese and Indian clinical isolates (n = 405); the substitution of Phenylalanine for 
Serine at codon 83 in the gyrA gene occurred mostly in Viet Nam isolates. The 
substitution of Tyrosine for Serine was only detected within Indian isolates. 
Investigating the mechanism responsible for nalidixic acid resistance in seven S. Typhi 
isolates in India, Capoor did not find any strains with a substitution at position 83 in the 
gyrA gene [190]. Double and triple mutations were also found to be uncommon in this 
Indian study. Whilst the triple amino acid substitution (Ser83 —► Phe, Asp87 —» Gly in
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gyrA and Ser80—file in parC) genes in our study confirmed the result of Gaind’s 
findings [191],Capoor and Dimitrov found that ciprofloxacin resistant S. Typhi strains 
had a different mutation in gyrA gene to those detected here [190,213]. A similar study 
conducted in twenty-five and six strains of S. Typhi which had decreased susceptibility 
to ciprofloxacin and were ciprofloxacin susceptible, respectively, attempting to identify
the genetic basis of nalidixic acid resistant and reduced susceptibility to
(
fluoroquinolones S. Typhi did not find any mutation in the QRDR of the gyrB, parC 
and parE  genes [226]. In other studies conducted with S. Typhi isolates in India, 
Kuwait, mutations were also identified outside the QRDR of the gyrA, parC  genes 
[213].
The basis of a strong association between fluoroquinolone resistance and gyrA 
mutations which are frequently observed at codon 83 and codon 87 is a clustering of 
these mutations around the active site at location Tyr 122 in the protein structure [83], 
this is known to be the binding site of fluoroquinolones (Figure 4.18). Consequently, 
mutations at this location change the structure and the electrical charge of the enzyme 
active site, ultimately, the bactericidal activity of fluoroquinolones is hampered due to 
an inhibition of binding activity of chemical to the DNA gyrase [227].
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Figure 4.18 The A subunits of gyrase enzyme of gram negative bacteria
The figure was adapted from Cabral et al. [228]. (A) The light blue shape depicts the 
subunit A of gyrase, enzyme active site Tyrosine 122 is presented as yellow star and 
double strands DNA are depicted as red and green ribbons. (B) The crystal structure of 
the active site region of gyrase. Helix-turn-helix motifs are shown in yellow and red, 
some secondary structure elements are indicated in light green and dark blue. Two 
commonly mutated loci, Serine 83 and Aspartic acid 87, are shown as numbered black 
spheres.
Although plasmid mediated quinolone resistance has been widely observed in other 
gram negative bacteria, and occasionally defined in ciprofloxacin resistant S. Typhi 
[191], w e did not detect any qnrA and qnrS genes in the collection across Asian
countries. Our work is supported by a study conducted in 499 Salmonella strains in
*•*
France. In this study, none of qnrA, qnrB and qnrS genes were detected in all quinolone 
resistant Salmonella strains including 13 S. Typhimurium strains, 11 S. Enteritidis 
strains and 63 S. Hadar strains except one S. Concord strain which haboured ESBL 
encoded genes (blacix-M-i?) also carried the qnrAl gene [229]. This is consistent with 
the theory that S. Typhi and other Salmonella species maybe genetically isolated and 
organisms have limited opportunity of uptaking genes via conjugation or bacteriophage 
mediated transduction. In order to observe the resistance mechanisms which may be 
related to reducing drug uptake or enhancing efflux pump activity, we additionally 
screened S. Typhi strains for organic solvent resistance using hexane and cyclohexane. 
The screening results showed no cyclohexane resistance in the S. Typhi strains tested. 
However, further experiments using molecular approaches could be designed to
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investigate any genomic variations or gene expression changes that may aid 
understanding of resistance mechanisms. The new application of DNA pyrosequencing 
in this study permitted a level of high throughput sequencing to detect mutations in the 
QRDR of gyrA gene in a large number of S. Typhi strains. However, for extensive 
investigation of mutations, conventional DNA sequencing is still the gold standard. 
There may be an additional need to extend the sequencing of the QRDR regions of 
genes encoding gyrases and topoisomerases VI in the study of fluoroquinolone 
resistance in S. Typhi since recent reports of the presence of mutations related to 
resistant phenotype that lie outside the QRDR region [206].
To understand the correlation between mutations and the MICs of fluoroquinolones, we 
analyzed the mutations in the associations with ofloxacin, ciprofloxacin and 
gatifloxacin which are the current antimicrobial agents used clinically in typhoid 
treatment. Most S. Typhi mutants had high MICs to nalidixic acid, demonstrating a 
significant increase with respect to the non - mutant isolates. The MIC value 
comparisons between the different groups of mutants and the non - mutants to 
ofloxacin, ciprofloxacin and gatifloxacin demonstrated statistically significant variation. 
The MIC comparison among mutation groups showed the triple mutants had the highest 
MIC level, the next highest was the double mutants and the lowest increase was the 
single mutants. We found a linear relationship in MIC values among the mutants 
between ofloxacin and ciprofloxacin to gatifloxacin. This linear relationship was the 
most prominent with respect to the increase in MIC to ofloxacin and ciprofloxacin. This 
is probably due to the similarity in the action mechanism of these antimicrobials to S. 
Typhi isolates and that these chemicals differ from the antimicrobial activities (active 
site target) of gatifloxacin. Gatifloxacin has different capabilities in comparison to other
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fluoroquinolones as it is known to equally affect both the gyrase of Enterobacteriaceae 
and topoisomerase VI in gram-positive bacteria [230],
We found that the MIC levels to fluoroquinolones showed a significant difference 
between the mutants and non - mutants and there was a variation in the MIC level 
amongst the mutants. However, the bactericidal effects of these antimicrobial agents to 
strains with differing mutations were not directly comparable by MIC comparison 
alone. To understand the bactericidal related effect of gyrA and parC  mutations of S. 
Typhi strains, we applied the time - kill experiments to evaluate the resistance 
phenotype of the different S. Typhi mutants detected in Asian clinical collection. 
Historically, time - kill curves have been used in evaluating the efficacy of new drugs. 
Time - kill curves are rarely used to guide therapeutic doses of an antimicrobial. Both 
concentration-dependent and time-dependent bactericidal activities of antimicrobial 
agents can be studied using time - kill analysis [231],
Time - kill analysis demonstrated that a significant increase in survival correlated with 
the number of mutations at 4x MIC of ofloxacin but was not associated with the number 
of mutations at the same concentration of gatifloxacin within 4 hours of exposure. This 
means that combinations of mutations in gyrA and parC  gene influence the resistance to 
ofloxacin, but that mutation combination seems to not affect the efficacy of 
gatifloxacin, however, the triple mutant was an exception. Thus, the time - kill 
experiments suggest that the choice of the fluoroquinolones and the dose used for the 
treatment of S. Typhi may be critical and underlines clearly that resistance measured 
purely by MIC may not be the best marker of dosage. Continued use of the older 
generation fluoroquinolones (ofloxacin and ciprofloxacin) may encourage the 
persistence of resistant isolates and lead to the development of new mutations which
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might compromise the efficacy of the newer generation treatments. Gatifloxacin (and 
potentially other newer generation fluoroquinolones) may prove a better choice , for use 
in typhoid fever as it showed better response in the time - kill assays and may work 
more efficiently than other fluoroquinolones at a corresponding MIC. This provides a 
clear rationale for the clinical assessment of these drugs in randomized controlled trials 
in typhoid fever. If these in vitro data are supported by clinical results then newer 
generation fluoroquinolones should be recommended for the treatment of typhoid fever 
instead of ciprofloxacin and ofloxacin.
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5. Reconstruction of fluoroquinolone resistant mutations in gyrA and parC  genes 
in S. Typhi
5.1 Introduction
Fluoroquinolone resistant phenotypes in Salmonella species have been demonstrated 
here to be associated with mutations in topoisomerase genes which encode gyrase and 
topoisomerase IV enzymes [219,223,226]. In chapter 4, during DNA gyrase screening, 
the substitutions of an amino acid at Ser83 and Asp87 in the gyrA and the substitutions 
of the amino acid at Ser80 in the parC gene of S. Typhi strains were the most 
commonly found mutations. These substitutions have been observed both in clinical 
isolates [162,226,232-234] and when Salmonella isolates have been exposed to 
fluoroquinolones under experimental conditions [220].
Our work demonstrated the overall relationship and the distribution of mutations in the 
parC and gyrA genes with respect to fluoroquinolone resistance in clinical isolates. 
Despite the association of gyrA and parC mutations with fluoroquinolone resistance, the 
real impact of fluoroquinolone resistant mutants has not been investigated in either 
clinical isolates or in vitro selected S. Typhi strains. We know that from data presented 
here that fluoroquinolone resistant S. Typhi has become common and we hypothesize 
that these strains have disseminated across Asia, responding to the common use of these 
chemicals. In other words, these organisms are now under a strong natural selective 
pressure, as demonstrated by SNP selection by Roumagnac et al. [71]. Additionally, 
due to most of the work being performed on clinical isolates, the overall effect of such 
mutations is difficult to assess. Bacterial chromosomes are complex and along with 
mutations associated with antimicrobial resistance there may be compensatory 
mechanisms, in the form of regulators or other mutation sites. Therefore, to assess the 
overall effect, albeit in a laboratory setting, the strains used for such comparisons
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should be isogenic. As a result of introducing point mutations into a known genetic 
background of an attenuated S. Typhi strain, Turner et al. (2006) showed that the single 
amino acid substitution in gyrA was sufficient for resistance to the nalidixic acid but 
remained susceptible to fluoroquinolones. Full resistance to fluoroquinolones required 
more than one mutation in gyrA and a mutation in parC genes [131].
Allelic exchange methodology is recognized as the method of choice for specific 
reconstructive mutagenesis in bacterial genes [235], The allelic exchange method has 
been frequently used in bacteria to generate knockout genes, to carry out phenotypic 
analysis and to learn about their function [235], This method is more suitable than other 
systems for generating individual nucleotide changes as the target site is easily 
controllable and does not leave a genetic “scar”. Other advantages of such vectors are, 
they do not damage the bacterial chromosome (in other locations) and they permit a 
combination of several mutations in the same genetic background [236]. Suicide 
plasmids are so called as they usually contain the sacB gene, which leads to the death of 
the transformed bacteria when they are plated in the presence of sucrose [237]. The 
first application of the allelic exchange method using the suicide vector pJCB12 (as 
used here) constructed deletion mutations in an E. coli vaccine candidate [118], 
followed by secondary study which introduced fluoroquinolone resistance mutations 
into the topoisomerases of S. Typhi strains [131]. Introducing a mutation into bacterial 
cells using allelic exchange methodology involves two steps. Firstly, the entire plasmid 
is integrated into the chromosome by a single-crossover between the homologous 
region, producing a chromosomal duplication. Secondly, the chromosomal duplication 
is segregated by homologous recombination between the flanking direct repeats. As a 
result of recombination, one copy of the gene is left on the chromosome, either the wild
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type copy or the mutant copy (Figure 5.1). Finally, the integrated plasmid is de-selected 
using the sacB expression system [238].
c
iCB-gyrA
o o o
Figure 5.1 Allelic exchange methodology applying for the construction of a 
mutation in the gyrA locus.
The open boxes represent gyrA fragments and the open arrows represent the gyrA gene. 
The line through these represents the point mutation. The other loci of the pJCB 12-gyrA 
are represented by different shaded boxes. Derivatives with pJCB12-gyrA incorporated 
at gyrA occurred depending on which side of the point mutation. The cross-over event 
occurs during homologous recombination. Likewise, following selection for 
recombinants that have lost the y]CB\2-gyrA DNA, both derivatives generate resistant 
mutants or susceptible revertants (adapted from Turner et al) [118].
Although gyrase and topoisomerase IV mutations have been demonstrated to be 
associated with resistance to fluoroquinolones, the real effect of the biological fitness of 
S. Typhi mutants has not been determined. Fitness can be determined in several ways, 
yet classically is usually determined by assessing the growth rate of bacteria in a 
suitable media [239]. Studies conducted with S. Typhimurium have shown that 
antimicrobial resistance conferred the fitness cost and caused the loss of ability to
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colonize the gut of a chicken [203,220]. The biological cost of fluoroquinolone 
resistance has not been assessed in S. Typhi.
To investigate the impact that point mutations generate in fluoroquinolone resistant S. 
Typhi strains, we applied the allelic exchange methodology to reconstruct the common 
gyrA and parC  mutations which were defined in Asian S. Typhi collection. To construct 
these mutants we used an attenuated S. Typhi strain, namely BRD 948. Here, to 
improve accuracy we developed and applied a pyrosequencing technique which is a 
quantitative method to measure the fitness cost of all reconstructed S. Typhi mutants. 
This pyrosequencing technique was carried out in the comparison with the classical 
colony counting method.
5.2 Results
5*2.1 Reconstruction of point mutations in gyrA and parC  genes in S. Typhi
Eight point mutations were chosen for introduction into the gyrA and parC  genes of the 
attenuated S. Typhi BRD 948 strain. These mutations generated five mutants which 
were detected in a collection of clinical isolates and two other unrelated natural 
mutations.
To make the individual mutants, DNA fragments which contained the target mutation 
were amplified by PCR before being digested and ligated into the suicide vector 
pJCB12. CC118Apir E. coli cells were transformed with the recombinant plasmid. The 
transformants which were able to grow on media supplemented with chloramphenicol 
were screened for transformation using specific gyrA (or parC) primers and plasmid 
primers (Figure 5.2). Colonies which gave positive PCR amplicons were subjected to 
plasmid extraction. Plasmid DNA was used for secondary transformation into S. Typhi
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BRD 948 or a S. Typhi BRD 948 derived strain which already harbored mutation(s) in a 
different locus in order to achieve an additional substitution in the same or an additional 
gene.
S. Typhi recombinants were screened using specific primers for gyrA (or parC) 
incorporations. For instance, the primers 47125 and gyrA-11 (or parC-24) (Table 2.4) 
were used for screening gyrA (or parC) gene incorporation respectively. The integration 
of gyrA fragment into the DNA chromosome of the BRD 948 S. Typhi was achieved 
after exposure to chloramphenicol and ampicillin and selection on 5% sucrose. A high 
quality PCR product of the target DNA was prepared for sequencing analysis (Figure 
5.3). A successful mutation reconstruction could only be determined if the nucleotide 
substitution was confirmed by comparing with the S. Typhi Ty2 DNA sequence, which 
was used as a reference (Figure 5.4).
Seven point mutations were engineered in the QRDR of the gyrA and parC  genes of the 
attenuated BRD 948 S. Typhi strain (Table 5.1). Three of these mutants were single 
substitutions, namely, WT 144; Asp87—> Gly (or D87G, replacing GAC with GGC in 
the gyrA gene), WT 297; Asp87—>Ala (or D87A, replacing GAC with GCC in the gyrA 
gene) gene and WT 304; Ser80—>Ile (or S80I, replacing TCG with TAG in the parC 
gene).
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Figure 5.2 PCR screening for the incorporation of gyrA gene in E. coli 
transformants (500bp)
Colonies grown on selective media after electrotransformation were randomly selected 
for screening gyrA gene incorporation using primer pair R6K-01 and gyrA-53. Lane 1 
—► 20, 22, 25, 27, 29—>36; positive bands represent the presences of transformed vector 
in CC118^pir E. coli. Land 21, 23, 24, 26 and 28; negative reactions, no plasmid 
transformed into CC118A,pir E. coli. Hyper ladder I (Bioline, UK) was used as a base 
pair size marker.
lOOO
soo 
600 .
Figure 5.3 DNA amplification of the mutated gyrA gene of the BRD 948 S. Typhi 
derivatives
Pfu PCR was performed with colony 15.8.1 (NAL sensitive) (Lane 1), colony 15.8.2 
(NAL resistance) (Lane 2), colony 15.8.5 (NAL resistance) (Lane 3), colony 25.14.1 
(NAL sensitive) (Lane 4), colony 25.14.6 (NAL resistance) (Lane 5) and colony 
25.14.11 (NAL resistance) (Lane 6). Hyper ladder I (Bioline, UK) was used. PCR 
fragment length was achieved using primers gyrA-31 and gyrA-11 (1.3kb).
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Table 5.1 List of reconstructed mutations in gyrA and parC  genes of the BRD 948 
S. Typhi strain
The seven reconstructed mutations include the substitutions of Glycine (G) and Alanine 
(A) for Aspartic acid (D) at position 87, the substitutions of Phenylalanine (F) and 
Glycine (G) for Serine (S) at position 83 of the gyrA genes and the substitutions of 
Isoleucine (I) for Serine (S) at position 80 of the parC genes.
Mutation types 
(n=7)
gyrA gene parC  gene
Single (3) D87G
D87A
S80I
Double (3) S83F D87G
D87G S80I
S83F D87A
Triple (1) S83F D87G S80I
Three out of seven mutants included two substitutions. Amongst these three mutants, 
two of them were the double gyrA reconstructed mutants which were the WT 141; 
replacing Ser83 with Phe and Asp87 to Gly (or S83F and D87G), and the WT 300; 
replacing Ser83 with Phe and Asp87to Ala (or S83F and D87A) in the gyrA gene. One 
double mutant was constructed, including a single gyrA mutation (Asp87—>Gly) 
combined with a single parC mutation (Ser80—>Ile), namely WT 287 (or D87G and 
S80I). The triple mutant; WT 286 was a combination of a double gyrA mutation, 
Ser83—>Phe and Asp87—>Gly and a single parC  mutation Ser80—>Ile (or S83FD87G 
and S80I). This triple mutant was constructed by introducing the Ser80Ile mutation in 
parC  locus into the engineered WT 141 mutant (Ser83—>Phe and Asp87—>Gly). These 
seven newly constructed mutants were combined with the BRD 948 and four previously 
made mutants, namely WT 21; Ser83—>Tyr (or S83Y, replacing TCC with TAC in the 
gyrA gene), WT 26; Ser83—>Phe (or S83F, replacing TCC with TTC in the gyrA gene), 
WT 37; Asp87—>Asn (or D87N, replacing GAC with AAC in the gyrA gene), WT 43;
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Ser83—>Phe and Asp87—>Asn (or S83F & D87N), therefore assays were performed with 
a total of 12 strains, as shown in Table 5.2.
5.2.2 Fluoroquinolone susceptibilities of the gyrA and parC  reconstructed S. Typhi 
mutants
To evaluate the susceptibilities to fluoroquinolones in the reconstructed S. Typhi 
mutants, we performed MIC testing on the reconstructed mutants using five 
fluoroquinolones and one quinolone, these were, nalidixic acid (NAL), ofloxacin 
(OFX), norfloxacin (NOX), ciprofloxacin (CIP), gatifloxacin (GAT) and levofloxacin 
(LVX) (Figure 5.5 and Table 5.2). The parental S. Typhi strain, BRD 948 and each 
reconstructed mutant were subjected to experimentation. The fluoroquinolone 
susceptibilities of 12 reconstructed mutants are represented in Table 5.2.
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Figure 5.5 MIC testing of the engineered S. Typhi strains performed by E-test
Six different patterns of fluoroquinolone MIC to reconstructed S. Typhi mutants are 
depicted, a; the wild type BRD 948 strain, b and c; single mutant WT26 (S83F) and 
WT37 (D87N) respectively, d; double mutant WT 287 (D87G in gyrA and S80I in parC  
genes), e; the double mutant WT43 (S83F and D87N), and f; the triple mutant WT286 
(S83F, D87G and S80I). The reconstructed mutants were exposed to six 
(fluoro)quinolones, in which nalidixic acid was embedded at the 12 o ’clock direction 
and the other antimicrobials are in clockwise order including gatifloxacin, 
ciprofloxacin, norfloxacin, ofloxacin and levofloxacin. The MIC values were 
interpreted following CLSI guideline and are represented in Table 5.2.
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5.2.2.1 The impact of the single and double substitution(s) in the gyrA gene on the 
MICs to nalidixic acid
To understand the impact of the different reconstructed mutations on the MICs of 
(fluoro)quinolones, we compared the MICs of nalidixic acid of the differing mutations 
to the parental S. Typhi strain, BRD 948. Almost all of the reconstructed gyrA and parC 
mutants'showed resistance to nalidixic acid (Table 5.2). The MICs to nalidixic acid of 
the reconstructed mutants ranged from 48 pg / mL with WT 37 (D87N), 64 pg / mL 
with WT 297 (D87A) and WT 43 (S83F and D87N) to higher than 256 pg / mL with 
single substitutions in WT 26 (S83F), WT 21 (S83Y) and WT 144 (D87G). The MIC to 
nalidixic acid was also higher than 256 pg / mL with the double mutants WT 141 (S83F 
and D87G), WT 300 (S83F and D87A), WT 287 (D.87G and S80I (parC)) and the triple 
mutant WT 286 (S83F and D87G and S80I (parCj) (Table 5.2).
Although MICs to nalidixic acid with the mutants was dependant on the location of the 
site of the mutation, the nalidixic acid resistant mutants could be grouped into 3 
subgroups. The low nalidixic acid resistance group included WT 37 (D87N), WT 144 
(D87G) and WT 297 (D87A) (NAL MIC 48 mg / mL); the intermediate resistance 
group, which included two double mutants, WT 43 (S83F and D87N) and WT 300 
(S83F and D87A) (NAL MIC 64 pg / mL and 192 pg / mL, respectively); and the high 
level resistance group, which included the single substitutions, WT 21 (S83Y), WT 26 
(S83F); the double substitutions, WT 287 (D87G and S80I(/?arC)), WT 141 (S83F and 
D87G); and the triple mutation WT 286, (S83F, D87G and S80I (parC)) with NAL 
MIC >256 pg / mL. The single parC  mutant, WT 304, was the only mutant which was 
susceptible to nalidixic acid with NAL MIC 3 pg / mL.
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The amino acid substitutions including Phenylalanine or Tyrosine for Serine at position 
83 of the gyrA gene depicted more resistance to nalidixic acid than the substitutions 
(Glycine, Alanine and Asparagine) for Aspartic acid at position 87 of the gyrA gene. 
The combination of S83F and D87N produced the lowest MIC to nalidixic acid (NAL 
MIC 64 pg / mL) compared with other double mutations and the single mutation S83F 
(NAL MIC >256 pg / mL). The double mutation, WT 287 (D87G (gyrA) and S08I 
(parC)) showed increased MIC of nalidixic acid compared with the single mutation 
D87G with NAL MIC >256 pg / mL and 48 pg / mL, respectively (Table 5.2).
5.2.2.2 The impacts of the single and double substitution(s) in gyrA gene on the 
MIC to fluoroquinolones
All the single and double reconstructed S. Typhi mutants were susceptible to the 
fluoroquinolones, according to the current standard CLSI guidelines (norfloxacin, 
ofloxacin, ciprofloxacin, gatifloxacin and levofloxacin). The fluoroquinolone MICs of 
the single and double reconstructed gyrA mutations did not significantly vary. These 
MICs ranged from 0.5 pg / mL to 1.5 pg / mL for norfloxacin; from 0.19 pg / mL to 
0.38 pg /.mL for ofloxacin, from 0.094 pg / mL to 0.25 pg / mL for ciprofloxacin, from 
0.094 pg / mL to 0.38 pg / mL for gatifloxacin and from 0.094 pg / mL to 0.25 pg / mL 
for levofloxacin (Table 5.2). In comparison with the parental BRD 948, the MIC mean 
to ofloxacin with the single and double gyrA mutants was 6-fold higher. The MIC 
means to norfloxacin, ciprofloxacin, gatifloxacin and levofloxacin were 12, 17, 19 and 
12-fold higher than the MIC value of the BRD 948 strain, respectively (Table 5.3). 
Thus, the single and double reconstructed gyrA mutations had the lowest increase in the 
MIC to ofloxacin when compared with that of other fluoroquinolones.
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Table 5.3 The correlation of (fluoro)quinolohe MIC with various S. Typhi 
reconstructed mutants and S. Typhi BRD 948
The increasing fold of MICs of nalidixic acid (NAL), norfloxacin (NOX), ofloxacin 
(OFX), ciprofloxacin (CIP), gatifloxacin (GAT) and levofloxacin (LVX) were 
performed by dividing the MIC of BRD 948 by MIC of mutant.
No S. Typhi reconstructed mutant group
M IC increase (folds)
NAL NOX OFX CIP GAT LVX
1 Single , double gyrA mutants na 12 6 17 19 12
2 Double gyrA and single parC  mutant* na 375 340 1000 250 250
3 Single parC  mutant 2 3 1 2 2 1
(*) the triple mutant
5.2.2.3 The impact of the triple mutation double gyrA mutations (S83FD87G) and 
a single parC  mutation (S80I) on the MIC to fluoroquinolones
The MICs of the triple mutant to fluoroquinolones, demonstrated a significant increase 
when compared with those of the S. Typhi BRD 948 strain. The triple mutant stimulated 
a 250-fold increase in the MICs to gatifloxacin and levofloxacin compared with the 
MICs of these antimicrobials to the parental BRD 948 (GAT MIC 0.008 pg / mL and 
LVX 0.012 pg / mL). The triple mutant demonstrated a 340-fold and 375-fold increase 
in MIC to ofloxacin and norfloxacin, respectively, when compared to the parent S. 
Typhi strain (OFX MIC 0.047 pg / mL and NOX MIC 0.064 pg / mL). The highest 
MIC increase to this triple mutant was stimulated by ciprofloxacin (1000-fold increase) 
compared with the MIC of ciprofloxacin to the BRD 948 strain (MIC 0.008 pg / mL).
5.2.2.4 The impact of the single parC  reconstructed mutant on the MICs of 
fluoroquinolones
A single parC  mutation has never been reported in clinical isolates. In this study, this
mutant was engineered in order to reveal its own role on the fluoroquinolone resistance.
The MICs of fluoroquinolones to the single parC  reconstructed mutant were equal to or
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a 1-fold increase than MICs of those antimicrobials to BRD 948 S. Typhi strain and the 
highest MIC increase (3-fold) compared with BRD 948 of this mutant was the MIC of 
norfloxacin (Table 5.3).
5.2.2.5 The bactericidal activity of fluoroquinolones
It is noticeable that some mutants showed similar resistance levels to some 
fluoroquinolones. The similar fluoroquinolone resistance pattern was found among 
norfloxacin, ofloxacin and ciprofloxacin and the lowest MIC to highest MIC of these 
antimicrobials were in the following order D87A / S83Y / D87N / D87G / D87G and 
S80I / S83F and D87N / S83F / S83F and D87G / S83F and D87A / S83F, D87G and 
S80I {parC). Whilst a similar fluoroquinolone MIC pattern was seen with gatifloxacin 
MICs and levofloxacin MICs, the strains with the lowest to the highest MIC with these 
antimicrobials followed this order; D87A / S83Y / D87N / D87G / D87G and S80I / 
S83F and D87N / S83F / S83F and D87G / S83F and D87A / S83F,D87G and S80I 
{parC). Interestingly, the double mutant WT 287 (D87G and S80I (parC)) showed a 
linear MIC decrease following the order of fluoroquinolone generation from old to new 
(nalidixic acid / norfloxacin / ofloxacin, ciprofloxacin / gatifloxacin and levofloxacin).
Although the MICs of (fluoro)quinolones were not statistically significantly related to 
the amino acid substitutions in the target enzymes of the S. Typhi strains, the mutation 
combinations provided evidence of the mutation roles to the level of fluoroquinolone 
resistance in S. Typhi. The level of fluoroquinolone resistance was dependent on the 
antimicrobial generation, i.e. the ofloxacin MIC level of single and double gyrA mutant 
group compared to that of the BRD 948 was a 6-fold increase, but the gatifloxacin MIC 
level was a 19-fold increase. The fluoroquinolone resistance mutation combinations
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giving the highest MIC was the substitution S83F combined with either the D87G or the 
D87A, and the triple mutants S83F, D87G and S80I (parC).
5.2.3 Time -  kill analysis
The susceptibilities of the S. Typhi reconstructed mutants to fluoroquinolones were 
demonstrated by the MICs investigation. However, the MICs only depicted the 
minimum concentration of antimicrobials to inhibit bacterial growth; the effective 
bactericidal dose of fluoroquinolones to each mutant required further investigation. To 
investigate the responses of each amino acid substitution reconstructed in the S. Typhi 
strains to the bactericidal of ofloxacin, each of the reconstructed mutant was challenged 
with different concentrations of ofloxacin (lx, 2x, 4x, 8x and 16x MIC). The rate of 
survival was evaluated at six time points as before (30 minutes, 1 hour, 2 hours, 4 hours, 
6 hours and 24 hours) (Figure 5.5).
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S. Typhi WT 287 (Asp87—»Gly in gyrA and Ser80—>Ile in parC) (k) and S. Typhi WT 
304 (Ser80—>Ile in parC) (1) were exposed to ofloxacin.
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Figure 5.5 In vitro time - kill experiments of reconstructed gyrA and parC 
mutations in S. Typhi
In vitro experiments were performed in duplicate and results represent the mean of 
duplicate values, errors with standard deviation. The y axis represents the logio value of 
S. Typhi CFU / mL. The x axis represents the time line and the S. Typhi growth was 
sampled at six time points, 0, 30 minutes, 1, 2, 4, 6 and 24 hours (section 2.6). Each line 
depicts an individual of ofloxacin concentration and the MIC concentrations used 
against the organism tested. The subtitle of each diagram represents mutation type and 
name of the mutant.
Each mutation group was selected for in vitro time - kill experiments. The mean 
changes in logio CFU / mL over the 24 hour period are presented in Figure 5.5.
Ofloxacin was bactericidal with respect to S. Typhi BRD 948, at all concentrations (2x, 
4x, 8x and 16x MIC) except lx MIC and gave total bacterial killing after 4 hours. A 
similar killing rate of ofloxacin to the WT 304, the single parC  mutation (S80I)* was 
also observed. In general, ofloxacin was fully bactericidal to all the mutants at 8x MIC 
and 16x MIC of ofloxacin after 24 hours. However, the killing rates of ofloxacin on 
differing mutants varied. No bactericidal effect was shown against the triple mutant 
(WT 286) with ofloxacin.
5.2.3.1 The bactericidal effect of ofloxacin to the single mutants
Bactericidal activity of ofloxacin to the single substituted mutants was also seen after 4 
hours, although the killing activity was not as high as when compared to the killing of 
the wild type strain. Four times the MIC of ofloxacin caused a decrease of bacterial 
concentrations of WT 26 (S83F), WT 21 (S83Y), WT 144 (D87G), WT 37 (D87N) and 
WT 297 (D87A) mutants from 107 CFU / mL to between 102 and 103 CFU / mL. Eight 
times and 16x MIC of ofloxacin concentrations killed all the single engineered mutants.
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5.2.3.2 The bactericidal activity of ofloxacin to the double mutants in comparison 
with the single and triple mutants
The mean S. Typhi inoculum calculated from all mutants against 4 times MIC of 
ofloxacin at the start of the killing assay (Time 0) was 3.3 x 107 CFU/mL (2.95 x 107 - 
3.65 x 107, Cl 95%). Therefore, the results calculated after 4 hours exposure to 4 times 
MIC of ofloxacin were dependant on the experimental behavoiur of the individual 
mutants and not the initial starting innoculum.
An overall bactericidal activity of 4x MIC of ofloxacin was not observed with all the 
double substituted mutants, this concentration only caused a decrease in the bacterial 
concentration from 107 CFU / mL to 103 CFU / mL. A small difference in the killing 
efficacy of ofloxacin was observed with WT 287, (D87G (gyrA) and S80I (parC)), as 
this strain showed more resistance to ofloxacin than other double reconstructed S. Typhi 
mutants. Eight times and 16x MIC of ofloxacin caused a reduced bacterial 
concentration from 107 CFU / mL to 103 CFU / mL. In addition, WT 287 (D87G (gyrA) 
and S801 (parC)) was also more resistant to ofloxacin than WT 144 (D87G) which has 
the same substitution at position 87 of the gyrA gene but harbored no substitution in 
parC. The triple mutant, WT 286 (S83F, D87G and S80I), was completely resistant to 
all MIC levels of ofloxacin.
Regardless of the highest ofloxacin MIC in the triple mutant, there was no correlation 
between the number of mutation and ofloxacin resistance level in S. Typhi 
reconstructed strains (p linear trend was 0.003, p  value for linear regression is 
significant when it is less than 0.001) (Figure 5.6).
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Figure 5.6 The killing rate relationship of ofloxacin to different reconstructed S. 
Typhi mutants and the S. Typhi BRD 948 strain
The y axis represents the logio CFU of the reconstructed S. Typhi strains after 4 hours 
of exposure to 4x MIC of ofloxacin. The x axis represents 4 S. Typhi groups including 
non - mutant (BRD 948), single, double and triple mutation groups. Each point 
represents mean of logioCFU / mL of an individual S. Typhi strain (n = 13). p  linear 
trend was 0.003 using linear regression test.
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5.2.4 Biological cost of reconstructed gyrA and parC S. Typhi mutants
The point mutations in gyrA and parC genes of the S. Typhi strains caused nalidixic
resistance and reduced fluoroquinolone susceptibilities. These S. Typhi strains have also
been reported to be persistent and transmissible globally
[147,162,190,191,199,226,232-234]. Moreover, it has been shown that their
transmission and dissemination are not only affected by the environment and host
factors, but also are influenced by the relative fitness of the drug resistant organisms in
the absence of selective pressure [240]. We assessed the fitness cost of the reconstructed
S. Typhi mutants both in growth supportive media (LB aro) and under stress in a high
concentration of oxgall. We also calculated the selective cost of each of the
reconstructed S. Typhi mutants in competition with the parental BRD 948 strain.
5.2.4.1 Independent growth
The growth rates of the reconstructed mutants in LB aro were measured separately. The 
representatives of eight reconstructed mutants were selected for this growth assay. 
These strains included the parent S. Typhi strain and the reconstructed S. Typhi mutants 
which were WT 144 (D87G), WT 37 (D87N), WT 26 (S83F), WT 300 (S83F and 
D87A), WT 141 (S83F and D87G), WT 286 (S83F, D87G and S80I) and WT 304 
(S83I). The growth was performed in LB supplemented with 1 % aro mix and the 
absorbance measurements were taken every 10 minutes over 24 hours (section 2.5.1). 
The mean of 2 independent growth cycles of each reconstructed S. Typhi strain is 
represented in Figure 5.7.
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Figure 5.7 The growth of the reconstructed S. Typhi mutants in LB aro
Absorbance value is displayed as OD600 (y axis). Growth experiments were conducted 
in duplicate. The S. Typhi strains used in this experiment were the parental S. Typhi 
BRD 948 strain and the reconstructed S. Typhi mutants including WT 144 (D87G), WT 
37(D87N), WT 21 (S80Y), WT 26 (S80F), WT 300 (S83F and D87A), WT 141 (S83F 
and D87G) and the triple mutant WT 286 (S83F, D87G (gyrA) and S80I (parC)). 
Negative was LB aro in which no bacteria were inoculated. The arrow represents the 
end of lag phase at time point 40 minutes.
All of the reconstructed S. Typhi mutants observed had similar growth rate to the 
parental S. Typhi BRD 948 strain, there was no variation in the growth over a 24 hour 
period with these strains.
The reconstructed S. Typhi mutants were also challenged in LB aro medium 
supplemented with 8 % oxgall (Section 2.3). Eight percent oxgall was chosen to 
evaluate the growth abilities in stress media of reconstructed mutants since the growth 
of these mutants showed the most diversity in this concentration compared with their
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growth in LB aro supplemented with different oxgall concentrations (0.0193 % - 7 %) 
(Section 2.3). Meanwhile, the growth of the reconstructed mutants in LB aro 
supplemented with higher concentrations of oxgall (9 % - 12 %) was not reproducible 
(Section 2.3). In 8 % oxgall media, we perfonned the growth experiment for 10 
reconstructed S. Typhi mutants along with BRD 948 S. Typhi strain used as a control. 
Figure 5.8 shows the growth dynamics of all reconstructed S. Typhi strains in 8 % 
oxgall over 24 hours. The mean of each mutant growth rate was calculated from 9 
replicates in three separate experiments.
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(A) The growth of the reconstructed S. Typhi mutants in oxgal 8 % in 24 hour.
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Figure 5.8 The growth of the reconstructed mutants in LB aro supplemented with 
8 % oxgall
Absorbance value is displayed as OD6oo- The growth experiments were conducted in LB 
aro containing 8 % oxgal and the means were calculated from 9 replicates in three 
separate experiments. Eleven S. Typhi strains for this experiment include the parental S. 
Typhi BRD 948 (no mutation) and the reconstructed S. Typhi mutants including WT 
144 (D87G), WT 297 (D87A), WT 21 (S80Y), WT 26 (S80F), WT 300 (S83F and 
D87A), WT 141 (S83F and D87G), WT 287 (D87GS80I), WT 304 (S80I) and the triple 
mutant WT 286 (S83FD87G (gyrA) and S80I (parC)). The number represents the end of 
lag phase at time point 1 hour 50 minutes.
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All of the S. Typhi strains showed reduced growth rates in LB aro 8 % oxgall compared 
to their growth in LB aro (Figure 5.8A and Figure 5.7). The lag phase of growth of the 
reconstructed mutants in 8 % oxgall was extended by 1 hour and 50 minutes in 
comparison with their growth in LB aro medium without oxgall. In fact, the lag growth 
phase of the reconstructed mutants in LB aro was 40 minutes. Additionally, the growth 
of BRD 948 S. Typhi and the reconstructed mutants in LB aro 8 % oxgall did not reach 
similar stationary phase with those grown in LB aro without oxgall. In addition, the 
growth rates in LB aro with 8 % oxgall after 4 hours depicted that the single mutants 
WT 21 (S83Y) and the WT 304 (S80I (parC)) had reduced the growth rates compared 
with other gyrA mutants including WT 144 (D87G), WT 297 (D87A), WT 21 (S80Y), 
WT 26 (S80F), WT 300 (S83F and D87A), WT 141 (S83F and D87G) and WT 287 
(D87G and S80I) (Figure 5.8B). This would indicate that these strains would reach the 
exponential phase slower, even though they had the same growth kinetics with other 
mutants after 24 hours. Both WT 21 (S83Y) and WT 304 (S80I (parC)) showed the 
same OD600 means 0.43 nm at 4 hours compared with O D 6oo means 0.50 nm of the BRD 
948 strain at the same time point.
5.2.4.2 Competition growth
Only subtle differences between strains were noticeable in the 24 hour growth period 
monitored by independent growth assays. To assess any potential growth advantage or 
disadvantage between the strains over a prolonged period we performed protracted 
mixed culture competition assays as previously performed to assess bacterial fitness in 
E. coli [241]. The reconstructed mutants were subjected to the competition assay against 
the parental S. Typhi BRD 948 strain.
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Two methods were applied for this competition investigation. Initially, the classical 
colony counting was applied to determine the viable bacteria of each S. Typhi strain. 
However, owing to the large dilution factors and potential fluctuations in growth rate 
we found that colony counting only gave a marker of either negative or positive 
selective growth effects. The method of subtracting the number of organisms grown of 
selective media from those grown on non - selective media was not found to be 
reproducible over the 15 day subculture period. Data showing an inherent error in the 
assay is presented in Figure 5.9; fluctuations were seen in the ratio of organisms over 
the 15 days and with all the mutants. A linear regression test was performed on all the 
assays (Table 5.4) and was found to be none significant over the fifteen day growth 
period. Linear regression models the relationship between one or more variables 
denoted y  and one or more variable denoted x, in this case proportion of bacteria at each 
time point. In the case of the colony counting method, none of the assays were deemed 
to be statistically significantly higher or lower than 0. However, whilst a pattern of 
increase or decrease in mutant proportions could be observed over fifteen days, this was 
highly variable and non - reproducible (Figure 5.9).
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Figure 5.9 Plots of colony counting from competitive growth assays
All strains were mixed in a 1:1 ratio and sub-cultured daily for 15 days. Bacterial 
generations were assessed by calculating the number of doubling events from the initial 
inoculation and the final stationary phase concentration of bacteria. The frequency of 
resistance was calculated by subtracting the number of organisms grown on selective media 
from those grown on non - selective media. Each coloured line represents the frequency a 
different strain with respect to the parent strain over time, dark blue; WT 300, red; WT141, 
dark green; WT 286, purple; WT 21, light green; WT 144, orange; WT 37, light blue; WT 
287, pink; WT 297, turquoise; WT 43 and lilac, WT 26.
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Colony counting at each time point was performed not only to establish the ratio of 
mutant to wild type but also to calculate the numbers of inoculated bacteria per day and, 
therefore, we could accurately calculate bacterial doubling time and generations. The 
number of bacterial generations (which is dependent on inoculum size) was highly 
reproducible over 3 independent growth assays and between all mutants with the non - 
mutant. In total we calculated that each individual assay went through 9 - 1 1  
generations per 24 hour period (after a prolonged stationary phase). Over the fifteen day 
period the organisms went through between 134 and 158 generations, this was not 
significantly variable between differing assays or strains (data not shown). Therefore, 
these values were used for all experimental assays.
To improve sensitivity, accuracy and reproducibility we developed and ultimately 
applied a pyrosequencing method to calculate bacterial proportions in the assay. The 
competition assays were performed as with colony counting, yet population changes 
were assessed using a pyrosequencing method specific for the SNP loci in the gyrA 
gene (Figure 5.11). The pyrosequencing method calculates the ratio of a SNP in a single 
position in a mixed reaction after PCR amplification (Figure 5.11). The pyrosequencing 
was compared with colony counting and known dilutions of mixed organisms were 
compared in order to validate the assay procedure. Figure 5.10 shows a comparison of 
the colony counting method and the pyrosequencing method with strain S. Typhi WT 21 
and S. Typhi BRD 948. Whilst the overall change over 155 generations is same, the 
pyrosequencing method can be seen to be more accurate and the linear regression 
coefficient of the pyrosequencing method is statistically significantly greater than 0. 
This demonstrates a selective advantage of S. Typhi WT 21 over the parental strain S. 
Typhi BRD 948, which can be detected by pyrosequencing but not by colony counting.
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Figure 5.10 Comparison of colony counting and pyrosequencing for measuring 
competitive growth between two strains
The proportion of mutant to non - mutant was calculated by two different methods from 
the same assay for the strain S. Typhi WT 21 (S83Y) competed with S. Typhi BRD 948. 
This assay was performed over 15 days (155 generations). The general trend is an 
increase in the proportion of the mutant strain with both of the techniques, colony 
counting; blue and pyrosequencing; red. This tendency is shown with a polynomial 
trend line, colour corresponds as above. The linear regression for the colony counting (- 
0.067178) with r2=0.0891 is none significant; however a significant linear regression is 
shown with the pyrosequencing method (0.1277) with r2=0.9397.
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Figure 5.11 An example of py-program pyrosequencing traces detecting the ratio 
of a SNP between a reconstructed S. Typhi mutant in competition with S. Typhi 
BRD 948
(A) The py-program depicts 100% Cytosine (C) at locus 83 of the gyrA gene in the non 
- mutant S. Typhi BRD 948 strain. In comparison (B) detects 98.5% of Adenosine (A) 
in the same location of the gyrA gene in a mixed assay of S. Typhi BRD 948 and WT 
21 (S83Y) which has a substitution of TAC for TCC at position 83 of the gyrA gene.
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We performed competitive assays of all 10 mutants with the parental S. Typhi BRD 948 
strain and detected the ratio of mutant to non - mutant with the pyrosequencing method. 
The data for these assays are presented in Table 5.4 and Figure 5.12. Table 5.4 shows 
the change in percentage and the corresponding linear regression, selection co-effiecient 
and relative fitness over the 15 days of the assay which included 155 bacterial 
generations. The selection coefficient (S) and relative fitness (F) were calculated by the 
linear regression model using a method previously described by Lindgren et al: [242]. 
The in vitro selection coefficient (S) per generation of each mutant can be calculated by 
linear regression as the slope [(number of mutant cells / number of wild-type cells) / 
(number of generations / number of cycles)] x ln2. Relative fitness (F) (with respect to 
S. Typhi BRD 948) is defined as 1 + S. Additionally, to ensure reproducibility the 
assays were performed in triplicate, and the ratio of mutant to non - mutant was 
calculated on day 0 and at the final time point on day 15 (Table 5.4).
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Figure 5.12 Plots of non - mutant / mutant ratios as detected by pyrosequencing 
from competitive growth assays
All strains were mixed in a 1:1 ratio and sub-cultured daily for 15 days. Bacterial 
generations were assessed by calculating the number of doubling events from the initial 
inoculation and the final stationary phase concentration of bacteria. The frequency of 
resistance was calculated by measuring specific SNP proportions in the mixed culture. 
Each coloured line represents the frequency of a different strain with respect to the 
parent strain over time.
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The pyrosequencing assays were found to have a reproducible trend for all ten strains. 
This was shown by comparing the medians of three independent assays at the beginning 
and end of the experiment with the individual assays sampled at each time point (Figure 
5.12). Over the 150 generations, five strains demonstrated a selective advantage over 
the parental strain including WT 21, WT 43, WT 141, WT 287 and WT 297, two strains 
had a slight selective advantage (WT 26 and WT 144), one was unchanged (WT 37) and 
two had a selective disadvantage (WT 300 and WT 286).. The linear regression for all 
strains was calculated and all but one strain WT 37 (D87N) were significant, this strain 
demonstrated the smallest variation from a relative fitness of 1 (Table 5.4). The largest 
selective advantages were seen with strains WT 21 (S83Y), WT 287 (D87G and S80I) 
and WT 297 (D87A) which all demonstrated relative fitness greater than 1. The lowest 
relative fitness was seen with strains WT 300 (S83F and D87A) and the triple mutant 
WT 286 (S83F, D87G and S80I).
Whilst demonstrating similar growth rates as grown independently in two media, the 
supportive medium (LB aro) and the LB aro supplemented with 8 % oxgall medium, 
almost all the reconstructed mutants outcompeted with the S. Typhi BRD 948 strain. 
However, two of these S. Typhi mutants including the double mutant WT 300 (S83F 
and D87A) and the triple mutant WT 286 (S83F, D87G and S80I) demonstrated 
disadvantaged growth in competition with the S. Typhi BRD 948 strain.
5.3 Discussion
Although the mutations related to quinolone resistance and reduced susceptibility to 
fluoroquinolones have been extensively detected in clinical isolates 
[162,219,220,223,226,232-234], the genetic background of such clinical isolates is 
poorly defined. Here, the mutants carrying defined quinolone resistant mutations were
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reconstructed in an isogenic background of quinolone susceptible BRD 948, so it was 
assured that all the mutants had an identical genetic background and any phenotypic 
differences could only be dependent on the introduced mutation(s). These reconstructed 
mutants were investigated for their levels of quinolone resistance and reduced 
susceptibility to fluoroquinolones, their rate of killing over the time by ofloxacin, their 
growth rates and finally their biological costs in competition with the parental S. Typhi 
BRD 948 strain.
The reconstructed mutants were shown to influence fluoroquonolone resistance in a 
laboratory S. Typhi strain, however any comparison between wild type S. Typhi isolates 
and reconstructed S. Typhi mutants is inappropriate since their genetic backgrounds are 
neither comparable nor known. It was observed that the bactericidal trend of ofloxacin 
to the WT141 (S83F D87G; ofloxacin MIC 0.38 pg / mL) was substantially different 
from that of the same substitution mutant, DT 18, which was isolated clinically from 
Viet Nam (ofloxacin MIC 2 pg / mL) (Figure 4.14g). The clinical S. Typhi strain was 
more resistant to ofloxacin than the reconstructed S. Typhi strain. Similarly, the double 
mutation S. Typhi isolate, AG 152 (OFX MIC 3 pg / mL) showed a better survival 
ability under prolonged ofloxacin exposure, compared to the same double reconstructed 
mutant WT 43 (S83FD87N; ofloxacin MIC 0.38 pg / mL), (Figure 4. 14h). Thus, it 
would be worthwhile to look at other fluoroquinolone resistance mechanisms since the 
result suggested that more than one mechanism is involved in the ofloxacin resistance 
phenotype in S. Typhi isolates.
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5.3.1 Nalidixic acid resistance and reduced susceptibility to fluoroquinolones of the 
reconstructed S. Typhi mutants
Our study confirmed the hypothesis that point mutations in gyrA gene caused nalidixic 
acid resistance and reduced susceptibility to fluoroquinolones in S. Typhi strain, while 
the mutation in parC alone was not related to (fluoro)quinolone resistance. Our study 
was supported by previous data that was also conducted based on the reconstructed 
mutations in gyrA and parC genes of S. Typhi strains, but differing amino acids were 
substituted, and several new, additional mutations were compared [131].
5.3.2 The impact of the amino acid substitutions on MIC and corresponding 
bactericidal activity of the (fluoro)quinolones
Although all reconstructed mutants were resistant to nalidixic acid, the level of nalidixic 
acid resistance depended on amino acid substitutions. Our findings clearly demonstrated 
that even though the gyrA mutations were not the primary mechanism of 
fluoroquinolone resistance, they caused reduced susceptibilities to fluoroquinolones and 
the level of fluoroquinolone resistance depended on the amino acid substitutions and the 
antimicrobial used. The amino acids substituted lead to the alteration of the chemical 
characteristics of the enzyme active site [84]. This alternative protein formation inhibits 
the formation of the antimicrobial-enzyme complex. As a consequence, the 
antimicrobial cannot achieve its full bactericidal capacity.
5.3.3 The role of the triple mutation on fluoroquinolone resistance
Among the gyrA mutants, it seems that the combination of the substitution S83F with 
the D87G depicted the most (fluoro)quinolone resistance phenotype. However, high 
fluoroquinolone resistance required a combination of the double gyrA (S83F D87G) and 
one parC  (S80I) mutations. Previous studies which were performed with an S. Typhi
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strain [131] and an E. coli strain [239] demonstrated similar results; that the 
combination of gyrA and parC substitutions play a role in the fluoroquinolone 
resistance mechanism. However in these studies, different amino acids were described, 
in particular the combination of S83F (or Y) and D87N in gyrA gene with E84K in 
parC gene in the S. Typhi study [131] or a combination of S83L and D87G (gyrA) and 
S80I (parC) in the E. coli study [239]. The fluoroquinolone resistance rate of the triple 
mutant showed that the MIC of ciprofloxacin was lower (1000-fold) when compared 
with those of gatifloxacin and ofloxacin; 250-fold and 340-fold, respectively. Similarly, 
Turner et al. also found that the MIC of ciprofloxacin increased 4000-fold compared 
with 500-fold of ofloxacin and 188-fold of gatifloxacin [131]. Additionally, the triple 
mutant showed a similar growth rate to the parental S. Typhi strain and other mutants in 
nutrient LB aro, but. slightly slower in LB supplemented with 8 % oxgall after four 
hours. In the competition assay with the parental BRD 948 strain, the triple mutant 
represented the largest growth disadvantage after 15 days (155 generations). Although 
representing weaker competing ability with the parental strain, under pressure of high 
concentration of ofloxacin (lx  to 16x MIC), the triple mutant, WT 286 was completely 
resistant to this antimicrobial. Thus, although demonstrating a fluoroquinolone resistant 
S. Typhi strain with low biological cost when growing alone, the triple mutant had the 
lowest selective advantage in the competitive assay. It is a known phenomenon that 
antimicrobial resistant organisms generally have a selective disadvantage compared to 
their sensitive counterparts [243-246], Therefore, this result is unsurprising as resistance 
is combined with a substantial fitness cost, a caveat that potentially prevents such 
organisms undergoing a dominant clonal expansion. These data suggest why, 
potentially, this triple mutant was only found in a small number of clinical isolates due 
to the negative fitness cost, yet high level resistance.
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5.3.4 The role of parC  mutation on fluoroquinolone resistance
The parC  mutation (S80I) alone had no effect on (fluoro)quinolone resistance 
phenotype, this finding supported by a previous study [118,239]. Our observations have 
added further weight to the hypothesis that the topoisomerase IV is a secondary target 
for fluoroquinolones [247] and strengthened by not detecting a parC  mutant in clinical 
S. Typhi isolates [131,162,220,226,232,233,239]. The fluoroquinolone resistant 
phenotype could only be detected when parC  mutations combined with at least one 
gyrA mutation [239]. In fact, this study showed that apart from the triple mutant, the 
complement of parC mutation to the single gyrA mutation D87G of the strain WT 287 
(D87G (gyrA) and S80I (parC)) prolonged its survival in 8x and 16x MIC of ofloxacin 
compared with the single D87G substitution (WT 144). The role of parC  mutation in 
the biological cost of the mutants was unclear since the combination of S80I with other 
gyrA mutations did not influence the selective advantage in the competition 
environment.
5.3.5 The bactericidal efficacy of ofloxacin concentrations on the single and double
S. Typhi mutants
The single and double substitutions, although mostly expressing stronger survival 
compared with the parental BRD 948, showed no significant difference in the time - kill 
of ofloxacin amongst the single and double substitutions. As a result, the 4x MIC of 
ofloxacin used in clinical typhoid treatment needs to be reevaluated as the majority of 
the mutants, except the WT 304 (S80I), WT 37 (D87N) did not demonstrate total cell 
killing after 24 hours exposure to ofloxacin.
Perhaps the most alarming and interesting result of this work is the competitive 
advantage shown by seven of ten reconstructed mutants tested. As acknowledged
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above, antimicrobial resistant organisms often have a natural selective disadvantage in 
the absence of antimicrobials. Here we found the opposite, demonstrating that these 
reconstructed mutants actually have a selective advantage in the presence and absence 
of fluoroquinolones. These data tentatively explain the abundance of the single S83 
gyrA mutants that were detected in the majority of nalidixic acid resistant clinical 
isolates. The spread of nalidixic acid resistant S. Typhi organisms has been shown by 
Roumagnac and Holt [69,71]. These studies demonstrated the clonal expansion of 
certain haplotypes (specifically the H58 haplotype) suggesting a further selective 
advantage on the basis of corresponding nalidixic acid resistant strains. However, it was 
assumed that this occurred due to the overuse and constant exposure of organisms to 
low level of fluoroquinolones. Our findings suggest that such organisms have a natural 
selective advantage and the use of such antimicrobials may have forced these organisms 
through a bottleneck and permitted rapid clonal expansion. These findings require 
further studies to ascertain and understand how such antimicrobial resistant pathogenic 
organisms are selected and spread through human populations.
The evolution of a fluoroquinolone resistant S. Typhi strain is not only dependent on the 
mutation in the target genes, but is also influenced by compensatory mechanism, host 
adaption, antimicrobial usage and even living environment. Although our study has 
only contributed the roles of specific gyrA and parC  resistance mechanisms in S. Typhi 
strains, these data are an important foundation for further investigations on the 
development and dissemination of-S. Typhi in susceptible populations.
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6. Development of the Multiplex Ligation dependent-Probes Amplification 
(MLPA) for S. Typhi isolates in Asian countries
6.1 Introduction
S. Typhi is a human restricted bacterial pathogen and studies of the populations of the 
organisms (both local and global) have shown limited variation [248]. Genotyping of 
bacterial populations is important to study evolution and the dissemination of the 
organism in question. Genotyping S. Typhi has been performed by several methods, 
including non DNA sequence based and DNA sequence based techniques. None 
sequence based approaches have included ribotyping, plasmid typing, phage typing, 
Random Amplified Polymorphic DNA (RAPD-PCR) [70,249-251]. Lately, Pulsed 
Field Gel Electrophoresis (PFGE) was the ‘gold standard’ method for S. Typhi 
genotyping although the results produced by PFGE only have limited discriminatory 
power [252-254]. The development of the PCR based Amplified Fragment Length 
Polymorphism (AFLP) method permitted better resolution and had a higher 
discriminatory power for strain differentiation when compared to PFGE [255]. The 
downside to all these aforementioned techniques is a lack of reproducibility and 
understandable phylogeny.
The only useful marker applicable for performing molecular epidemiology is DNA 
sequence variation. In 2002, Kidgell et al. performed the first sequence based 
phylogenetic study on S. Typhi [68]. This multi locus sequence typing (MLST) of a 
global collection of S. Typhi organisms found only limited sequence diversity and 
because of this limited diversity MLST was unsuitable for a universal typing scheme. 
The MLST study paved the way for a more intense investigation of nucleotide variation 
in the S. Typhi population.
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A robust genotyping of S. Typhi was provided only by the development of mass DNA 
sequencing based techniques. These methods have been shown to improve 
discriminatory ability in genotyping a highly clonal (monophyletic) pathogen like S. 
Typhi. Currently Single Nucleotide Polymorphism (SNP) typing is the most robust 
methodology for genotyping S. Typhi [69,71,256]. Based on the results of SNP 
detection in 200 gene fragments on the S. Typhi chromosome, fifty-nine haplotypes 
were found to be circulating globally and haplotype H58 was the most prevalent in Viet 
Nam and southern Asia. Four additional haplotypes (HI, H50, H58 and H63) have also 
found to be circulating in Viet Nam [71]. However, H58 predominates and is associated 
with the Ser83 nalidixic acid resistance mutation in the gyrA gene [71]. Additionally, in 
Viet Nam, Le et al. demonstrated the occurrence of microevolution within an S. Typhi 
clone [257]; and even though independent outbreaks of multi - drug resistant typhoid 
fever in southern Viet Nam were demonstrated to be caused by single bacterial strain, 
different outbreaks were not caused by a single S. Typhi strain [41]. The stimulus 
behind the regional spread of fluoroquinolone resistant Salmonella belonging to 
genotype H58 is still unknown, although data presented here suggests a selective 
advantage of these strains even in the absence of fluoroquinolone usage [71].
SNP typing has been developed and is currently based on investigating the nature of 
some 1,700 differing SNP loci in S. Typhi isolates, these data provide a fully resolved 
phylogenetic tree which allows one to trace the genetic changes that occurred during 
clonal diversification [258]. Whilst the SNP method is the current ‘gold standard’ for 
such bacterial populations these techniques are somewhat labor intensive and 
expensive, as they require sophisticated equipment. Therefore, SNP typing cannot 
directly be applied to studying S. Typhi populations in locations where S'. Typhi is 
endemic. We wished to develop a simple universal methodology that could be used to
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perform genotyping in a basic molecular laboratory in a developing country. However, 
to understand the phylogeny of the S. Typhi populations in these settings, this new 
methodology needed to be based upon the current phylogenetic data from SNP typing 
and genome sequencing. To achieve such a typing method we selected Multiplex 
Ligation Dependent-Probes Amplification (MLPA) to detect specific chromosomal 
markers. MLPA was first applied to investigate host genetic polymorphisms and is a 
relatively simple and robust multiplex assay which allows simultaneous genotyping 
and, in our case, the detection of drug resistance mutations [156]. In order to develop 
and validate an appropriate method for genotyping nalidixic acid resistant S. Typhi 
isolates in endemic countries, we generated an MLPA assay to study our observed gyrA 
mutations and phylogenetic insertion and deletion fragments in the S. Typhi 
chromosome (Figure 6.1) [69]. To ensure we could detect the major haplotypes, this 
method was applied in comparison with the conventional Golden Gate SNP typing 
technique.
186
G enotyping o f S. Typhi isolates
H1
H45
Q,R
H42 H46
H50A,J
H59
H55H85
H8H10
H58
H52
Figure 6.1 Haplotype spanning tree based on SNP typing and showing insertion 
and deletions in the S. Typhi population
The phylogenetic insertion -  deletion tree was provided by Holt [69]. Branch colours 
indicate different lineages of S. Typhi haplotype; Branch lengths were differentiated by 
the representative deletions. The block capital represents the deletion / insertion 
fragment.
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6.2 Results
Seventy three S. Typhi strains isolated between 1994 and 2006 and representative of 
strains from seven Asian countries were selected for genotyping (Table 2.5). These 
strains were examined previously in. Chapter 4 and any mutations in their gyrA or parC 
genes had been identified. These strains were initially subjected to discrimination by the 
Illumina GoldenGate SNP typing assay at the Wellcome Trust Sanger Institute in 
Cambridge, United Kingdom and by the MLPA assay which was designed in house to 
detect 16 distinguishable fragment lengths as section 2.8.2.
6.2.1 S. Typhi SNP typing by the Golden Gate assay
In this study, genotyping was firstly performed by a SNP interrogation using the 
GoldenGate system [259]. This assay not only detects specific SNPs at each specific 
locus but also can detect SNPs which are demonstrative of insertions, deletions and 
plasmid sequences. From 73 representative strains from Bangladesh, China, India, 
Indonesia, Laos, Pakistan and Viet Nam selected for genotyping (Table 2.5) seven 
haplotypes were detected. In total, 72.6 % (53 / 73) of S. Typhi strains observed were of 
the H58 haplotype. The H58 haplotype was detected in 5 Asian countries including 
Bangladesh, India, Laos, Pakistan and Viet Nam. In Viet Nam, 4 / 45 S. Typhi strains 
belonged to the HI haplotype and the remaining 41 strains belonged to the H58 group. 
Haplotype H58 was detected in 4 / 5 strains from Bangladesh; the remaining strain was 
H42, the only isolated belonging to this haplotype. Four from five of the S. Typhi 
strains from India belonged to group H58, the other Indian S. Typhi strain was 
haplotype H50. Three haplotypes were detected from Laos and were HI, H5 and H58. 
Three haplotypes were also detected in S. Typhi strains from Pakistan, these were H42, 
H50 and H58 (Table 6.1).
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Haplotype H58 is currently the dominant strain circulating in southern Asia [71]. 
However, H58 was not detected in China or Indonesia. Amongst the S. Typhi strains 
isolated from China, 3 / 5  belonged to haplotype H52 and 2 / 5  strains belonged to 
group H50. While 1 / 3 of the S. Typhi strains and 2 /3  strains from Indonesia belonged 
to haplotypes H50 and H59, respectively (Table 6.1).
Table 6.1 The S. Typhi haplotypes found in seven Asian countries
Seventy three S. Typhi strains including 45 Vietnamese strains, 5 Bangladeshi strains, 5 
Chinese strains, 5 Indian strains, 3 Indonesian strains, 5 Laotian strains and 5 Pakistani 
strains were subjected to SNP detection using the GoldenGate method.
Country Year No o f strain  
(n = 73)
G enotype
(7)
Viet Nam 1 9 9 4 -2 0 0 4 4 HI
41 H58
Bangladesh 2003 1 H42
4 H58
China 2002 2 H50
3 H52
India 2003 1 H50
4 H58
Indonesia 2002 1 H50
2 H59
Laos 2003 2 HI
2 H52
1 H58
Pakistan 2002 1 H42
1 H50
3 H58
We hypothesized that S. Typhi haplotype may be related to the multidrug resistance 
phenotype. Therefore, we interpreted the haplotype discrimination amongst 71 S. Typhi 
strains in the correlation with the MDR phenotypes which were presented in Chapter 3. 
Forty six percent (33 / 71) MDR S. Typhi were detected to belong to haplotypes HI (1
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strain), H42 (1 strain) and H58 (30 strain), while other 53.5 % (38 / 71) non - MDR S. 
Typhi were found to belong to haplotypes HI (3 strains), H42 (2 strain), H50 (5 strains), 
H52 (5 strains), H58 (20 strains), H59 (2 strains) and H85 (1 strain). Thus, the MDR 
phenotype was defined only in haplotypes HI, H42 and H58.
A phylogenetic tree of 92 S. Typhi strains including 73 S. Typhi strains from the Asian 
collection and 19 S. Typhi control strains was constructed based on SNP database 
(Section 2.8.1) (Figure 6.2). To generate the tree, the phylip file of SNP database was 
analyzed using the RAxML program. The maximum-likelihood phylogeny was 
analyzed using a GTR substitution model. The maximum-likelihood was preferred since 
it showed fast handling missing data well and the GTR model provided the best fit to 
this data using model test. The phylogenetic tree was drawn using Dendroscops version
2.3 based on the S. Typhi SNPs database [260].
We analyzed the genetic variation of S. Typhi by interpreting the phylogenetic tree 
(Figure 6.2). We divided the S. Typhi strains into the 7 main polymorphic groups. 
Approximately 67 % (62 / 92) S. Typhi strains accounted for phylogenetic group 6. 
These strains included the Bangladeshi, Indian, Moroccan (the control strain ISP-03- 
7467), Pakistani strains which were isolated in 2003 - 2004 and Vietnamese strains 
which were isolated in 1994 -  2004. Approximately 32 % (29 / 92) S. Typhi strains 
accounted for other 6 genetic groups including group 1 to group 5 and group 7. The 
control S. Typhi E-00-7866 strain accounted for group 1. Group 2 comprised 6 strains 
including 2 Chinese strains, 1 Indonesian strain, . 1 Pakistani strain and 2 S. Typhi 
control strains (E-98-3139 and M 223). Phylogenetic group 3 included an Indian strain 
and a Kenyan control strain (E-98-0664). Whilst, phylogenetic group 4 included 14 
strains, in which 5 Indonesian strain (2 S. Typhi isolates and 2 control strains), 2
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Pakistani strains, 2 Laotian strains, and 5 Vietnamese strains were involved, and 
phylogenetic group 7 included 2 strains from Laos and 2 control strains (Ty2 and E-01- 
6750).
Thus, H58 haplotype was spanned in Asian countries in the years 2003 and 2004. 
Notably, almost all S. Typhi isolated from Viet Nam during 13 years (1994-2006) 
belonged to H58 haplotype. The phylogenetic tree based on SNP typing demonstrated 
that although S. Typhi strains in Asian countries was closely related they were divided 
into seven sub-groups, in which most of strains from Viet Nam represented a unique 
group.
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6.2.2 Developing the Multiplex Ligation Dependent - Probes method for S. Typhi 
genotyping
We included 18 S. Typhi strains which had been previously haplotyped with defined 
insertion - deletion profiles as controls for MLPA genotyping. Sixteen-probe pairs were 
designed in a mastermix based on 11 insertion - deletion fragments discovered by Holt 
et al. [69], including two pairs of probes detecting changes at position 83 and 87 of the 
gyrA and position 80 of the parC  genes of S. Typhi strain and three probe pairs worked 
as internal controls for S. Typhi species (section 2.8.2).
The MLPA results were visualized by the automated ABI sequencer in which the results 
were analyzed using the Gene Mapper software version 4.0 (Figure 6.3). In addition the 
conventional agarose gel electrophoresis was used as an alternative method for 
fragment visualization (Figure 6.4).
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Figure 6.3 Representative of fragment length analysis of the multiplex ligation- 
dependent probe amplification (MLPA)
Thirteen peaks of the Pakistani S. Typhi strain BL 3723 depict the presences of 6 
representative deletion markers including Q (158 bp), A (175 bp), S (275 bp), F (308 
bp), H (414 bp), N (465 bp) and D (494 bp); two common deletions including B (139 
bp) and K (204 bp) which were always depicted peaks. A gyrA peak (238 bp) for 
detecting mutation(s) and three S. Typhi controls including aroCl (267 bp), fliCl (374 
bp) and ssaVl (429 bp) are indicated by arrows.
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.4 15 16 17 18 19
Figure 6.4 The representative fragment length analysis by agarose electrophoresis
Each lane depicts an S. Typhi strain including 15 S. Typhi haplotype controls including 
the E98-2068 (Lane 1), E98-0664 (Lane 2), E98-3139 (Lane 3), Ty2 (Lane 4), 404TY 
(Lane 5), E02 - 1180 (Lane 6), E00 - 7866 (Lane 7), E03 - 9804 (Lane 8), ISP - 03 - 
07467 (Lane 9), ISP - 04 - 06979 (Lane 10), E02 - 2759 (Lane 11), E03 - 4983 (Lane 
12), 150 (98) S (Lane 13), 8(04)N (Lane 14) and M 223 (Lane 15); and six S. Typhi 
isolates including DoniC 4 (Lane 16), J 2018 (Lane 17), BL 2513 (Lane 18), BL 820 
(Lane 19), AG 3 (Lane 20) and DoniC 42 (Lane 21). Each band either represents an 
insertion fragment, a gyrA / parC mutation or the internal controls. Fourteen bands 
include Q (158 bp), A (175 bp), S (275 bp), F (308 bp), H (414 bp), N (465 bp) and D 
(494 bp); two deletions including B (139 bp) and K (204 bp); gyrA or parC  mutations 
(130 bp and 238 bp, respectively). Three S. Typhi control fragments include the aroCl 
(267 bp), fliC 1 (374 bp) and ssaVl (429 bp).
By MLPA, we could define 5 genetic polymorphic groups (A, B, F, E and S). Group A 
was haplotype H59, group B included HI, H42 and H85, group F was haplotype H50, 
group E represented haplotype H58, group K included H8 and H55 and group S 
includes haplotypes H10 and H52.
The genotyping results achieved by MLPA were confirmed by the SNP typing results 
which were represented in Table 6.2.
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Table 6.2 Haplotype comparisons between SNP typing and MLPA of the S. Typhi 
strains in Asian countries
Sixty eight representative S. Typhi strains including 5 strains from Bangladesh, 5 strains 
from China, three strains from India, three strains from Indonesia , 4 strains from Laos, 
5 strains from Pakistan and 43 strains from Vietnamese collections and 18 haplotyped S. 
Typhi control strains were subjected for genotyping comparison. The deletions were 
depicted in capital letters according to Holt et al. [69] and MLPA profile was named 
according to the deletion representative of each haplotype group.
(*) Deletion profile was based on SNP typing database.
Country Year No of strain 
(n = 68)
Deletion profile* M LPA
profile
Genotype
(6)
Viet Nam 1 9 9 4 -2 0 0 4 3 K,B B HI
40 B,K,C,E E H58
Bangladesh 2004 1 K,B B H42
4 B,K,C,E E H58
China 2004 2 K,F F H50
3 K,B,C,S S H52
India 2004 . 1 K,F F H50
2 B,K,C,E E H58
Indonesia 2004 1 k ,f F H50
2 K,B,A A H59
Laos 2004 1 K,B B HI
2 K,B,C,S . S H52
1 B,K,C,E E H58
Pakistan 2004 1 K,B B H42
1 K,F F H50
3 B,K,C,E E H58
6.2.3 The relationship between mutations conferred nalidixic acid resistance and 
S. Typhi haplotype
Mutations in gyrA conferring nalidixic acid resistance could be detected in S. Typhi 
isolates by MLPA method. Amongst 55 S. Typhi strains detected to be harbored gyrA 
mutation(s), 50 strains were haplotype H58 and approximately half of the strains (26 / 
50) represented MDR phenotype haplotype. No parC  mutation was detected by MLPA 
technique.
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By designing specific primer pairs to directly detect the deletions from genomic DNA, 
we could demonstrate the presence or absence of these deletion fragments in the S. 
Typhi collection. However, the PCR condition for each specific primer pair was not 
similar; therefore PCR conditions were established separately for each assay. The 
deletions were defined either by the presence of a shortened length of a band or the 
absent of any band. The results achieved by conventional PCR were identical to the 
MLPA results.
6.3 Discussion
6.3.1 S. Typhi genotyping in Asian countries
This study compared a large collection of geographically diverse S. Typhi strains 
collected in typhoid endemic regions. Amongst 7 haplotypes identified in this study, 
H58 were predominant and found in 5 / 7 Asian countries.
Our findings are supported by a previous report which demonstrated the circulation of 
several S. Typhi haplotypes in Asian countries [71,256]. By performing SNP analysis 
on 105 global S. Typhi collection, Roumagnac et al. showed the presence of haplotypes 
H45, H57 and H60-65 in Asian countries along with haplotypes HI, H42, H50, H52, 
H58 and H85, while the result here demonstrated the presence of H59 in Indonesian S. 
Typhi strains along with haplotypes HI, H42, H50, H52, H58 and H85 [71]. The 
presence of haplotype H59 in Indonesian S. Typhi strains was also reported previously 
[73], Additionally, 3 out of 18 Asian S. Typhi strains analyzed in this study were also 
described by Roumagnac et al., however this study yielded different results compared 
by SNP typing analysis, instead of belonging to haplotype H65, H74 and H73 [71], our 
SNPs data divided 3 strains (E48 (India), DoniC51 (China), AS 18977 (Bangladesh)) 
into haplotypes H58, H50 and H42, respectively.
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A study conducted in a province of northern Viet Nam showed that S. Typhi strains 
were genetically related [177]. Similarly, we proved that almost all of the S. Typhi 
strains belonged to H58 genotype even though these S. Typhi strains were isolated from 
different outbreaks in the south of Viet Nam over a 12 year period (1994-2005). By 
genotyping & Typhi strains from 4 different outbreaks in Viet Nam from 1993-1997, 
Connerton et al showed that multidrug-resistant typhoid fever in southern Viet Nam 
was caused by single bacterial strains and different outbreaks were not clonally related 
[41]. This point of view was supported by a another study which showed multiple 
clones of S. Typhi circulating in the population [261]. Furthermore, microevolution and 
differences in gene content within a clone was also demonstrated [257,262] and it is 
probable that the clonality of an organism depends on the relative concept of each study 
setting [263].
Further investigations of the presence of mutations conferring fluoroquinolone 
resistance have shown that 89.3 % S. Typhi strains of haplotype H58 carried gyrA 
mutation and 52 % of these S. Typhi were MDR. Moreover, the co-persistence of H58 
haplotype S. Typhi strains with gyrA mutations delivering fluoroquinolone resistance 
with diversity in multidrug resistant phenotypes was continuously detected in Viet Nam 
for 15 years (1994-2006). Thus, the MDR phenotype may not account for the 
emergence of H58 S. Typhi clone which carries gyrA mutation(s) throughout Asian 
countries. There are several different hypotheses for this phenomenon. Our study 
seemingly supports the idea that the extensive use of fluoroquinolones in typhoid 
therapy is responsible for the dissemination of fluoroquinolone resistant S. Typhi strains 
along with the low biological cost which might enable this genotype to spread widely. 
Yet, the persistence of H58 with gyrA mutation(s) implies that the advantage of this 
clone is not only due to antimicrobial selective pressure but also to host and
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environmental adaptations. The H58 S. Typhi clone maybe able to survive persistently 
in asymptomatic carriers, and can therefore, transmit to others via a oral - fecal route 
and it may be able to cause infection under specific advantageous conditions. However, 
the spread of this clone would not solely be affected by those components. Other 
influential factors could also be mutation, recombination, gene acquisition [73], genetic 
drift [69], the loss of functional genes or rearrangement in the genetic structure 
[264,265]: Moreover, the combination of haplotype and phenotype would provide a 
considerable insight into the genetic structure of the S'. Typhi population. This study 
may be considered limited due to the small size of S. Typhi strains compared. 
Therefore, to study the genetic diversity of S. Typhi, to boost the understanding of 
evolution of S. Typhi a large sample collection is required.
6.3.2 MLPA typing
The recent advances of high throughput DNA detection technologies, such as dHPLC 
and whole genome approaches (the 454 and the Solexa sequencing), have greatly 
facilitated genotyping of high conserved bacterial pathogens [69,71,256], Such 
techniques have revealed greater information on the evolution of S. Typhi. There has 
been a lack of a transferable technique which permits the genotyping of S. Typhi in 
typhoid endemic countries. Here we aimed to design and validate an optimum 
methodology for S. Typhi genotyping in such settings. The correlation between the 
genetic background and FQ resistance phenotype could not be interpreted by SNP 
typing since the specific gyrA mutations could not be designed on the GoldenGate 
platform. MLPA appeared to be a promising technique, as this assay can detect both 
haplotypes and resistance phenotype. Using MLPA, the gyrA and parC  mutations can 
visualized along with other genomic markers, but the exact nucleotide substitution 
needs to be confirmed by sequencing. Compared with other typing techniques,
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evolutionary information of the organisms can be shown by MLPA. Additionally, this 
approach allows visualizing deletion patterns both by agarose electrophoresis and 
fragment length analysis. Thus, this technique can be flexibly transferred in different 
setting and the data gained can be transposed from laboratory to laboratory. This 
method also demonstrated advantages in terms of cost effectiveness, when compared 
with other high throughput methodologies. Although requiring some technical training, 
the MLPA method is relatively straight forward to perform and the results achieved are 
reproducible and reliable. Furthermore, for rapid screening of haplotypes and gyrA and 
parC mutations in S. Typhi isolates, MLPA is an ideal alternative and appropriate for 
epidemiological surveillance in developing countries.
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7. General discussion
This work investigated the antimicrobial resistance patterns of 2,028 S. Typhi isolates in 
8 typhoid endemic regions including Bangladesh, China, Indonesia, India (2003, 2006), 
Pakistan, Laos, Nepal and Viet Nam (1994-2005). The results have contributed to the 
knowledge of current antimicrobial resistant typhoid in endemic countries. As discussed 
in Chapter 3, the burden of typhoid caused by antimicrobial resistant S. Typhi was 
significant in 5 countries including Bangladesh, India, Nepal, Pakistan and Viet Nam. In 
contrast, typhoid caused by resistant S. Typhi strains was substantially less in Indonesia, 
China and Laos. In fact, in this study, no MDR S. Typhi strains were identified in 
Indonesia and China and no NAR S. Typhi strains were detected in Indonesia and Laos. 
MDR S. Typhi strains with additional nalidixic acid resistance and reduced 
susceptibility to fluoroquinolones were prevalent in other countries. However, 
azithromycin resistance was only detected in Chinese and Indian S. Typhi strains and 
low level of ceftriaxone resistance was solely found in Nepalese S. Typhi strains. The 
distinctive antimicrobial resistance profiles in China and Indonesia were supported by 
molecular genotyping investigations. The most predominant genotype (H58), which is 
associated with nalidixic acid resistance and reduced susceptibility to fluoroquinolones, 
was identified in Bangladesh, India, Pakistan and Viet Nam, and none of the S. Typhi 
strains isolated in China and Indonesia were of the H58 haplotype. It is evident that 
specific haplotypes with different resistance phenotypes circulate in specific locations 
despite the overall dominance of the H58 genotype.
The MDR phenotype was found to be persistent in Viet Nam over the last 13 years; 
conversely there was a decrease in MDR strains found in India between 2003 and 2006. 
It has been postulated that the loss of MDR phenotype is a result of a sequential sub- 
culturing in vitro, since plasmids may not be stable in S. Typhi because of defects in the
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partition of new plasmids in new bacterial cells [266]. Additionally, a shift in the use of 
first line antimicrobials in typhoid treatment to fluoroquinolones has also lead to the 
loss of plasmids in S. Typhi strains due to the removal of selective pressure caused by 
antimicrobial treatment [266]. Further evidence suggests that there may be a decrease in 
typhoid fever caused by MDR organisms in some areas [127,189,267]. The reversion to 
sensitivity to older antimicrobial may allow for alternative therapies, however, these 
patterns may only be short lived.
The burden of antimicrobial resistance in S. Typhi was demonstrated across several 
Asian countries, our data suggests that Viet Nam was a hot spot of both MDR and 
nalidixic acid resistant and reduced susceptibility to fluoroquinolones problem over the 
last 13 years. As reported in 2008, 70.8 % of the population of southern Viet Nam is 
rural and Ho Chi Minh City is the most crowded area in the country, with the 
population density of 3,155 person / Km2 [268]. The infrastructure of this area has not 
grown at the same pace as the population or personal economic wealth. Therefore, there 
is a lag in providing clean Water, as well as hygiene and sanitation improvements. 
Typhoid fever disease was demonstrated to be significant in school-age children and 
young adults in Mekong Delta provinces, these findings indicate poor sanitation in this 
region [42]. Health care services in rural areas of Viet Nam, particularly in the south are 
inadequate to support a large number of residents (personal information). Regardless of 
socioeconomics, outbreaks of MDR typhoid fever in the last decade in Mekong River 
Delta may have also been influenced by geographical and environmental characteristics. 
The river density and annual flooding for 2 - 4  months during the wet season may 
enhance S. Typhi transmission in the region.
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A second aim of this study was to investigate the molecular mechanisms of 
fluoroquinolone resistant S. Typhi isolated in endemic countries. Seven types of 
chromosomal mutations were found in 462 S. Typhi isolates. These mutations were 
demonstrated to be significantly related to fluoroquinolone resistant phenotypes, in 
which the substitution of Phe for Ser at codon 83 of the gyrA gene was dominant. High 
level fluoroquinolone resistance was demonstrated to correlate with the triple mutation 
(S83F and D87G (gyrA gene) and S80I (parC gene)). Although resistance phenotypes 
were associated with gyrA and parC  mutants, the impact of these substitutions was 
unknown. To demonstrate the influence of gyrA and parC mutations on the 
fluoroquinolone resistance phenotypes, these chromosomal mutations were re-generated 
in S. Typhi BRD 948. The fluoroquinolone susceptibilities of these mutants showed that 
at least one mutation at codon 83 or / and 87 of the gyrA gene were the key to nalidixic 
acid resistance and reduced susceptibility to fluoroquinolones and the parC  mutation 
alone did not cause resistance. The level of resistance was dependant on the amino acid 
substitution, the locus where mutation occurred and the generation of fluoroquinolones. 
The triple mutant had a highest level of fluoroquinolone resistance, yet had an increased 
biological cost during independent growth and a selective disadvantage in direct 
competition with the parental BRD 948 S. Typhi strain. Moreover, the S83F mutant, the 
most prevalent fluoroquinolone resistant mutant observed in wild type S. Typhi strains, 
was demonstrated to have a substantial selective advantage in the competition assay. 
These data suggest a reasonable explanation for the spread of this S83F S. Typhi mutant 
in Asian countries.
Antimicrobial resistance has caused increasing concern in the management of not only 
typhoid but also other bacterial infections. Antimicrobial resistance can be transmitted 
to offspring vertically (such as chromosomal mutations) or horizontally (such as MDR
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plasmids). Making the investigation of molecular mechanisms of antimicrobial 
resistance is crucial in a wide variety of organisms. Studying the biological cost of 
bacteria would not be comprehensive without placing them in the context of clinical and 
epidemiological features to aid the understanding of transmission dynamics in human 
populations. Bacterial fitness could also be related to their growth characteristics within 
a specific host, such as, the organism’s ability to withstand environmental stresses 
within and between different hosts and the organism’s ability to disseminate and infect 
new hosts [269]. Many aspects associated with bacterial biological fitness should be 
considered to develop a greater understanding. To this end, reconstructing competitive 
assays using a surrogate infection model, such S. Typhimurium in mice, may add 
greater insight into understanding of biological fitness of S. Typhi.
Using whole genome sequence data, the MLPA based typing method on representative 
deletions has been developed. This technique is appropriate for a multiple locus 
genotyping approach on S. Typhi strains and on other pathogens in endemic countries. 
This method generates reliable and reproducible data and is sufficiently flexible to 
apply in laboratory settings such that in Viet Nam. The combination of MLPA and the 
high throughput pyro-sequencing applications support epidemiological investigations of 
antimicrobial resistant pathogens. Although representative deletions applied in this 
study may not provide efficient information on the overall genetic relatedness of the 
strains, the results achieved offer the data on basic bacterial genotypes as well as 
resistant phenotypes providing helpful initial grounding in the genetic structure of 
bacterial populations in an endemic area.
The impact on human health of antimicrobial resistance S. Typhi infection is apparent 
as the disease causes increased morbidity, increased cost of treatment due to increasing
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length of hospital duration and concurrent loss of earning for patients [269]. The overall 
management of typhoid fever requires improving drinking water sources, the upgrading 
of sewage systems and hygienic food; however these are all long term goals [74]. 
Therefore, antimicrobial therapy is still essential for typhoid in resource-poor settings 
[74]. It is a controversial issue for the control of typhoid fever as to what is more 
important, the continuous usage of fluoroquinolones, the development of new potential 
antimicrobials or the development and deployment of new vaccines. Vaccines against S. 
Typhi are the most applicable choice for the elimination of the disease as well'as 
effectively controlling antimicrobial resistance. Vaccination development is suitable not 
only for S. Typhi but also for other enteric bacteria such as S. Paratyphi. Current 
typhoid vaccines are only protective against S. Typhi infections whereas an imbalance 
in the competition between enteric organisms may, potentially, cause a serotype shift 
from S. Typhi to S. Paratyphi [72,270]. Nevertheless, mass vaccination programmes in 
endemic countries have rarely been applied even though they are recommended by the 
World Health Organization [74].
This study has contributed to the understanding of the antimicrobial susceptibilities and 
the underlying molecular biology of this important enteric pathogen. Future studies may 
be focused not only on mechanisms of fluoroquinolone resistance but also on the 
abilities of the organisms to survive and spread both in intro and in vivo conditions. 
Effective tracking of transmission routes through asymptomatic carriers and 
environmental vehicles should also be investigated. Extensive molecular 
epidemiological surveillance using the MLPA technique, or an equivalent, should be 
established regionally and internationally for the purpose of understanding the 
circulation of S. Typhi organisms. This research, despite unavoidable limitations, is the 
first study investigating the molecular epidemiology of fluoroquinolone resistant S.
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Typhi in Asia in general and in Viet Nam in particular, making a great effort in 
describing the resistance and its mechanisms and its survival features. It also provides 
crucial information for the public health workers on the disease prevention and control 
programmes as well as updating reliable and effective treatment regimens for patients.
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